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Zusammenfassung 
Bei der X-gebundenen juvenilen Retinoschisis (engl. X-linked juvenile retinoschisis, XLRS) 
handelt es sich um eine degenerative Erkrankung der Netzhaut, welche auf Grund ihres X-
chromosomalen Vererbungsmusters vorwiegend bei Männern auftritt (George et al., 1995). 
Charakteristisch für die XLRS ist eine Aufspaltung der retinalen Schichten (Schisis) und eine 
defekte Signalweiterleitung von Photorezeptor- zu Bipolarzellen. Ursächlich für diese 
Erkrankung sind Mutationen im RS1-Gen (Sauer et al., 1997). Das vom RS1-Gen kodierte 
Protein, Retinoschisin, wird in der Retina spezifisch von Photorezeptoren und Bipolarzellen 
exprimiert und bindet an die Plasmamembranen dieser Zelltypen. Die Verankerung von 
Retinoschisin an der Plasmamembran wird dabei von der retinalen Na/K-ATPase vermittelt 
(Friedrich et al., 2011), welche bereits in einer früheren Studie als ein Interaktionspartner von 
Retinoschisin identifiziert wurde (Molday et al., 2007).  
Der molekulare Pathomechanismus der XLRS und inwiefern die retinale Na/K-ATPase in der 
XLRS-Pathogenese involviert ist, ist bisher nicht bekannt. Ziel dieser Arbeit war es daher, 
funktionelle Konsequenzen sowie die strukturelle Basis der Retinoschisin-Na/K-ATPase 
Interaktion zu untersuchen.  
Für die folgenden Studien wurden zunächst die kodierenden Sequenzen für Retinoschisin und 
eine pathogene Retinoschisin-Variante, RS1-C59S, mit einem Myc-Tag fusioniert und in einen 
Expressionsvektor kloniert, was die Aufreinigung rekombinanten Retinoschisins ermöglichte. 
Die aufgereinigten Retinoschisin-Varianten wurden in die weiteren Versuche zur 
Retinoschisin-Na/K-ATPase Interaktion eingesetzt.  
Das erste Projekt hatte zum Ziel, einen möglichen Einfluss von Retinoschisin auf 
Proteinmengen oder Membranstabilität der Na/K-ATPase in Netzhautexplantaten des RS1-
Knock out (Rs1h-/Y) Mausmodells oder in Hek293 Zellen, welche heterolog die retinale Na/K-
ATPase exprimierten, aufzuklären. Rekombinantes Retinoschisin hatte in keinem der beiden 
Modellsysteme einen Einfluss auf Na/K-ATPase Proteinmengen, weder in Gesamtzelllysaten 
noch in angereicherten Membranfraktionen. 
Ein weiteres Projekt befasste sich mit einem möglichen Effekt von Retinoschisin auf die aktive 
Ionenpumpfunktion der Na/K-ATPase. Rekombinantes Retinoschisin hatte dabei keinen 
Einfluss auf die ATP-Hydrolyserate oder Substrataffinitäten der Na/K-ATPase in Rs1h-/Y-
Netzhautexplantaten. Ebenso hatte es keinen Einfluss auf die Ionentransportaktivität der 
heterolog in Xenopus leavis Oozyten exprimierten, humanen retinalen Na/K-ATPase. 
Im Rahmen des dritten Projekts wurde untersucht, ob Retinoschisin die Na/K-ATPase abhän-
gige Signaltransduktion beeinflussen kann. Die Zugabe von Retinoschisin, nicht aber von RS1-
C59S, verminderte die Aktivität von c-RAF und ERK1/2, zentraler Komponenten des MAPK 
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(Mitogen-aktivierten Proteinkinase) Signalweges, in Rs1h-/Y Netzhautexplantaten sowie in der 
humanen Retinoblastom-Zelllinie Y-79. Außerdem verminderte Retinoschisin die Expression 
der MAPK Zielgene c-FOS und EGR1 in beiden retinalen Modellsystemen. Weitere Studien 
zur Retinoschisin-abhängigen Regulation von Signalkaskaden fokussierten sich auf Rs1h-/Y 
Netzhautexplantate. Es zeigte sich, dass die Zugabe von rekombinantem Retinoschisin, nicht 
aber von RS1-C59S, die Aktivität von Src, welches als initialer Signaltransmitter der Na/K-
ATPase beschrieben wurde (Cui und Xie, 2017), mindert. Ebenso verminderte Retinoschisin 
die Aktivität des Ca2+ Signalweg-Markers Camk2. Die Aktivität des PI3K/AKT Signalwegs, 
repräsentiert durch Akt, wurde von Retinoschisin nicht beeinflusst. Immunhistochemische 
Analysen muriner, wildtypischer Netzhäute zeigten überlappende Signale des Retinoschisin-
Na/K-ATPase-Komplexes mit Signalen von Gerüstproteinen und Transmittern, denen eine 
Beteiligung an der Na/K-ATPase-Signalweiterleitung zugesprochen wird. 
Des Weiteren wurde der Einfluss von Retinoschisin auf die zelluläre Homöostase untersucht. 
Die Behandlung von Y-79-Zellen mit rekombinantem Retinoschisin hatte keinen Einfluss auf 
deren Überlebensrate, Zellgröße oder Proliferation. Jedoch zeigte sich nach Zugabe von re-
kombinantem Retinoschisin eine Minderung der apoptotischen Aktivität sowohl in Y-79-Zellen 
als auch in Rs1h-/Y Netzhautexplantaten. Die Expression des pro-apoptotischen Markergens 
BAX wurde in beiden Modellsystemen beeinflusst und nach unten reguliert. Ebenso zeigten 
Y-79 Zellen nach Behandlung mit Retinoschisin eine verminderte Caspase-3-Aktivität. 
Netzhautexplantate der Rs1h-/Y Maus, die für eine Woche in Gegenwart von Retinoschisin ex 
vivo kultiviert wurden, zeigten eine deutlich reduzierte Photorezeptordegeneration.  
Das letzte Projekt befasste sich mit der Identifikation der Retinoschisin-Interaktionsfläche der 
Na/K-ATPase. Neun verschiedene Na/K-ATPase-Isozymkombinationen (ATP1A1, ATP1A2, 
und ATP1A3 in Kombination mit ATP1B1, ATP1B2, oder ATP1B3) wurden hinsichtlich ihrer 
Fähigkeit, Retinoschisin zu binden, untersucht. Eine Retinoschisin-Bindung fand nur an Na/K-
ATPasen, welche die ATP1B2-Untereinheit enthielten, statt. Die Herstellung chimärer 
ATP1B2-ATP1B1-Untereinheiten ermöglichte es, die Interaktionsstelle weiter auf die 
extrazelluläre Domäne der ATP1B2-Untereinheit einzuschränken. Mit Hilfe bioinformatischer 
Analysen wurden anschließend zwei mögliche Protein-Interaktionsregionen auf ATP1B2 
identifiziert. Durch gerichtete Mutagenese wurden diese Regionen gezielt entfernt, in dem die 
entsprechenden Aminosäuresequenzen von ATP1B1 eingefügt wurden. Retinoschisin-
Bindeversuche an diese chimären ATP1B2-Mutanten ergaben eine Kanditatenregion für die 
Retinoschisin-Interaktionsstelle in der zweiten Interaktionsregion, an Aminosäure T240. 
Zusammenfassend liefert diese Arbeit neue Einblicke in initiale pathologische Prozesse der 
XLRS, was die Erforschung neuer therapeutischer Strategien für diese bisher unheilbare 
Krankheit vorantreiben könnte.  
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Summary 
X-linked juvenile retinoschisis (XLRS) is a degenerative disease of the retina which primarily 
affects males due to an X-chromosomal recessive mode of inheritance (George et al., 1995). 
Mutations in the RS1 gene were shown to be causative for XLRS (Sauer et al. 1997) which is 
characterized by a splitting of the retinal layers (schisis) as well as defects in signal 
transduction between photoreceptors and bipolar cells (Molday et al. 2012). The protein 
encoded by RS1, retinoschisin, is specifically expressed and secreted by photoreceptors and 
bipolar cells in the retina and was found to bind to plasma membranes of these cell types. 
Membrane anchorage of retinoschisin was shown to be mediated by the retinal Na/K-ATPase 
(Friedrich et al., 2011), which had been identified as a retinoschisin interacting protein before 
(Molday et al., 2007).  
The molecular pathomechanism of XLRS and a putative involvement of the Na/K-ATPase in 
XLRS pathogenesis remain elusive. Therefore, aim of this study was to investigate functional 
consequences and the structural basis of retinoschisin-binding to the Na/K-ATPase.  
To this end, the coding sequences for retinoschisin and a pathogenic retinoschisin variant, 
RS1-C59S, were fused to a Myc-tag and cloned into expression vectors, enabling purification 
of the recombinant proteins. These purified proteins were then used in further studies 
addressing the interaction between retinoschisin and the Na/K-ATPase. 
The first project aimed to delineate whether retinoschisin influences Na/K-ATPase levels or 
membrane stability in murine retinal explants of an RS1 knock out (Rs1h-/Y) mouse model or 
in Hek293 cells heterologously expressing retinal Na/K-ATPase subunits ATP1A3 and 
ATP1B2. Recombinant retinoschisin had no effect on Na/K-ATPase protein levels in total cell 
lysates or enriched plasma membrane fractions from both model systems. 
A second project assessed the effect of retinoschisin on the active ion pump function of the 
Na/K-ATPase. Retinoschisin treatment did not affect Na/K-ATPase catalysed (pump function 
dependent) ATP cleavage or substrate affinities in Rs1h-/Y retinal explants. Neither did it affect 
ion transport activity of the heterologously expressed human retinal Na/K-ATPase in Xenopus 
leavis oocytes. 
The third project investigated an influence of retinoschisin on Na/K-ATPase mediated 
signaling. Recombinant retinoschisin, but not RS1-C59S, was shown to reduce the activity of 
mitogen activated protein kinase (MAPK) signaling constituents c-RAF and ERK1/2 in Rs1h-/Y 
retinal explants as well as the human retinoblastoma cell line Y-79. MAPK pathway target 
genes EGR1 and c-FOS were also downregulated upon retinoschisin treatment in both model 
systems. Further studies on signal regulation by retinoschisin focused on Rs1h-/Y retinal 
explants as model system. Recombinant retinoschisin, but not C59S, was found to decrease 
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the activity of the non-receptor tyrosine kinase Src, an initial signal transmitter in Na/K-ATPase 
mediated signaling (Cui and Xie, 2017). Retinoschisin also decreased the activity of Ca2+ 
signaling marker Camk2, but not activation of PI3K/AKT signaling marker Akt. 
Immunohistochemistry in murine wildtype retinae showed overlapping signals of the 
retinoschisin-Na/K-ATPase complex and scaffolding proteins as well as signal transmitters 
involved in Na/K-ATPase mediated signal transduction. 
The next project assessed the effect of retinoschisin on cellular homeostasis. Retinoschisin 
treatment did not influence cell viability, cell size or proliferation of Y-79 cells. However, 
retinoschisin but not RS1-C59S treatment lead to decreased apoptotic activity in Y-79 cells 
and Rs1h-/Y retinal explants: Expression of the pro-apoptotic marker gene BAX was down 
regulated in both model systems. In Y-79 cells, retinoschisin reduced the activity of apoptosis 
marker Caspase-3. Rs1h-/Y retinal explants, cultivated in the presence of retinoschisin for one 
week ex vivo, exhibited significantly decreased photoreceptor degeneration.  
The last project focused on the identification of the Na/K-ATPase interaction site to 
retinoschisin. Retinoschisin binding to nine different Na/K-ATPase isozyme combinations 
(ATP1A1, ATP1A2, and ATP1A3 in combination with ATP1B1, ATP1B2, or ATP1B3) was 
tested and revealed that retinoschisin specifically binds to ATP1B2. Applying ATP1B2-ATP1B1 
chimera, the interaction site was further narrowed down to the extracellular domain of ATP1B2. 
Next, bioinformatics analyses identified two putative protein-interaction sites on the 
extracellular domain of ATP1B2. These two "docking patches" patches on ATP1B2 were each 
mutated by introducing the respective sequences of ATP1B1. Analysis of retinoschisin binding 
to ATP1B2 docking-patch mutants revealed a candidate region in docking patch II, in specific 
the amino acid (aa) T240, putatively involved in retinoschisin binding.   
Taken together, this work provides novel insight into initial pathological processes of XLRS 
and could thus enhance the development of novel therapeutic options for this currently 
untreatable disease. 
 
  
Introduction 
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1 Introduction 
1.1 X-linked Juvenile Retinoschisis (XLRS) – Clinical Features  
X-linked juvenile retinoschisis (XLRS) is a hereditary retinal dystrophy and represents one of 
the most common forms of early onset macular degeneration in males (George et al., 1995). 
XLRS was first described in two brothers by the Austrian ophthalmologist Josef Haas in 1898 
(Haas, 1898) and later identified to be of X-linked inheritance (Pagenstecher, 1913). Due to 
the X-chromosomal recessive mode of transmission, mostly males are affected. Female 
carriers, in general, are asymptomatic, with few documented cases of subtle retinal changes 
(Wu et al., 1985, Rodriguez et al., 2005, Saldana et al., 2007). The worldwide estimated 
prevalence of XLRS ranges between 1:5000 and 1:20000 with hotspots of elevated prevalence 
for example in Finland, where XLRS was found to be the most common X-linked disease due 
to three founder mutations in the Finish population (Tantri et al., 2004). XLRS is almost fully 
penetrant (~ 98 %), and shows a juvenile onset in most patients (Molday et al., 2012). Affected 
boys often present for ophthalmologic examination at school age when reading difficulties are 
detected, but symptoms of XLRS were also found in patients being under one year of age, 
suggesting a congenital onset of the disease (George et al., 1995, Prasad et al., 2006, Renner 
et al., 2008, Lee et al., 2009).  
The clinical manifestations of XLRS are highly variable even within families, but there are 
phenotypic changes characteristic for a specific diagnosis. As the name “X-linked juvenile 
retinoschisis” suggests, the disease is characterized by retinal ”schisis“, i.e. a splitting of retinal 
layers mainly affecting ganglion cell layer and inner nuclear layer, which can be visualized by 
spectral domain optical coherence tomography (OCT-SD) (Figure 1 A). Retinal schisis is 
mainly found to affect the fovea in a majority of XLRS patients, but peripheral manifestations 
are also seen in around 50 % of affected individuals (George et al., 1995, Molday et al., 2012). 
Alongside with retinal schisis goes the development of large, fluid-filled cysts, also known as 
schisis cavities. The presence of foveal cysts causes a distinctive spoke-wheel like schisis 
pattern which is characteristic for XLRS and is used as a main indicator for diagnosis (Figure 
1 B). Retinal schisis was shown to be more pronounced in young patients and decreases when 
patients grow older (George et al., 1995, Molday et al., 2012). A further characteristic feature 
of XLRS is the so called "negative" electroretinogram (ERG). Compared to healthy individuals, 
XLRS patients show a lower b-wave response, whereas the a-wave remains almost normal 
(Figure 1 C). The decreased b-wave indicates a defective transmission of visual signals from 
photoreceptor to bipolar cells (Khan et al., 2001). Since there have been reports of XLRS 
patients showing normal ERG responses (e.g. Eksandh et al., 2005, Vincent et al., 2013) and 
clinical manifestation of XLRS is highly variable with regard to disease onset, progression and 
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severity even in siblings, a combined approach of fundus autofluorescence imaging, OCT 
imaging, ERG measurement, and molecular-genetic testing is nowadays used to diagnose 
XLRS (Renner et al., 2008). 
Secondary complications like vitreous haemorrhages or retinal detachment can occur in 
addition to the characteristic clinical features of XLRS. Approximately 5 % of all patients are 
affected by these secondary complications which in most cases develop in the first decade of 
life (Molday et al., 2012). Macular holes have also been reported to arise as side effects of 
XLRS (Brasil et al., 2011; Shukla et al., 2006). 
 
Figure 1: Clinical features of XLRS 
A) Fundus autofluorescence images of a healthy individual and a XLRS patient. A spoke-wheel like foveal schisis 
can be detected in the patient’s image. B) SD-OCT images of a healthy individual and a XLRS patient. A marked 
splitting of retinal layers is seen in the foveal area of the XLRS patient’s retina between the ganglion cell layer (GCL) 
and inner nuclear layer (INL) C) ERG recordings from a healthy individual and a XLRS patient. The patient’s ERG 
exhibits a strongly reduced b wave (Images adapted from Molday et al., 2012 (A, XLRS patient), Cuba and Gomez-
Ulla, 2011 (A, healthy individual), Sergeev et al., 2011 (B) and Bowles et al., 2011 (C)). 
1.2 Mutations in the RS1 Gene are Causative for XLRS 
After localizing the XLRS-locus in close proximity to Xg blood group markers in 1984 (Wieacker 
et al., 1984), it was not until 1997 that the XLRS gene was identified by a positional cloning 
approach (Sauer et al., 1997). The identified gene was termed RS1 and localizes to the short, 
distal arm of the X-chromosome at Xp22.2. The RS1 gene is 32.4 kb in length and is organized 
in 5 introns and 6 exons. The mRNA transcript arising from RS1 is 3.1 kb long and encodes a 
224 amino acid (aa) long protein named retinoschisin. RS1 expression was found to be 
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exclusive to photoreceptor and bipolar cells of the retina (Sauer et al., 1997, Grayson et al., 
2000, Molday et al., 2001,) as well as to the pinealocytes of the pineal gland (Takada et al., 
2006). Its specific expression is controlled by an upstream CpG island and two opposing CRX 
(Cone-Rod Homeobox) transcription factor binding regions (Langmann et al., 2008, Kraus et 
al., 2011). RS1 expression in murine retina is detectable already at postnatal day 1 (p1) and 
reaches adulthood levels at p5 to p7 which then stay constant throughout life (Weber and 
Kellner, 2007). Due to the X-chromosomal recessive mode of inheritance, the lack of 
correlation of mutation type and disease phenotype, and various biochemical studies on 
mutant retinoschisin, it is thought that XLRS arises as a result of a functional loss of the 
retinoschisin protein (e.g. Wang et al., 2002, Wu and Molday, 2003, Vijayasarathy et al., 2010; 
reviewed by Molday; 2007). 
1.3 Rs1h Knock Out Mice – A Model System for XLRS 
Identification of the RS1 gene has not only facilitated XLRS diagnostics but also provided the 
possibility to generate a mouse model for XLRS. Murine retinoschisin is termed Rs1h and 
shares 96% sequence identity with its human homologue. Rs1h knock out mouse lines were 
generated and characterized independently by several groups (Weber et al., 2002, Zeng et al., 
2004, Jablonski et al., 2005). The phenotype resulting from Rs1h-/Y knock out models reflects 
the human condition of XLRS in the independent mouse lines: Retinal structures are 
disorganized and a marked retinal splitting is observable in the inner nuclear layer. Also, the 
characteristic negative ERG is comparable to the human condition (Molday et al., 2012). 
Together, these features render the retinoschisin-deficient mice excellent model systems for 
studies on XLRS pathomechanisms as well as treatment options.  
1.4 Prospect on Therapeutic Strategies for XLRS  
To date, there is no cure for XLRS. Prescription of low-vision aids is still the most common 
treatment for XLRS patients and the only drug which is under testing for XLRS treatment is 2 
% dorzolamide, a carbonic anhydrase inhibitor (CAI). CAIs such as dorzolamide and 
acetozolomide have been used to successfully treat macular oedema, where inhibition of 
carbonic anhydrase in the retinal pigment epithelium leads to acidification of the retina and 
elevated fluid extrusion. This, in turn, results in a lowered intraocular pressure (Wolfensberger, 
1999). Because of this known beneficial effects on macular oedema, CAIs were also 
suggested to reduce schisis cavities in XLRS. Studies have analysed the effects of CAI 
treatment in 8 or 9 XLRS patients and observed positive effects on foveal thickness, cystic 
spaces and/or visual acuity in 7 or 5 of these, respectively (Apushkin and Fishman 2006, 
Verbakel et al., 2016). Successful CAI treatment of XLRS patients was also shown to be 
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irrespective of the class of disease-associated mutation (Walia et al., 2009). However, there 
are also studies that have reported no improvement in visual acuity after CAI treatment, but 
only a decrease in retinal splitting (Genead et al., 2010, Khandhadia et al., 2011). For a subset 
of XLRS patients, CAI treatment had no effect at all (Apushkin and Fishman 2006, Genead et 
al., 2010, Khandhadia et al., 2011, Verbakel et al., 2016). A clinical evaluation on the use of 2 
% dorzolamide or 1 % brinzolamide, another CAI, in 66 XLRS patients for 18 months has been 
completed in October 2016 (https://clinicaltrials.gov/ct2/show/NCT02331173, accessed 
August 31st 2017), but final data on the outcome of this study are not yet available. Due to the 
few and partially conflicting studies on XLRS patients treated with CAIs, this type of medication 
is not routinely used in XLRS treatment. 
RS1 gene replacement using AAV (adeno-associated virus) vectors in the Rs1h-/y mouse 
model has successfully reduced XLRS phenotypes and opened up gene replacement therapy 
as a novel way to cure XLRS (Zeng et al., 2004, Janssen et al., 2008, Park et al., 2009, Ou et 
al., 2015, Ye et al., 2015, Bush et al., 2016a). Pre-clinical evaluations had already confirmed 
that the vectors are well tolerated in both mice and Cynomolgus macaques: vector DNA was 
only detectable in eyes and there were no antibodies against the exogenously expressed 
retinoschisin (Ye et al., 2015a, Ye et al., 2015b). Currently there is a Phase I clinical trial 
ongoing on gene replacement therapy for XLRS using AAV based vectors 
(https://clinicaltrials.gov/ct2/show/NCT02317887, accessed August 2nd 2017). Solid Lipid 
Nanoparticles (SLNs) have also been used to deliver RS1 to the eyes of Rs1h-/Y mice resulting 
in reduced photoreceptor loss and schisis formation (Apaolaza et al., 2015, Apaolaza et al., 
2016). SLNs may thus provide an alternative approach to viral gene replacement therapies. 
For all three XLRS therapeutic approaches, however, further studies and especially long-term 
follow up of patients will be needed to evaluate their value for XLRS treatment.  
1.5 The Retinoschisin Protein 
Due to the very limited therapeutic options for XLRS, several research groups aim to dissect 
the basic pathomechanisms caused by retinoschisin deficiency, and thus the function of 
retinoschisin in the retina. Retinoschisin is a 24 kDa protein and highly conserved among 
species. It exhibits four distinct domains: an N-terminal signal peptide (23 aa), a discoidin 
domain (157 aa), an RS1 domain (39 aa), and a short C-terminal fragment of 5 aa (Sauer et 
al., 1997, Molday, 2007) (Figure 2 A). 
The signal peptide is responsible for retinoschisin secretion and is cleaved off during this 
process. Two cleavage sites, between aa 21-22 and aa 23-24 have been identified within the 
signal peptide, resulting in two mature retinoschisin isoforms which differ by two aa in length 
in mouse (Vijayasarathy et al., 2006). Next follows the RS1 domain, which has been given its 
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name due to the lack of sequence homology with any other known protein (Molday et al., 2012). 
The subsequent discoidin domain, however, is highly conserved and found in many other 
proteins. After the discoidin domain, the last element to follow in the retinoschisin protein is the 
short C-terminal segment. 
The discoidin domain makes up about 75 % of the mature retinoschisin protein and is thought 
to be the major functional unit of retinoschisin (Wu et al., 2003, Molday, 2007). A discoidin 
domain was first identified in the discoidin I protein of Dictyostelium discoideum (Poole et al., 
1981) and later found as a recurrent motif in a huge variety of eukaryotic and prokaryotic 
proteins (Baumgartner et al., 1998, reviewed by Kiedzierska et al., 2007). Discoidin domain 
containing proteins are involved in a plethora of cellular processes such as cellular adhesion, 
fertilization, migration, signaling and development (reviewed by Kiedzierska et al., 2007). 
Discoidin domains are organized in a core domain which is highly conserved, and so called 
spike or loop regions which, in contrast, are highly variable (reviewed by Kiedzierska et al., 
2007). The core domain of discoidin domains consists of a five-stranded antiparallel ß-sheet 
which is tightly packed up against a three-stranded antiparallel ß-sheet forming a distorted 
barrel like structure. From this core barrel two or more of the highly variable spike regions are 
protruding. The spike regions form a groove which serves as the recognition site for discoidin 
domain’s interaction partners. Since the spike regions are highly variable, discoidin domains 
can bind to a variety of ligands including lipids, carbohydrates and proteins which goes along 
with the diverse functions they have been attributed (reviewed by Kiedzierska et al., 2007). 
Even though the 3-D structure of the retinoschisin discoidin domain has not been determined 
yet, the availability of high resolution structures of many other discoidin domains allowed for 
modelling of the retinoschisin discoidin domain. In case of the retinoschisin discoidin domain, 
three spikes protrude from one end of a core hydrophobic structure of eight ß-strands (Wu and 
Molday, 2003). 
Retinoschisin is secreted from photoreceptors and bipolar cells as a homo-octameric complex 
(Figure 2 B). Oligomerization was shown to take place before the protein is secreted from the 
endoplasmatic reticulum (ER) (Molday et al., 2001, Wu and Molday, 2003, Wu et al., 2005). 
Intensive studies on known pathogenic retinoschisin variants determined the cystein residues 
responsible for retinoschisin oligomerisation: While two retinoschisin monomers are linked 
together by a disulfide bond between their cystein residues at aa position 40 (C40), 
octamerization is achieved by disulfide bonds between cystein at position 59 (C59) in the RS1 
domain and cystein at position 223 (C223) in the C-terminal segment of two retinoschisin 
monomers (Wu and Molday, 2003, Wu et al., 2005). Recently, technical advances enabled the 
determination of the structure of the retinoschisin octamer. Using single particle electron 
microscopy, Bush and colleagues were the first to present retinoschisin to be arranged in a 
cog-wheel like ring structure, with the RS1 domains facing the inside of the ring and the 
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discoidin domains and especially their spikes facing outwards (Bush et al., 2016). Using 
cryoelectron microscopy, Tolun and colleagues refined the structure and Ramsay and 
colleagues analysed the influence of XLRS associated mutants on the octamer struc ture 
(Tolun et al., 2016, Ramsay et al., 2016). Tolun and colleagues also provided evidence that 
two retinoschisin octamers assemble in a back-to-back fashion, forming a hexadecamer 
(Figure 2 C). 
 
Figure 2: Schematic presentation of retinoschisin domains and 3D structure of hexadecameric complexes 
A) Schematic representation of the retinoschisin domains, arrows depict cystein residues which are essential for 
retinoschisin oligomerization. B) Top view onto a retinoschisin double-octamer organized into a cog-wheel like 
structure. C) Side view onto two retinoschisin octamers organized into a hexadecamer in a back-to-back fashion. 
Subfigures B) and C) were created using the 3D structure of retinoschisin provided by Ramsay et al., 2016 as a 
template with the EXPASY swissmodell tool available at https://swissmodel.expasy.org/repository/uniprot//O15537. 
 
Immunolabelling experiments detected retinoschisin on the inner segments of both rod and 
cone photoreceptors, as well as in plexiform layers with most intensive staining found in 
photoreceptor inner segments (Figure 3) (Grayson et al., 2000, Molday et al., 2001, Reid et 
al., 2003, Takada et al., 2004). 
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1.6 Categorization of XLRS Associated Mutations  
To date, 197 pathogenic variants of the RS1 gene have been reported 
(https://databases.lovd.nl/shared/genes/RS1, accessed August 3rd 2017). In 2012, a review 
by Molday and colleagues categorized the then known 191 XLRS-associated mutations as 
follows: 13 % were deletions, 3 % duplications, 1.5 % insertions, 1.5 % insertions/deletions 
and the majority of 80 % were single nucleotide polymorphisms (SNPs) which may result in 
pre-mature stop-codons, aa changes or alterations of splice sites. Around 40 % of these 
mutations are expected to be true null alleles, not allowing translation (Molday et al., 2012). 
The rest is represented by missense mutations categorized into three different classes with 
regard to their position in the retinoschisin protein and thus their effects on retinoschisin protein 
folding, secretion and stability/octamerization.  
The first class of missense mutations is represented by mutations in the discoidin domain 
which seems to be a hotspot for missense mutations and harbours 85 % of all RS1 missense 
mutations. The discoidin domain missense mutations biochemically characterized so far in 
general led to defects in retinoschisin secretion caused by ER retention (Wang et al., 2002, 
Wu et al., 2003, Iannaccone et al., 2006, Wang et al., 2006, Walia et al., 2009, Gleghorn et al., 
2010). As shown by Gleghorn and colleagues, misfolded retinoschisin does not induce the 
unfolded protein response (UPR), which suggests that it is rather the null phenotype that 
causes disease than cellular stress induced by UPR (Gleghorn et al., 2010). 
Missense mutations in the signal peptide of retinoschisin represent the second class of 
distinctive RS1 mutations. These mutations (e.g. RS1-L12H (NM_000330.3(RS1):c.35T>A 
[p.Leu12His] and RS1-L13P (NM_000330.3(RS1):c.38T>C [p.Leu13Pro]) were shown to 
prevent translocation of the nascent protein into the ER, resulting in complete absence of 
mature retinoschisin and thus a null phenotype (Wang et al., 2002, Vijayasarathy et al., 2010). 
The third class of RS1 mutations leads to protein variants which are still secreted, but exhibit 
abnormal oligomerization. As shown by Wu and colleagues the cystein residues C59 and C223 
are essential for assembly of retinoschisin octamers and mutations at both of these residues 
Figure 3: Immunolabeling of a murine 
retinal cryosection showing 
retinoschisin localization 
Left: DIC/DAPI (differential interference 
contrast/ 4′,6-Diamidin-2-phenylindol) 
visualisation of nuclei in retinal layers. 
Right: Immunohistochemistry (IHC) with an 
anti-retinsochsin antibody OS/IS: 
outer/inner segments; OPL/IPL outer/ inner 
plexiform layers; ONL/INL: outer/inner 
nuclear layer; GCL: ganglion cell layer. 
(Molday et al., 2012) 
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have been reported in XLRS patients (Wu et al., 2005). Pathogenicity of these mutations led 
to the suggestion that octamer formation is necessary for correct retinoschisin function.  
There are few known mutations which have also been characterized biochemically, and do not 
fit into any of the mutation categories described above. The retinoschisin variants RS1-R141H 
(NM_000330.3(RS1):c. 422G>A [p.Arg141His]), RS1-R141G (NM_000330.3 
(RS1):c.421>T/G [p.Arg141Gly]), RS1-H207Q (NM_000330.3(RS1):c. 621C>G 
[p.His207Gln]), and RS1-R209H (NM_000330.3(RS1):c.626G>A [p.Arg209His]) have been 
shown to be secreted as octameric complexes. Ramsay and colleagues analysed the 
structural changes introduced into the retinoschisin octamer by mutations R141H and H207Q. 
Whereas H207Q was reported to destabilize both the retinoschisin monomer and octamer, 
R141H did not affect overall protein stability. It was suggested that the pathomechanism 
underlying the R141H mutation potentially arises from defective interaction of the mutant 
protein with its interaction partners (Ramsay et al., 2016).  
1.7 Towards Retinoschisin Function – Proposed Interaction Partners  
In spite of the clinical features being well defined and the disease causing gene being known 
for 20 years, the pathomechanism of XLRS still remains elusive. Efforts have been made to 
identify the molecular mechanisms underlying retinoschisin function and determine why 
retinoschisin deficiency has such tremendous consequences for retinal integrity. Retinoschisin 
has been proposed to interact with galactose, phosphatidylserine, extracellular matrix proteins 
like laminin, L-type voltage gated ion channels, as well as the retinal Na/K-ATPase (Fraternali 
et al., 2003, Steiner-Champliaud et al., 2006, Vijayasarathy et a., 2007, Molday et al., 2007, 
Dyka et al., 2008, Shi et al., 2009, Kotova et al., 2010, Friedrich et al., 2011, Shi et al., 2017), 
each interaction partner providing room for speculations towards retinoschisin function. 
1.7.1 Phospholipids 
One of the molecules retinoschisin was proposed to interact with is phosphatidylserine. 
Phosphatidylserine is an acidic membrane phospholipid which is found in the plasma 
membrane. A possible interaction of retinoschisin and phosphatidylserine was assumed 
because other discoidin domain containing proteins were also shown to interact with 
phosphatidylserine (Ortel et al., 1992, Zwaal et al., 1998). An initial study addressing the 
interaction between retinoschisin and phosphatidylserine was conducted by Fraternali and 
colleagues in 2003. Bioinformatical evaluation of XLRS associated mutations leading to aa 
exchanges at Y89, V90, W92, Y93, F108, and I144 revealed that these aas may form a 
hydrophobic and exposed region on retinoschisin similar to sites on Factor V and Factor VIII 
which mediate interactions with phospholipid bilayers (Fraternali et al., 2003). Later studies 
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showed retinoschisin to co-purify with phosphatidylserine (Vijayasarathy et al., 2007) and 
atomic force microscopy analyses by the same group detected retinoschisin binding to 
phosphatidylserine containing planar lipid bilayers (Kotova et al., 2010). However, other groups 
were not able to verify an interaction between retinoschisin and phosphatidylserine (Molday et 
al., 2007, Friedrich et al., 2011). In addition to the contradictory experimental data obtained by 
different in vitro systems, the physiological relevance of an interaction between retinoschisin 
and phosphatidylserine is also questionable. In a native cellular system phosphatidylserine 
mostly localizes to the inner leaflet of plasma membranes whereas retinoschisin binds to the 
outer plasma membrane, hence the proposed interaction might not be feasible in a native 
system (Molday et al., 2012).  
1.7.2 Galactose 
Discoidin proteins from Dictyostelium discoideum were shown to function as lectins and exhibit 
a high affinity for galactose residues to promote cell aggregation (Poole et al., 1981, Valencia 
et al., 1989). This finding encouraged Dyka and colleagues to analyse whether retinoschisin 
is capable of binding to immobilized carbohydrates. They found efficient retinoschisin binding 
to agarose-coupled galactose and lactose, whereas no retinoschisin binding was observed to 
agarose-coupled N-acetylgalactosamine, N-acetylglucosamine, mannose or heparin (Dyka et 
al., 2008). To date, there are no further studies addressing the physiological relevance of the 
interaction between retinoschisin and galactose. Nevertheless, its high affinity to galactose has 
been used to purify recombinant retinoschisin (e.g. Bush et al., 2016).  
1.7.3 Extracellular Matrix Proteins 
In an affinity chromatography based approach to identify retinoschisin binding proteins, the 
extracellular matrix component β2-laminin and αB crystalline were found to bind to immobilized 
retinoschisin (Steiner-Champliaud et al., 2006). Interaction with extracellular matrix proteins 
would strengthen the notion that retinoschisin is involved in cell-cell contact formation, but no 
further investigations with regard to a physiological relevance of these interactions have been 
conducted so far.  
1.7.4 L-Type Voltage Gated Calcium Channels 
In 2009, Shi and colleagues performed co-immunoprecipitations and Yeast-2-Hybrid 
experiments which identified L-Type Voltage Gated Calcium Channels (L-VGCCs) as novel 
retinoschisin interaction partners (Shi et al., 2009). L-VGCCs are heteromeric complexes of 
four different subunits which span the plasma membrane and function as Ca2+ specific 
channels (De Waard et al., 1996). Mutations in the gene encoding the Cav1.4 α1 subunit of L-
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VGCCs (CACNA1F) were shown to cause X-linked stationary night blindness. Cacna1f knock 
out in mice resulted in a negative ERG, highlighting the importance of L-VGCCs in 
photoreceptor bipolar synapse integrity (Mansergh et al., 2005). As a negative ERG is also a 
clinical hallmark of XLRS, an involvement of L-VGCCs in XLRS pathogenesis, possibly due to 
misregulation in a retinoschisin deficient retina, might be conclusive. A more recent study by 
Ou and colleagues also showed that retinoschisin is needed to maintain the synaptic 
localization of L-VGCC in retina (Ou et al., 2015). The latest publication by Shi and colleagues 
described successful co-immunoprecipitation of retinoschisin and Cav1.3 and Cav1.4 from 
porcine retinae. Furthermore, retinoschisin was shown to increase L-VGCC currents in 
transfected Hek293 cells. The same study also presented immunohistochemical analyses 
indicating that Cav1.4 expression is reduced in retina of Rs1h-/Y mice, but does not provide 
quantification (Shi et al., 2017). This finding is contradictory to results from Ou and colleagues, 
who did not observe any differences in Cav1.4 expression (quantification given) when 
comparing Rs1h-/Y and wildtype murine retinae. In addition, Cav1.4 α1 subunits are only 
expressed and located at release sites of mammalian photoreceptors in the outer plexiform 
layer, additionally exhibiting a punctate immunostaining in the mouse inner plexiform layer 
(Boycott et al., 2000, Ball and Greg, 2002, Berntson et al., 2003, Baumann et al., 2004). 
Retinoschisin signals in contrast are most abundant in the photoreceptor inner segments. 
Finally, immunohistochemical analyses reveal poor colocalization of Cav1.4 and retinoschisin 
in the plexiform layers. (Shi et al., 2017). Further analysis will be needed to gain deeper insight 
into possible effects of retinoschisin on L-VGCC regulation.  
1.7.5 The Retinal Na/K-ATPase 
Another proposed protein interaction partner of retinoschisin is the retinal Na/K-ATPase 
consisting of Na/K-ATPase subunits α3 and ß2. This complex was first identified by co-
immunoprecipitation of human (and bovine) retina by Molday and colleagues in 2008 (Molday 
et al., 2008). This study also showed a perfect colocalization of retinoschisin and the retinal 
Na/K-ATPase in retinal cryosections (Molday et al., 2008). Later studies at the Institute of 
Human Genetics at the University of Regensburg confirmed the importance of the Na/K-
ATPase for membrane anchorage of retinoschisin (Friedrich et al., 2011). Heterologous 
expression of ATP1A3 and ATP1B2 in Hek293 cells was sufficient to enable retinoschisin 
binding to Hek293 membranes. Western blot and immunohistochemical analyses 
demonstrated that retinoschisin no longer binds to retinal membranes in Atp1b2 deficient mice. 
In return, immunostaining of the Na/K-ATPase subunits α3 and ß2 in Rs1h-/Y retinae revealed 
retinal Na/K-ATPase localization different from that in wildtype mice, suggesting an effect of 
retinoschisin on Na/K-ATPase localization and/or stabilization in the membrane (Friedrich et 
al., 2011).  
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1.8 The Na/K-ATPase 
1.8.1 Structure of the Na/K-ATPase 
The Na/K-ATPase is a plasma membrane spanning ion pump which is ubiquitously expressed. 
The minimal functional unit of this enzyme is a heterodimeric complex composed of an α and 
a ß subunit (Figure 4).  
 
The α subunit is the catalytic subunit of the complex, responsible for ion transport as well as 
ATP cleavage (Skou et al., 1957). It is also responsible for signal transmission upon binding 
of cardiac glycosides (reviewed in Cui and Xie, 2017). The α subunit is an integral membrane 
protein of 110-130 kDa which has 10 transmembrane domains, 5 short extracellular loops, and 
4 cytosolic domains. Specific functions have been attributed to the first and second intracellular 
loops and three domains have been named accordingly: the first loop comprises the nucleotide 
(ATP) binding domain (N domain), while the second loop contains the phosphorylation domain 
(P domain) and the actuator domain (A domain) which is responsible for occlusion of cargo 
ions in the transmembrane binding sites and for dephosphorylation of the P-domain 
(Kühlbrandt, 2004) (Figure 4). 
Four different isoforms of the Na/K-ATPase α subunit have been identified and were shown to 
be expressed in a tissue specific manner. The α1 isoform is omnipresent in all tissues and the 
predominant isoform in epithelial and heart tissue. The α2 isoform is mainly expressed in heart 
and skeletal muscle, as well as in astrocytes and glial cells of the brain. The α3 isoform is most 
strongly expressed in neuronal tissue and α4 was exclusively detected in testis (summarized 
in Kaplan 2002, Cui and Xie, 2017, Clausen et al., 2017). The α1, α2, and α3 isoforms share 
about 87 % aa sequence identity while α4 is about 78 % identical to the other three α isoforms 
(Shamraj and Lingrel, 1994). Even though there are sequence differences, the overall three 
dimensional structure of all four α isozymes seems to be identical and mainly the extracellular 
surface of the protein differs between the individual isoforms (Clausen et al., 2017). However, 
Figure 4: Schematic overview of the 
Na/K-ATPase structure.   
The α subunit is shown in medium 
purple, numbers 1-10 represent the 10 
transmembrane domains; The 
actuator (A) domain is shown in 
orange, the phosphorylation (P) 
domain in blue and the nucleotide 
binding (N) domain in green. The ß 
subunit is depicted in light purple, N-
linked glycosylation of the extracellular 
domain is indicated by white 
hexagons; shown in dark purple is an 
auxiliary FXYD subunit (modified after 
Horisberger 2004). 
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there are functional differences in the catalytic activity of the isoforms, affecting substrate 
affinities, voltage dependency and pump activity (Crambert et al., 2000, Blanco, 2005).  
Within the retina, different α isoforms were attributed to different retinal cell types. In rodent 
retina, α1 was found in Müller cells, horizontal cells and to a small extent in photoreceptors, 
α2 only in some Müller cells, and α3 in photoreceptors and other neuronal cells (Wetzel et al., 
1999, Schneider and Kraig, 1990). 
The ß subunit does not have any catalytic properties, but is responsible for correct assembly, 
membrane integration and stability of the α-ß heterodimeric Na/K-ATPase complex 
(Ackermann and Geering, 1990, Geering 2001, Reinhard et al., 2013). Further, the ß subunit 
was also shown to modulate activity of the α subunit (Jaisser 1994, Horisberger and Rossier 
1992; Eakle et al. 1994; Blanco et al. 1995) and is also involved in mediating intracellular 
adhesion (e.g. Antonicek et al., 1987, Shoshani et al., 2005, Vagin et al., 2012, Tokhtaeva et 
al., 2016).  
The ß subunit consists of a short cytosolic N-terminal part, a single transmembrane domain 
and a large extracellular domain (reviewed in Kaplan 2002, Reinhard et al., 2013) (Figure 4). 
Three different isoforms of the ß subunit have been identified, which in contrast to the α 
isoforms, show only little aa sequence identity (35-47 % in humans) (Reinhard et al., 2013). A 
common feature of all three ß isoforms is post-translational modification by N-linked 
glycosylation: ß1 has three glycosylation sites, while ß2 has eight and ß3 two glycosylation 
sites, respectively (Miller and Farley, 1988, Malik et al., 1996, Tokhtaeva et al., 2010).  
Similar to the α subunits, the different ß subunits also show a tissue specific expression pattern. 
Expression of ß1 has been detected in brain, heart, and kidney, ß2 subunits are expressed 
predominantly in brain, pineal gland and retina and ß3 expression has been detected in lung, 
liver and testis (Shyjan and Levenson, 1989, Shyjan et al., 1990, Arystarkhova and Sweadner, 
1997). In rodent retina, ß1 is expressed in photoreceptors, horizontal, amacrine and ganglion 
cells, ß2 is expressed in bipolar cells, photoreceptors and Müller cells, while ß3 is restricted to 
photoreceptors (Wetzel et al., 1999, Schneider and Kraig, 1990).  
In several tissues, members of the FXYD proteins build accessory subunits of the Na/K-
ATPase. FXYD proteins are type I membrane proteins, which have a single membrane 
spanning domain (Swaender and Rael, 2000). The FXYD protein family consists of seven 
members, five of which are associated with the Na/K-ATPase complex. FXYD1 
(phospholemman), FXYD2 (γ-subunit of Na-K-ATPase), FXYD3 (Mat-8), FXYD4 (CHIF), and 
FXYD7 were shown to interact with the Na/K-ATPase via their transmembrane domain and 
are capable of regulating its function (reviewed by Geering, 2006). FXYD family members 
exhibit a distinct, tissue specific expression, but, until now, there is no data on FXYD protein 
expression in the retina. 
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1.8.2 The Na/K-ATPase as an Ionpump 
The most crucial function of the Na/K-ATPase is the maintenance of a steep gradient of Na+ 
and K+ ions across the cellular plasma membrane. This gradient is essential for many 
processes such as neuronal excitability, cellular uptake of ions, nutrients, or neurotransmitters, 
but also for regulation of cell volume and intracellular pH (reviewed by Reinhard et al., 2013). 
At the expense of one molecule of ATP, the Na/K-ATPase transports three Na+ ions out of and 
two K+ ions into the cell. For a single cell, this process may consume up to 80 % of the energy 
stored in ATP molecules. At baseline activity, Na/K-ATPases go through an average of 60-80 
phosphorylation-dephosphorylation cycles per minute (reviewed by Orlov et al., 2017). The 
Na/K-ATPase is a member of the so called P-Type ATPase family of proteins, which all share 
the presence of a phosphorylated enzyme intermediate during their reaction cycle (Pedersen 
and Carafoli, 1987). The reaction cycle of the Na/K-ATPase confers two major steps and 
enzyme conformations, E1 and E2, and is described by the Albers-Post scheme (Figure 5). 
The E1 state is also referred to as the Na+-bound state and the E2 as K+-bound state. The 
change from one state to the other is accompanied by many intermediate states and 
conformational changes. 
 
The transition of the Na/K-ATPase through its reaction cycle can be prevented by the 
application of a variety of inhibitors. The most commonly used and best studied Na/K-ATPase 
inhibitors are so called cardiotonic steroids (CTS). Low levels of endogenously produced CTS 
digoxin, ouabain and marinobufagenin have been detected in mammalian tissue and biological 
fluids (Schoner and Schreiner-Bobis, 2005, Aperia et al., 2016). For decades, the main medical 
use of CTS has been for treatment of congestive heart failure. Most frequently used CTS are 
the plant-derived digoxin, ouabain and the vertebrate-derived bufalin and marinobufagenin 
Figure 5: Schematic picture of the 
Albers-Post reaction cycle of the Na/K-
ATPase 
Per reaction cycle the Na/K-ATPase 
transports three Na+ ions (yellow circles) 
out of the cell and two K+ ions (purple 
circles) inside. During this reaction cycle 
one molecule of ATP is hydrolysed and 
the Na/K-ATPase becomes 
phosphorylated. E1: Na+-bound 
conformation, E2: K+-bound conformation, 
E1P/E2P: phosphate-bound states of 
E1/E2. 
The Na/K-ATPase specific class of 
cardiotonic steroid inhibitors (CTS, orange 
triangle) binds to the Na/K-ATPase in its 
E2P conformation and puts the reaction 
cycle to a halt at this stage. 
(Figure adapted from Orlov et al., 2017) 
Introduction 
18 
(Schoner and Schreiner-Bobis, 2007). CTS bind to the Na/K-ATPase from the extracellular 
side and enter the putative ion-exchange pathway with highest affinities for the E2P state 
(Laursen et al., 2015). By putting the pump to a halt in this position, no more Na+ ions are 
transported out of the cell and intracellular Na+ levels rise, which leads to an inhibition of the 
Na+/Ca2+ exchanger (NCX). In patients suffering from congestive heart failure, CTS treatment 
via NCX inhibition leads to raised cytoplasmic Ca2+ levels, which allows for enhanced 
contractility of the diseased cardiac muscle (reviewed in Kaplan 2002, Clausen et al., 2017).  
1.8.3 Na/K-ATPase Mediated Signaling  
There is growing evidence that the Na/K-ATPase also functions as a receptor for signal 
transduction via CTS as hormones (summarized in Aperia et al., 2016, Cui and Xie, 2017). 
First findings were made in the 1970s, when several studies showed effects of low (sub-pump-
inhibitory) nM concentrations of ouabain on gene expression, differentiation and proliferation 
(Cuff and Lichtman, 1975, Kaplan, 1978, summarized in Cui and Xie, 2017). Later studies from 
many laboratories then showed that CTS treatment could stimulate different intracellular 
signaling pathways in various cell types and by that also affect cellular processes like 
proliferation, development, or apoptosis (e.g. Huang et al., 1997, Kometiani et al., 1998, Xie et 
al., 1999, Haas et al., 2000, Haas et al., 2002, Dmitrieva and Doris, 2003, Golden and Matrin, 
2006, Ramirez-Ortega et al., 2006, Kulikov et al., 2007, Wang et al. 2015). Until today, there 
is experimental evidence that CTS can trigger the activation of the mitogen activated protein 
kinase (MAPK) signaling pathway, the phosphoinositide 3-kinase/ Protein kinase B (PI3K/AKT) 
pathway as well as Ca2+ dependent signaling cascades (reviewed in Aperia et al., 2016, Cui 
and Xie, 2017, Orlov et al., 2017).  
The extracellular signal-regulated (ERK) pathway, one of the four MAPK pathways (Lewis et 
al., 1998, Chang and Karin, 2001), was the first Na/K-ATPase activated signaling pathway to 
be discovered by Kometiani and colleagues (Kometiani et al., 1998). Upon binding of CTS, 
various cell types show a strong activation of intracellular ERK signaling. The non-receptor 
tyrosine kinase SRC is widely accepted to be involved in activation of MAPK signaling through 
the Na/K-ATPase. However, the exact mechanism of how SRC is implicated in this pathway is 
discussed controversially (Haas et al., 2000, Haas et al., 2002, Tian et al., 2005, Weigand et 
al., 2012, Gable et al., 2014, Yosef et al., 2016). Despite the discrepancies on the mechanism 
of SRC activation by the Na/K-ATPase, SRC is thought to act as the initial, Na/K-ATPase 
associated signal transmitter which gets activated upon CTS binding to the Na/K-ATPase. 
Activated SRC stimulates the endothelial growth factor receptor (EGFR), which then signals 
on towards the MAPK cascade through RAS and RAF (Figure 6).  
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The PI3K/AKT pathway has also been shown to be activated by CTS-bound Na/K-ATPases, 
in a manner independent of SRC kinase activation (Liu et al., 2007). It was described to be 
induced by a physical interaction of the p85 subunit of phosphatidyl inositol 3 kinase (PI3K) 
with the Na/K-ATPase α subunit, which then causes AKT activation (Liu et al., 2007, Wu et al., 
2013) (Figure 6).  
The third signaling cascade activated upon CTS binding to the Na/K-ATPase is Ca2+ dependent 
signaling. Two different mechanisms were suggested to be responsible for Ca2+ pathway 
activation via the Na/K-ATPase. Several studies described a direct interaction of the Na/K-
ATPase α subunit with the inositol trisphosphate receptor (IP3R). Upon CTS binding to the 
Na/K-ATPase structural alterations of the Na/K-ATPase α subunit are suggested to act on the 
IP3R and induce Ca2+ oscillations from the ER, leading to variable Ca2+ dependent cellular 
responses (Aizman et al., 2001, Miakawa-Naito et al., 2003, Yuan et al., 2005) (Figure 6). An 
involvement of Phospholipase C (PLC) in the Na/K-ATPase-IP3R interaction is under 
discussion (Yuan et al., 2005). Other studies report on an involvement of the NCX in the 
induction of Ca2+ signaling. Activation of the NCX by CTS was originally thought to arise from 
elevation of intracellular Na+ upon CTS dependent inhibition of the Na/K-ATPase (Langer 
1972, Blaustein et al., 1998). However, more recent studies provide evidence of a direct 
interaction between NCX and the Na/K-ATPase, leading to the formation of specific Ca2+ 
signaling microdomains (Song et al., 2006, reviewed in Tian and Xie, 2008).  
 
Figure 6: Schematic overview of Na/K-ATPase associated signaling cascades 
CTS-bound Na/K-ATPases are implicated in the induction of three different signaling pathways. The MAPK pathway 
was described to be activated via SRC and the EGFR, the AKT pathway via PI3K, and Ca2+ dependent signaling 
can be activated via the IP3R, which can modify Ca2+ oscillations from the endoplasmatic/sarcoplasmatic reticulum 
(ER/SR) or may also be induced by the NCX (Figure modified after a figure kindly provided by Dr. Ulrike Friedrich, 
Institute of Human Genetics, University of Regensburg).  
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It is important to notice that most studies mentioned above were conducted with α1 subunit 
containing Na/K-ATPases. Until now, there is very little data on signaling properties of the other 
three α subunits. The α2 subunit was shown to be able to restore ion pumping but not α1 
signaling function in a α1 knock out cell line (Xie et al., 2015), which rises the question whether 
α2 is capable of functioning as a signal transmitter. In contrast, the α3 subunit was shown to 
activate the MAPK cascade upon CTS treatment, but notably, in a mechanism independent of 
SRC activation (Madan et al., 2017). CTS treatment was also demonstrated to activate ERK 
signaling in an α4 expressing murine spermatogenic cell line, but no data on the mechanism 
were provided in this study (Upmanyu et al., 2016).  
1.8.4 Na/K-ATPases in Intracellular Adhesion 
In addition to its ion transport and signaling functions, the Na/K-ATPase further acts as a 
mediator of intracellular adhesion. Transdimerization of the ß1 subunit was shown to tether 
two cells together (Shoshani et al. 2005, Cereijido et al., 2012, Vagin et al., 2012, Tokhtaeva 
et al. 2016). The ß2 subunits mediates heterotypic adhesions between astrocytes and 
neighbouring neurons (Antonicek et al., 1987, Antonicek and Schachner, 1988, Gloor et al., 
1990, Vagin et al., 2012). The mechanism underlying intracellular adhesion mediated by the 
ß2 subunit has not been resolved, yet. Transdimerization of two ß2 subunits was not consistent 
with experimental data and other factors or proteins are believed to be involved in the ß2 
mediated intercellular interaction. 
1.9 Aim of this Study  
Despite substantial research efforts in the last 20 years, the consequences of retinoschisin 
deficiency and thus the initial pathomechanisms of XLRS are still not fully understood. 
Nevertheless, it has been shown that the Na/K-ATPase is an essential interaction partner of 
retinoschisin in retinal membranes (Molday 2007, Friedrich 2011). The present study focused 
on functional consequences and the molecular interface of this interaction. 
A first project investigated an effect of retinoschisin on Na/K-ATPase levels in retinal model 
systems. In addition, an effect of retinoschisin on two functions of the Na/K-ATPase, namely 
ion transport and intracellular signal transduction, was assessed. Furthermore, the influence 
of retinoschisin on several cellular processes (cell volume, proliferation, viability, and 
apoptosis) associated with XLRS was investigated. Finally, it was sought to identify the 
interaction site between the Na/K-ATPase and retinoschisin.  
Results of these investigations are suited to provide insight into the basic molecular 
pathomechanisms of XLRS, and should help to obtain a deeper understanding to initiate 
innovative targeted therapeutic approaches for this currently untreatable disease.  
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2 Material  
2.1 Mouse Strains 
Table 1: Mouse strains used  
Mouse Strains Source    
Rs1tm1Web (Rs1h-/y) 
Bernhard HF Weber, Institute of Human Genetics, 
University of Regensburg, Germany  
C75BL/6 The Jackson Laboratory, Bar Harbor, Maine, USA 
 
2.2 Escherichia coli (E.coli) Strains 
Table 2: E. coli strain used  
Strain Source     
E. coli strain DH5α Life Technologies, Carlsbad, CA, USA 
2.3 Eukaryotic Cell Lines 
Table 3: Names and tissues of origin of cell lines used  
Cell Line Organism Tissue of Origin Source 
Hek293 Homo sapiens Embryonic kidney 
ATCC;LGC Standards GmbH, 
Wesel, Germany 
Hek293 
+RS1 
Homo sapiens 
Embryonic kidney, cell line 
stably transfected with an 
RS1 expression vector   
Institute of Human Genetics, 
University of Regensburg, 
Germany 
Y-79 Homo sapiens Retinoblastoma  
ATCC;LGC Standards GmbH, 
Wesel, Germany 
2.4 Oligonucleotides for PCR and Sequencing Reactions  
Table 4: Names, sequences and purposes of oligonucleotides used for cloning of retinoschisin (RS1) and 
Na/K-ATPase expression constructs 
Name 5‘-3‘ Sequence Purpose 
RS1-HindII-F 
AAG CTT TTC ATG TCA CGC AAG 
ATA GAA GGC TTT TTG 
Expression cloning of RS1 
RS1-XhoI-R 
CTC GAG TCA GGC ACA CTT GCT 
GAC GCA CTC 
RS1-EcoRI-F 
GAA TTC ATG TCA CGC AAG ATA 
GAA GGC TTT TTG 
Cloning of Myc-tagged RS1 
variants 
 
RS1-n-termMyc-R 
TGA TCA ATT TCT GCT CCG ATA ATC 
CCA ATG TGG CTT CAT AGC CAA AGA 
GA 
RS1-ntermMyc-F 
TGA TCA GTG AGG AAG ATC TGT CTA 
CCG AGG ATG AAG GCG AGG ACC 
CCT 
RS1-C59S-mut-F 
CCA CCT CCT TGG ACA GTA TAC CAG 
AAT GCC Site directed mutagenesis of 
RS1 RS1-C59S-mut-R 
GGC ATT CTG GTA TAC TGT CCA 
AGG AGG TGG 
hATP1A2_NotI-F 
GCG GCC GCA TGG GCC GTG GGG 
CTG GCC GTG AG 
Expression cloning ATP1A2 
Material 
22 
hATP1A2_BamHI-R 
GGA TCC TCA GTA GTA TGT CTC 
CTT CTC CAC 
hATP1B3-KpnI-F 
GGT ACC ATG ACG AAG AAC GAG 
AAG AAG TCC 
Expression cloning ATP1B3 
hATP1B3-XhoI-R 
CTC GAG CTA TGC ACG TGC TGT 
GAT TTT GAA 
 
Table 5: Names, sequences and purposes of oligonucleotides used for generation of ATP1B2 chimeric 
constructs 
Name 5‘-3‘ Sequence Purpose 
MscI-hATP1B1_OD_F 
TGG CCA ACC ATC AGT GAA TTT 
AAG CCC AC Expression cloning of 
ATP1B1 OD hATP1B1-XhoI-R 
CTC GAG TCA GCT CTT AAC TTC AAT 
TTT T 
hATP1B1-KpnI-F 
GGT ACC ATG GCC CGC GGG AAA 
GCC AAGG Expression cloning of 
ATP1B2 OD MscI-hATP1B1_ID_R 
TGG CCAG GGC CAC TCG GTC CTG 
ATA TGT GGG 
hATP1B2_I163L_Q5_F 
CCG GCC TTG GGG ACT CCA CCC 
ACT ATG G 
Site directed mutagenesis of 
ATP1B2 (I163L, Patch I 
Region 1) hATP1B2_I163L_Q5_R 
AGC AGT TGC CCA GCT GGG TCC 
GGT TGA A 
hATP1B2_T119QA201T
_Q5_F 
TGT ACT GGG AAG CGA GAT GAA 
GAT GCTG Site directed mutagenesis of 
ATP1B2 (K247QL249T, 
Patch I Region 2) 
hATP1B2_T119QA201T
_Q5_R 
TTG AAC ATT CAT GCT CTG GTT TGC 
TCC T 
hATP1B2_K247QL249T
_Q5_F 
TTC ACG AAT GTG ACC CCC AAC 
GTG GAG Site directed mutagenesis of 
ATP1B2 (T119QA201T, 
Patch I Region 3) 
hATP1B2_K247QL249T
_Q5_R 
CTG CACAGC CAC CAG GGG CTG 
TGT GTAG 
hATP1B2-Mut214-221-F 
AGT ACT TCG GCC TGG GCA ACA 
GCC CCA ACA TCG ACC TCA TGT 
ACT TCC CCT ACT AT 
Insertion of ATP1B1 
Fragment into ATP1B2 
(Amplification of C-terminal 
part, Patch I Region 4) hATP1B2_XhoI_R 
CTC GAG GGT TTT GTT GAT GCG 
GAG TTT GA 
ATP1B2-Mut214-221-R 
AGT ACT CCA CGT TGC CGA GAT 
TCT CAG CAT CTT CAT CT 
Insertion of ATP1B1 
Fragment into 
ATP1B2(Amplification of N-
terminal part, Patch I Region 
4) 
B2_KpnI_F 
CCC GGT ACC ATG GTC ATC CAG 
AAA GAG AAG 
Region I Docking Patch 
II_F 
CCTCAGATCGAGAACCTTGATGTCAT
TGTCAATGTCAGTG Site directed mutagenesis of 
ATP1B2 (Patch II Region 1) Region I Docking Patch 
II_R 
AATCTGTGTCAAGCCCGGTGTGGCC
AG 
hATP1B2_PatchII_Reg2
_1F 
AGT TAG GTT CTT GGA GCC TTA 
CAA CG 
Site directed mutagenesis of 
ATP1B2 (Step 1 of 3 
subsequent mutagenesis 
reactions, Patch II Region 2) 
hATP1B2_PatchII_Reg2
_1R 
ATGTTC AGA ACA TGC TGG TCC 
CAG CT 
hATP1B2_PatchII_Reg2
_2F 
CAA AGA CTC TAT CCA AGC CCA 
AAA G 
Site directed mutagenesis of 
ATP1B2 (Step 2 of 3 
subsequent mutagenesis 
reactions, Patch II Region 2) 
hATP1B2_PatchII_Reg2
_2R 
CAA AGA CTC TGC CCA AGC CCA 
AAA G 
hATP1B2_PatchII_Reg2
_3F 
CAA AGA CTC TGC CCA AGC CCA 
AAA G 
Site directed mutagenesis of 
ATP1B2 (Step 3 of 3 
subsequent mutagenesis 
reactions, Patch II Region 2) 
hATP1B2_PatchII_Reg2
_3R 
TAC TTC TCC AAGAAC CTA AC 
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Region 3 Docking Patch 
II_F 
AAC CGA GTC ATC AAC TTC TAT 
GCA G Site directed mutagenesis of 
ATP1B2 (Patch II Region 3 ) Region 3 Docking Patch 
II_R 
GAG CTT GAT GAA GAC ACA GGG 
CTG 
Region 4 Docking Patch 
II_F 
CGT GAA CTA CCT GCA GCC CCT GG 
Site directed mutagenesis of 
ATP1B2 (Patch II Region 4 ) Region 4 Docking Patch 
II_R 
TGG AAC TTT TTG CCA TAG 
 
Table 6: Names, sequences and purposes of oligonucleotides used for confirmation of positive clones and 
Sanger sequencing  
Name 5‘-3‘ Sequence Purpose 
pTLN1_fwd GAA TAC AAG CTT GCT TGT TCT 
Vector primer for pTLN1 
pTLN1_rev CGA ATC TCTGAG GTA AGC CC 
M13F 
CGC CAG GGT TTT CCC AGT CAC 
GAC 
Vector primer for pGem®-T 
M13R 
AGC GGA TAA CAA TTT CAC ACA 
GGA 
T7_F TAA TAC GAC TCA CTA TAG GG 
Vector primer for pCDNA3.1 
BGH_R TAG AAG GCA CAG TCG AGG 
pCEP fwd GGA CTT TCC AAA ATG TCG TAA TAA 
Vector primer for pCEP4 
pCEP rev 
CAA ATA AAG CAA TAG CAT CAC 
AAA T 
hATP1A3Seq1F ATG GGG GAC AAG AAA GAT GA 
Sequencing of ATP1A3 
 
hATP1A3Seq2F CCC AGA GTG GGT CAA GTT TT 
hATP1A3Seq3F GTG GAG ATC AAG GGT GGA GA 
hATP1A3Seq4F GCA CTT CAT CCA GCT CAT CA 
hATP1A3Seq5F GAC AGG GAC CCT CAC TCA GA 
hATP1A3Seq6F TAC CAG CTC TCC ATC CAT GA 
hATP1A3Seq7F CCT TCGACT GTG ATG ACG TG 
hATP1A3Seq8F AGC AAATCG ACG AGATCC TG 
hATP1A3Seq9F CCT ACA CCC TGA CCA GCA AT 
hATP1A3Seq10F TTG GAA TGA TCC AGG CTC TC 
hATP1A3Seq1R ATG CCA GGT ACA GGT TGTC 
hATP1A3Seq2R GTC AGG GAG GAG TTG TCC A 
hATP1A3Seq3R GGA AGA TGA CAG CCT CAA GC 
hATP1A3Seq4R CAG GTG TGC GAA CTC TTG TC 
hATP1A3Seq5R ACC AGC AGG TAT CGG TTG TC 
hATP1A3Seq6R GGT GAC CAT GAT GAC CTT GA 
hATP1A3Seq7R CCA CAA TGA TGA GCT TCT GC 
hATP1A3Seq8R CAT GAT GAA CAG CAG GAA GG 
hATP1A3Seq9R ACT GCT GCC CGT AAC TGT CT 
hATP1A3Seq10R TCA GTA GTA GGT TTC CTT CTC CA 
hATP1B2Seq1F ATG GTC ATC CAG AAA GAG AAG AA 
Sequencing of ATP1B2 
hATP1B2Seq2F CCC CAA GAC TGAGAA CCT TG 
hATP1B2Seq3F TCC ACC CAC TAT GGT TAC AGC 
hATP1B2Seq1R TTT GGG CTT GGA TA GAG TCG 
hATP1B2Seq2R ATG ACG AAG TTG CCG AGA TT 
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hATP1B2Seq3R TCA GGT TTT GTT GAT GCG GAGT 
hRS1-ex4-5-F AGT CAA GGC TTT GGG TGT GCC TG 
Sequencing of RS1 
hRS1-ex6-R TGG CAA TGC GGA CGT GCC AG 
RT-hRS1_F TGG TAC CAA AAA GCA TGC AA 
RT-hRS1_R CAC CCA AAG CCT TGA CTG TT 
hATP1A1/2_Seq1_F CCT CAG CAA GCC CTT GTG AT 
Sequencing of ATP1A1 and 
ATP1A2 
hATP1A1/2_Seq1_R GTC ATC TTC CTC ATC GGA TC 
hATp1A1/2_Seq2_F TGG TGA TGA AGG GGC CCC A 
hATp1A1/2_Seq2_R TGG GGC CCC TTC ATC ACC A 
hATp1A1/2_Seq3_F CTG GAT GAC AAC TTT GCC TC 
 
All oligonucleotides were purchased from Metabion, Planegg, Germany.  
2.5 Oligonucleotides and Corresponding Probes Used for qRT-PCR  
Table 7: Name, sequence and corresponding probe numbers for oligonucleotides used for qRT-PCR 
Name 5'-3' Sequence  Gene 
Roche Universal 
Probe Library #  
hEGR1-qRT-F AGC CCT ACG AGC ACC TGA C 
EGR1 22 
hEGR1-qRT-R GGT TTG GCT GGG GTA ACT G 
hMYC-qRT-F GCT GCT TAG ACG CTG GAT TT 
MYC 66 
hMYC-qRT-R TAA CGT TGA GGG GCA TCG 
hBAX-qRT-F ATG TTT TCT GAC GGC AAC TTC 
BAX 57 
hBAX-qRT-R ATC AGT TCC GGC ACC TTG 
hHPRT-qRT-F TGA CCT TGA TTT ATT TTG CAT ACC 
HPRT 73 
hHPRT-qRT-R CGA GCA AGA CGT TCA GTC CT 
mEGR1-qRT-F CCT ATG AGC ACC TGA CCA CA 
Egr1 22 
mEGR1-qRT-R TCG TTT GGC TGG GAT AAC TC 
mMYC-qRT-F CCT AGT GCT GCA TGA GGA GA 
Myc 77 
mMYC-qRT-R TCC ACA GAC ACC ACA TCA ATT 
mBAX-qRT-F GTG AGC GGC TGC TTG TCT 
Bax 83 
mBAX-qRT-R GGT CCC GAA GTA GGA GAG GA 
mHPRT-qRT-F TGA CAC TGG TAA AAC AAT GCA 
Hprt 95 
mHPRT-qRT-R TCC TTT TCA CCA GCA AGC TTG 
 
All oligonucleotides were purchased from Metabion, Planegg, Germany and all probes from 
Roche, Basel, Switzerland.  
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2.6 Plasmids and Expression Constructs 
Table 8: List of expression constructs, application and source 
Vector Name Application Source 
pCEP_RS1 Expression of RS1  
Institute of Human 
Genetics, University of 
Regensburg 
pCEP_RS1_C59S 
Expression of 
RS1_C59S 
Institute of Human 
Genetics, University of 
Regensburg 
pCDNA3_RS1_Myc 
Expression of Myc-
tagged RS1 
Generated during this 
project 
pCDNA3_RS1_C59S_Myc 
Expression of Myc-
tagged RS1_C59S 
Generated during this 
project 
pCEP_ATP1A3_ATP1B2 
Bicistronic expression of 
ATP1A3 and ATP1B2  
Institute of Human 
Genetics, University of 
Regensburg 
pCEP_ATP1A1 Expression of ATP1A1 
Generated during this 
project 
pCEP_ATP1A2 Expression of ATP1A2 
Institute of Human 
Genetics, University of 
Regensburg 
pCEP_ATP1A3 Expression of ATP1A3 
Generated during this 
project 
pCEP_ATP1A3_RD 
Expression of ATP1A3 
(ouabain insensitive)  
Generated during this 
project 
pCEP_ATP1B1 Expression of ATP1B1 
Institute of Human 
Genetics, University of 
Regensburg 
pCEP_ATP1B2 Expression of ATP1B2 
Institute of Human 
Genetics, University of 
Regensburg 
pCEP_ATP1B3 Expression of ATP1B3  
Generated during this 
project 
pCEP_ATP1B2_OD 
Expression of ATP1B2 
Outer Domain fused to 
ATP1B1 Inner Domain 
Institute of Human 
Genetics, University of 
Regensburg 
pCEP_ATP1B1_OD 
Expression of ATP1B1 
Outer Domain fused to 
ATP1B2 Inner Domain 
Institute of Human 
Genetics, University of 
Regensburg 
pCEP_ATP1B2_I163L 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 1 
Generated during this 
project 
pCEP_ATP1B2_T199Q_A201T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 2 
Generated during this 
project 
pCEP_ATP1B2_K247Q_L249T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 3 
Generated during this 
project 
pCEP_ATP1B2_227-237_ATP1B1 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 4 
Generated during this 
project 
pCEP_ATP1B2_MIRPKT_83-
88_TQIPQI 
Expression of ATP1B2 
Docking Patch mutant 
Patch II Region 1 
Generated during this 
project 
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pCEP_ATP1B2_QKLNKFLEPYNDSI 
108-121_LNIVRFLEKYKDSA 
Expression of ATP1B2 
Docking Patch mutant 
Patch II Region 2 
Generated during this 
project 
pCEP_ATP1B2_KMNR181-184_KLNR 
Expression of ATP1B2 
Docking Patch mutant 
Patch II Region 3 
Generated during this 
project 
pCEP_ATP1B2_T240L 
Expression of ATP1B2 
Docking Patch mutant 
Patch II Region 4 
Generated during this 
project 
pCEP_ATP1B2_227-
237_ATP1B1+I163L+T199Q_A201T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 1+2+4 
Generated during this 
project 
pCEP_ATP1B2_227-
237_ATP1B1+I163L+K247Q_L249T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 1+3+4 
Generated during this 
project 
pCEP_ATP1B2_227-237_ATP1B1 
+T199Q_A201T+K247Q_L249T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 2+3+4 
Generated during this 
project 
pCEP_ATP1B2_I163L+ 
T199Q_A201T+ K247Q_L249T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 1+2+3 
Generated during this 
project 
pCEP_ATP1B2_227-
237_ATP1B1+I163L 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 1+4 
Generated during this 
project 
pCEP_ATP1B2_227-
237_ATP1B1+T199Q_A201T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 2+4 
Generated during this 
project 
pCEP_ATP1B2_227-237_ATP1B1+ 
K247Q_L249T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 3+4 
Generated during this 
project 
pCEP_ATP1B2_227-
237_ATP1B1+I163L+ T199Q_A201T+ 
K247Q_L249T 
Expression of ATP1B2 
Docking Patch mutant 
Patch I Region 1+2+3+4 
Generated during this 
project 
pCEP_ATP1B2_MIRPKT_83-
88_TQIPQI+ KMNR_181-184_KLNR 
Expression of ATP1B2 
Docking Patch mutant 
Patch II Region 1+3 
Generated during this 
project 
pTLN1_ATP1B2 
ATP1B2 cRNA 
synthesis for X. leavis 
oocyte injection 
Generated during this 
project 
pTLN1_ATP1A3_RD 
ATP1A3 (ouabain 
resistant) cRNA 
synthesis for X. leavis 
oocyte injection 
Dr. Jan B. Koenderink, 
Department of 
Pharmacology and 
Toxicology, Nijmegen 
University, Netherlands 
pCEP4 Expression vector 
Themo Fisher Scientific, 
Waltham, MA, USA 
pTLN1 
Expression vector for X. 
leavis cDNA synthesis 
Prof. Karl Kunzelmann, 
Insitute for Physiology, 
University of 
Regensburg, Germany  
pGEM®-T Cloning 
Promega Corporation, 
Madison, WI, USA 
pCDNA3.1 Expression vector 
Themo Fisher Scientific, 
Waltham, MA, USA 
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2.7 Primary Antibodies 
Table 9: Specifications on primary antibodies used  
Antibody Type Species Dilution Application  Source  
RS1 mAB mouse 
1:10000/
1:1000 
WB/ 
IHC 
Professor Dr. Robert S. Molday, 
Department of Ophthalmology 
and Visual Sciences, University of 
British Columbia, Canada  
RS1 pAB rabbit 
1:10000/
1:1000 
WB/ 
IHC 
Professor Dr. Robert S. Molday, 
Department of Ophthalmology 
and Visual Sciences, University of 
British Columbia, Canada  
ß-Actin 
(#A2228) 
mAB mouse 1:10000 WB 
Sigma-Aldrich, St. Louis, MO, 
USA 
Myc-Tag 
(9B11) 
(#2276) 
mAB mouse 1:1000 WB 
Cell Signaling Technologies, 
Danvers, MA, USA  
p-ERK 
(#4370) 
pAB rabbit 1:1000 WB 
Cell Signaling Technologies, 
Danvers, MA, USA 
ERK 
(#M5670) 
pAB rabbit 1:1000 WB 
Sigma-Aldrich, St. Louis, MO, 
USA 
p-Raf  
(#9427) 
pAB rabbit 1:1000 WB 
Cell Signaling Technologies, 
Danvers, MA, USA 
Raf  
(#9422) 
pAB rabbit 1:1000 WB 
Cell Signaling Technologies, 
Danvers, MA, USA 
p-AKT 
(#4060) 
pAB rabbit 1:1000 WB 
Cell Signaling Technologies, 
Danvers, MA, USA 
AKT  
(#4691) 
pAB rabbit 1:1000 WB 
Cell Signaling Technologies, 
Danvers, MA, USA 
p-CAMKII 
(#PA1-26727) 
pAB rabbit 1:1000 WB 
Thermo Fisher Scientific, 
Waltham, MA, USA 
CAMKII 
(#PA5-
14033) 
pAB rabbit 1:1000 WB 
Thermo Fisher Scientific, 
Waltham, MA, USA 
p-SRC 
(#6943) 
pAB rabbit 1:1000 WB 
Cell Signaling Technologies, 
Danvers, MA, USA 
SRC  
(#2123) 
pAB rabbit 
1:1000/ 
1:250 
WB/ 
IHC 
Cell Signaling Technologies, 
Danvers, MA, USA 
Pan-Cadherin 
(#ab6528) 
mAB mouse 1:1000 WB Abcam, Cambridge, UK 
IP3R  
(#8568) 
pAB rabbit 1:250 IHC 
Cell Signaling Technologies, 
Danvers, MA, USA 
pLCγ1 
(#5690) 
pAB rabbit 1:100 IHC 
Cell Signaling Technologies, 
Danvers, MA, USA 
Caveolin 
(#3267) 
pAB rabbit 1:800 IHC 
Cell Signaling Technologies, 
Danvers, MA, USA 
ATP1A1 
(#55187-1-AP) 
pAB rabbit 1:1000 WB Proteintech, Rosemont, IL, USA 
ATP1A2 
(#16836-1-AP) 
pAB rabbit 1:1000 WB Proteintech, Rosemont, IL, USA 
ATP1A3 
(#MA3-915) 
mAB mouse 
1:0000/ 
1:500 
WB/ 
IHC 
Thermo Fisher Scientific, 
Waltham, MA, USA 
ATP1A3 
(# ab2826) 
mAB Mouse 1:1000 
WB 
(used in 
Figure 32) 
Abcam, Cambridge, UK 
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ATP1B1 
(#15192-1-AP) 
pAB rabbit 
1:1000/ 
1:50 
WB/ 
FACS 
Proteintech, Rosemont, IL, USA 
ATP1B2 
(#PA5-26279) 
pAB rabbit 
1:1000/ 
1:250/ 
1:50 
WB/ 
IHC/ 
FACS 
Thermo Fisher Scientific, 
Waltham, MA, USA 
ATP1B3  
(MAB1723) 
pAB mouse 
1:1000/ 
1:50 
WB/ 
FACS 
Abnova, Taipeh, Tawain 
Rho 1D4  mAB mouse  1:1000 IHC  
Professor Dr. Robert S. Molday, 
Department of Ophthalmology 
and Visual Sciences, University of 
British Columbia, Canada  
 
pAB: polyclonal antibody, mAB: monoclonal antibody, WB: Western blot, IHC immunohistochemistry; FACS: 
fluorescence activated cell sorting; indicated in brackets (#) are manufacturer’s product identification numbers 
where available 
2.8 Secondary Antibodies 
Table 10: Specifications on primary antibodies  
Antibody Dilution Application Source  
Goat Anti-Mouse IgG, 
Peroxidase Conjugated 
1:10000  
WB (Calbiochem) Merck Chemicals GmbH, 
Schwalbach, Germany  
Goat Anti-Rabbit IgG,  
Peroxidase Conjugated 
1:10000  
WB (Calbiochem) Merck Chemicals GmbH, 
Schwalbach, Germany  
Goat Anti-Mouse IgG, 
Alexa Fluor ® 488 
1:1000 
IHC/FACS Life Technologies, Carlsbad, CA, USA 
 
Goat Anti-Mouse IgG, 
Alexa Fluor ® 549 
1:1000 
IHC Life Technologies, Carlsbad, CA, USA 
 
Goat Anti-Rabbit IgG, 
Alexa Fluor ® 488 
1:1000 
IHC/FACS Life Technologies, Carlsbad, CA, USA 
 
Goat Anti-Rabbit IgG, 
Alexa Fluor ® 549 
1:1000 
IHC  Life Technologies, Carlsbad, CA, USA 
 
 
WB: Western blot, IHC: immunohistochemistry; FACS: fluorescence activated cell sorting 
2.9 Molecular Weight Standards 
Table 11: List of molecular weight standards  
Standard Purpose Source 
GeneRuler™ DNA 
Ladder Mix 
Size standard for agarose gel 
electrophoresis of DNA fragments 
Thermo Fisher Scientific, 
Waltham, MA, USA 
PageRuler™ Prestained 
Protein Ladder 
Molecular weight standard for 
protein analysis via SDS PAGE  
Thermo Fisher Scientific, 
Waltham, MA, USA 
Color-coded Prestained 
Protein Marker, High 
Range (43-315 kDa) 
Molecular weight standard for 
protein analysis via non-reducing 
SDS PAGE 
Cell Signaling 
Technologies, Danvers, 
MA, USA 
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2.10 Enzymes 
Table 12: Enzymes used 
Enzyme Source 
BamHI-HF New England Biolabs, Ipswich, MA, USA 
GoTaq® DNA Polymerase Promega Corporation, Madison, WI, USA 
HindIII  New England Biolabs, Ipswich, MA, USA 
KpnI-HF New England Biolabs, Ipswich, MA, USA 
NcoI  New England Biolabs, Ipswich, MA, USA 
NotI-HF New England Biolabs, Ipswich, MA, USA 
Pfu DNA Polymerase  Life Technologies, Carlsbad, CA, USA 
PfuUltra II Fusion HotStart DNA 
Polymerase 
Agilent Technologies, Santa Klara, CA, USA  
RevertAid™ Reverse Transcriptase 
(Fermentas) Thermo Fisher Scientific, Waltham, 
MA, USA 
T4 DNA Ligase New England Biolabs, Ipswich, MA, USA 
XhoI-HF New England Biolabs, Ipswich, MA, USA 
House Taq DNA Polymerase 
Institute of Human Genetics, University of 
Regensburg, Germany 
2.11 Kit Systems  
Table 13: List of kit systems used  
Kit Source 
BigDye Terminator v1.1, v3.1 Cycle 
Sequencing Kit 
Life Technologies, Carlsbad, CA, USA 
Clarity Max™ Western Blotting Substrate Bio-Rad Laboratories GmbH, Munich, Germany 
Clarity ™ Western Blotting Substrate  Bio-Rad Laboratories GmbH, Munich, Germany  
DC™ Protein Assay  Bio-Rad Laboratories GmbH, Munich, Germany 
EnzChek™ Caspase-3 Assay Kit #2 Thermo Fisher Scientific, Waltham, MA, USA 
GoTaq® Long Expand PCR Master Mix Promega Corporation, Madison, WI, USA 
mMESSAGE mMACHINE™ SP6 
Transcription Kit 
Thermo Fisher Scientific, Waltham, MA, USA 
NucleoBond® XtraMidi 
MACHEREY-NAGEL GmbH & Co. KG, Düren, 
Germany 
NucleoSpin® Gel and PCR Clean-up 
MACHEREY-NAGEL GmbH & Co. KG, Düren, 
Germany 
NucleoSpin® Plasmid 
MACHEREY-NAGEL GmbH & Co. KG, Düren, 
Germany 
pGEM®-T Vector  Promega Corporation, Madison, WI, USA 
Pierce™ Anti-c-Myc Agarose Thermo Fisher Scientific, Waltham, MA, USA 
Pierce™ Cell Surface Protein Isolation Kit Thermo Fisher Scientific, Waltham, MA, USA 
PureLink™ RNA Micro Kit Invitrogen, Carlsbad, CA, USA  
Q5®Site-Directed Mutagenesis Kit New England Biolabs, Ipswich, MA, USA 
RevertAid™ H Minus First Strand cDNA 
Synthesis Kit 
Thermo Fisher Scientific, Waltham, MA, USA 
RNeasy Micro Kit QIAGEN, Venlo, Netherlands 
TransIT® -LTI Transfectionreagent Mirus Bio LLC, Madison, WI, USA 
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2.12 Chemicals and Ready Made Solutions 
Table 14: List of chemicals used  
Chemical/Reagent Source  
2-(4-(2-Hydroxyethyl)-1-piperazinyl)-
ethansulfonicacid, C8H18N2O4S (HEPES) 
Merck Chemicals GmbH, Schwalbach, 
Germany 
25 % Glutaraldhyde Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) 
Sigma-Aldrich, St. Louis, MO, USA 
37 % Formaldehyde Merck Chemicals GmbH, Schwalbach, 
Germany 
4',6-Diamidin-2-phenylindol (DAPI)  Life Technologies, Carlsbad, CA, USA  
5-Bromo-4-chloro-3-indolyl β-D-
galactopyranoside, C14H15BrClNO6 (X-Gal) 
AppliChem GmbH, Darmstadt, Germany 
Acetic acid (100%), C2H4O2 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Adenosinetriphosphate potassium salt  Sigma-Aldrich, St. Louis, MO, USA 
Adenosinetriphosphate sodium salt  Sigma-Aldrich, St. Louis, MO, USA 
Agarose (Biozym LE) 
Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
Alexa Fluor ™488-conjugated peanut 
agglutinin 
Thermo Fisher Scientific, Waltham, MA, USA 
Ammoniumperoxodisulfat, (NH4)2S2O8 
(APS) 
AppliChem GmbH, Darmstadt, Germany 
Ampicillin sodium salt, C16H18N3NaO4S 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Bacto Agar BD Bioscience, Heidelberg, Germany 
Bacto Yeast Extract  BD Bioscience, Heidelberg, Germany  
Boric acid H3BO3 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Bovine Serum Albumin (BSA)  New England Biolabs, Ipswich, MA, USA  
Bromphenolblue sodium salt, 
C19H9Br4O5SNa 
Sigma-Aldrich, St. Louis, MO, USA 
Calcium chloride, CaCl2  
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Chloroquine, C18H26ClN3 
Merck Chemicals GmbH, Schwalbach, 
Germany  
Citric acid, C6H8O7 Merck Chemicals GmbH, Schwalbach, 
Germany  
Coomassie Brilliant Blue R-250, (sodium 
salt) C45H44N3NaO7S2  
VWR International Germany GmbH, 
Darmstadt, Germany 
Dako Fluorescence Mounting Medium Agilent, Santa Clara, CA, USA 
Dimethylformamid, C3H7NO Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Dimethylsulfoxid, C2H6OS (DMSO) AppliChem GmbH, Darmstadt, Germany 
dNTPs (dATP, dGTP, dCTP, dTTP) Genaxxon Bioscience, Ulm, Germany 
Ethanol ≥99,8 p.a, C2H6O 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Ethidiumbromide, C21H20BrN3 in H2O AppliChem GmbH, Darmstadt, Germany  
Ethylendiamintetraacetat disodium 
dihydrate salt C10H14N2Na2O8•2H2O (EDTA) 
Merck Chemicals GmbH, Schwalbach, 
Germany  
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Galactose, C6H12O6  
Merck Chemicals GmbH, Schwalbach, 
Germany 
Glucose, C6H12O6 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Glycerol 87%, C3H8O3 University of Regensburg, Chemical Supplies  
Glycine, C2H5NO2 
Merck Chemicals GmbH, Schwalbach, 
Germany 
HiDi™ Formamide, CH3NO Thermo Fisher Scientific, Waltham, MA, USA 
Hydrochloric acid 1M, HCl  
Merck Chemicals GmbH, Schwalbach, 
Germany 
Hydrochloric acid fuming 37%, HCl   
Merck Chemicals GmbH, Schwalbach, 
Germany 
Isopropaonol, C3H8O 
Merck Chemicals GmbH, Schwalbach, 
Germany  
Isopropyl β-D-1-thiogalactopyranoside, 
C9H18O5S (IPTG) 
AppliChem GmbH, Darmstadt, Germany  
Magnesiumsulfate heptahydrate, 
MgSO4•7H2O 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Malachit Green, C46H50N4•2HC2O4•C2H2O4 Sigma-Aldrich, St. Louis, MO, USA  
Mannose, C6H12O6 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Methanol, CH4O 
Merck Chemicals GmbH, Schwalbach, 
Germany 
NEG 50TM Frozen Section Medium  Thermo Fisher Scientific, Waltham, MA, USA  
Odyssey Blocking Buffer (TBS) LI-COR Biosciences, Lincoln, NE, USA  
Ouabain Octahydrate, C29H44O12•8H2O Sigma-Aldrich, St. Louis, MO, USA 
Paraformyaldehyde, (CH2O)n (PFA) AppliChem GmbH, Darmstadt, Germany 
Pepton  
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Phenylmethansulfonylfluoride, C7H7FO2S 
(PMSF) 
Merck Chemicals GmbH, Schwalbach, 
Germany  
PhosSTOP™ Phosphatase inhibitor Sigma-Aldrich, St. Louis, MO, USA 
Potassium chloride, KCl 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Potassium dihydrogen phosphate, 
KH2PO4 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Roti ®Quant 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Rotiphorese Gel 40% Acrylamide/ 
Bisacrylamide 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Saccharose, C12H22O11 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Silver nitrate, AgNO3 Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Skimmed Milk Powder  
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany  
Sodium chloride, NaCl 
VWR International Germany GmbH, 
Darmstadt, Germany 
Sodium dodecyl sulfate ≥99%, 
C12H25NaO4S (SDS) 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Sodium hydroxide, NaOH  
Merck Chemicals GmbH, Schwalbach, 
Germany  
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Sodium thiosulfate pentahydrate, 
Na2S2O3•5H2O 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Sodiumacetate trihydrate, CH3COONa•H2O 
Merck Chemicals GmbH, Schwalbach, 
Deutschland 
Sodiumcarbonate, Na2CO3 Merck Chemicals GmbH, Schwalbach, 
Germany 
ß-Mercaptoethanol, HSCH2CH2OH Sigma-Aldrich, St. Louis, MO, USA 
Tetramethylethylendiamin (TEMED), 
(CH3)2NCH2CH2N(CH3)2 
Merck Chemicals GmbH, Schwalbach, 
Germany 
Tris(hydroxymethyl)-aminomethan, 
NH2C(CH2OH)3 (Tris) 
Affymetrix,  Santa Clara, CA, USA 
Triton® X-100  AppliChem GmbH, Darmstadt, Germany 
2.13 Buffers and Solutions  
Table 15: Composition of buffers and solutions used  
Buffer/Solutions Composition Amounts 
0.1 M HCl in Isopropanol 
Isopropanol 
1 M HCl 
90 % (v/v) 
10 % (v/v) 
2x HBS 
NaCl 
KCl 
Na2HPO4 
HEPES  
H2O dest. 
280 mM 
10 mM 
1.5 mM  
50 mM 
5x Laemmli Buffer  
 
Bromphenolblue 
Tris-HCl pH 6.8  
β-Mercaptoethanol  
SDS  
Glycerol  
H2O dest. 
0.01 % 
60 mM 
5 % (v/v) 
2 % (w/v) 
10 % (v/v) 
 
Ammoniummolybdate Solution  
Ammoniummolybdate  
Hydrochloric acid  
4.2 % (w/v)  
4 M  
Antibody Solution for Immunohistochemistry 
Goat serum 
TritonX-100  
PB 
2.5 % (v/v) 
0.1 % (v/v) 
Antibody Solution for Western Blot  
1x TBS-T  
Skimmed Milk Powder 
 
5 % (w/v) 
ATP Stock Solution  ATP 
H2O dest. 
300 mM  
ATPase Testbuffer  
Tris-HCl, pH 7,4  
NaCl  
KCl  
MgCl2  
H2O dest. 
100 mM  
130 mM  
20 mM  
3 mM  
ATPase Testbuffer w/o K+ 
Tris-HCl, pH 7,4  
NaCl  
MgCl2  
H2O dest. 
100 mM  
130 mM  
3 mM  
ATPase Testbuffer w/o Na+ 
Tris-HCl, pH 7,4   
KCl  
MgCl2  
H2O dest. 
100 mM 
20 mM  
3 mM  
Blocking Solution for Immunohistochemistry Goat serum 10 % (v/v) 
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TritonX-100  
PB 
0.3 % (v/v) 
Blocking Solution for Western Blot  
1x TBS-T  
Skimmed Milk Powder 
5 % (w/v) 
Bromphenolblue Loading Buffer  
Bromphenolblue 
Glycerol 87% 
H2O dest.  
0.01 % (w/v) 
40 % (v/v) 
Coomassie Destaining Solution 
Methanol  
H2O dest l 
30 % (v/v) 
60 % (v/v) 
Coomassie Staining Solution 
Methanol  
Acetic acid  
Coomassie Brilliant Blue 
H2O dest. 
30 % (v/v)  
10 % (v/v) 
0.10 % (w/v) 
 
House Taq DNA Polymerase 10 x Buffer 
KCl 
Tris, pH 9.0 
MgCl2 
Triton X 
500 mM 
100 mM 
15 mM 
1 % (v/v) 
IPTG Solution  
IPTG  
H2O 
0.1 M 
 
LB Agar 
Trypton 
Yeast extract  
NaCl  
Bacto-Agar  
H2O dest. 
1 % (w/v)  
0.5 % (w/v) 
1 % (w/v) 
15 % (w/v) 
 
Lysogeny Broth (LB) medium  
Pepton 
Yeast extract 
NaCl  
H2O dest. 
1 % (w/v) 
0.5 % (w/v) 
1 % (w/v) 
 
Malachitgreen Solution 
Malachitgreen 
H2O dest. 
0.05 % (w/v) 
MTT Solution 
MTT 
1x PBS 
0.05 % (w/v) 
PB, pH 7.2 
Na2HPO4 
NaH2PO4 
H2O dest. 
78 mM 
26 mM 
PBS, pH 7.4  
NaCl  
KCl  
Na2HPO4 
KH2PO4  
H2O dest. 
137 mM  
0,27 mM  
10 mM  
1.8 mM  
PFA Solution  
PFA 
PBS  
4 % (w/v)  
Phosphate Reagent  
Ammoniummolybdate 
Solution  
Malachitgreen Solution 
25 % v(/v)  
 
75 % (v/v)  
SDS Running Buffer, pH 8.6 
Tris-HCl  
Glycin  
SDS  
H2O dest. 
0.25 mM 
0.2 M 
1 % (w/v) 
 
Silver Staining Solution A 
Acetic Acid 
Ethanol 
H2O dest. 
10 % (v/v) 
30 % (v/v) 
60 % (v/v) 
Silver Staining Solution B 
Sodiumacetate 
Na2S2O3•5H2O 
25 % Glutaraldehyde 
6.8 % (w/v) 
0.2 % (w/v) 
5 % (v/v) 
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Ethanol 
H2O dest. 
30 % (v/v) 
 
Silver Staining Solution C 
AgNO3 
H2O dest. 
0.2 % (w/v) 
 
Silver Staining Solution E 
Glycine  
H2O dest. 
1 % (w/v) 
 
Silver Staining Solution D 
Na2CO3 
H2O dest. 
2.5 % (w/v) 
 
SOC Medium 
Tryptone 
Yeast extract 
NaCl 
KCl 
MgCl2 
Glucose 
2 % (w/v) 
0.5 % (w/v) 
10 mM 
2.5 mM 
10 mM 
20 mM 
TBE, pH 8.0 
Tris  
Boric acid  
EDTA  
H2O dest. 
100 mM 
100 mM 
1 mM  
 
TBS, pH 7.5  Tris  
NaCl  
H2O dest. 
50 mM  
150 mM  
TBS-T 
Tween® 20  
TBS  
0.1 % (v/v)  
Towbin  
Glycine  
Tris 
Methanol  
H2O dest. 
190 mM 
0.25 mM 
20 % (v/v)  
X-Gal Solution 
X-Gal  
Dimethyformamid 
0.04 % (w/v) 
 
2.14 Cell Culture Media and Supplements 
Table 16: List of cell culture media and supplements/additives used  
Component  Source   
Antibiotic-Antimycotic (100X) Sigma-Aldrich, St. Louis, MO, USA 
DMEM Hams F12 Medium  Thermo Fisher Scientific, Waltham, MA, USA 
DMEM High Glucose Medium(4,5 g/L)  Thermo Fisher Scientific, Waltham, MA, USA 
Dulbecco‘s PBS (DPBS) Thermo Fisher Scientific, Waltham, MA, USA 
Fetal Bovine Serum Gold (FBS)  Thermo Fisher Scientific, Waltham, MA, USA 
G418 Sulfate solution, C20H40N4O10·2H2SO4  Thermo Fisher Scientific, Waltham, MA, USA 
Gentamicin (50 mg/ml) Thermo Fisher Scientific, Waltham, MA, USA 
Hygromycin B Thermo Fisher Scientific, Waltham, MA, USA 
Insulin (27 USP-units/mg) Thermo Fisher Scientific, Waltham, MA, USA 
L-Glutamin 200 mM (100x) Thermo Fisher Scientific, Waltham, MA, USA 
OptiMEMTM Medium  Thermo Fisher Scientific, Waltham, MA, USA 
Penicillin (10.000 Units)/Streptomycin (10 
mg/ml), (Pen/Strep)  
Thermo Fisher Scientific, Waltham, MA, USA 
Poly-L-Lysin Hydrobromide (0.1 mg/ml) Sigma-Aldrich, St. Louis, MO, USA  
RPMI Medium 1640  Thermo Fisher Scientific, Waltham, MA, USA 
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2.15 Consumables 
Table 17: List of consumables used  
Consumable  Source 
12-well tissue culture plate Corning Incorporated, Corning, NY, USA 
24-well tissue culture plate Life Technologies, Carlsbad, CA, USA 
5 ml Polystyrene Round-Bottom Tube BD Falcon, Franklin Lakes, NJ, USA  
6-well tissue culture plate Corning Incorporated, Corning, NY, USA 
Cell scrapers  Orange Scientific, Braine-l'Alleud, Belgium 
CryoPure tube 1.6 ml Sarstedt AG & Co., Nümbrecht, Germany 
Cuvettes   Sarstedt AG & Co., Nümbrecht, Germany  
Eppendorf tube pistills Hartenstein GmbH, Würzburg, Germany  
Eppendorf tube 0.5 ml Sarstedt AG & Co., Nümbrecht, Germany 
Eppendorf tube 1.5 ml Sarstedt AG & Co., Nümbrecht, Germany 
Eppendorf tube 2 ml Sarstedt AG & Co., Nümbrecht, Germany 
Falcontube 15 ml Sarstedt AG & Co., Nümbrecht, Germany 
Falcontube 50 ml Sarstedt AG & Co., Nümbrecht, Germany 
Flat bottom 96-well assay plate GreinerBio-One GmbH,Kremsmünster, Austria  
Matrix Pipet tips  Thermo Fisher Scientific, Waltham, MA, USA 
MicroAmpTM Optical 384-well plate Life Technologies, Carlsbad, CA, USA 
MicroAmpTM Optical Adhesive Film Life Technologies, Carlsbad, CA, USA 
Nitril gloves 
VWR International Germany GmbH, Darmstadt, 
Germany 
Pasteur pipet 3 ml 
VWR International Germany GmbH, Darmstadt, 
Germany 
PCR-Cups 0.5 ml 
Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
Petri dishes (10 cm) Sarstedt AG & Co., Nümbrecht, Germany 
Pipet tips 10 µl 
VWR International Germany GmbH, Darmstadt, 
Germany 
Pipet tips 100 µl 
VWR International Germany GmbH, Darmstadt, 
Deutschland 
Pipet tips 1000 µl 
VWR International Germany GmbH, Darmstadt, 
Deutschland 
Pipet tips, sterile, with filter Nerbe Plus GmbH, Winsen, Germany  
Plastic pipets 5/10/20 ml  Sarstedt AG & Co., Nümbrecht, Germany 
PVDF membrane Merck Chemicals GmbH, Schwalbach, Germany  
Slide-A-Lyzer™ MINI Dialysis Device, 
10K MWCO  
Thermo Fisher Scientific, Waltham, MA, USA 
Tissue culture dish 10 cm Sarstedt AG & Co., Nümbrecht, Germany   
Tissue culture flask T25 vent. Cap  Sarstedt AG & Co., Nümbrecht, Germany 
Whatman paper 3 mm Carl Roth GmbH + Co. KG, Karlsruhe, Germany 
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2.16 Instruments 
Table 18: List of instruments used  
Instrument Source 
Accu-jet Pipet Controller  Brand, Wertheim, Germany 
Autoclave „Autoklav V-150“ Systec GmbH, Wettenberg, Germany 
Bunsen burner Gasprofi1 WLD Tec, Göttingen, Germany  
CASY TT Cell Counter  Innovatis Roche AG, Bielefeld, Germany 
Centrifuge Biofuge fresco (table top for 
Eppendorf tubes) 
Heraeus Holding GmbH, Hanau, Germany 
Centrifuge Megafuge 1.0R (Falcon tubes) Heraeus Holding GmbH, Hanau, Germany 
Centrifuge Megafuge 3L (Falcontubes Heraeus Holding GmbH, Hanau, Germany 
Cold microtom Leica CM1850  Leica, Solmis, Deutschland  
Duomax 1030 Rocking Platform Shaker  
Heidolph Instruments GmbH & Co.KG, 
Schwabach, Germany  
FACSCanto-II flow cytometer BD Biosciences, San Jose, CA, USA 
Fine scales „Feinwaage Explorer“  OHAUS, Nänikon, Switzerland 
FLUOstar OPTIMA Microplate Reader  BMG Labtech, Allmendgruen, Germany  
Gelelectrophoresis chamber Blue Marine200 
SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Gelelectrophoresis chamber Mini 
PROTEAN® 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Icemachine AF 100  Scotsman, VerNicht Hills, IL, USA 
Incubator for bacteria 37°C Memmert GmbH, Schwabach, Germany 
Incubator Hera Cell 150  
Thermo Fisher Scientific, Waltham, MA, 
USA 
Matrix Equalizer Pipet 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Microwave KOR-6D07 Daewoo, Seoul, Korea 
Milli-Q-Synthesis Water Purification System 
Merck Chemicals GmbH, Schwalbach, 
Germany 
NanoDrop® ND1000 Spectrophotometer NanoDrop, Wilmington, DE, USA 
Odyssey FC Imager LI-COR Biosciences, Lincoln, NE, USA 
pH Meter Lab 850 SI Analytics GmbH, Mainz, Germany 
Power Pack Blue Power 500 
SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
Power Pack Blue Power Plus 
SERVA Electrophoresis GmbH, Heidelberg, 
Germany 
QuantStudio ® 5 Real-Time PCR System Life Technologies, Carlsbad, CA, USA 
RM5 Roller  
(Assistent®) Glaswarenfabrik Karl Hecht 
GmbH & Co KG, Sondheim/Rhön, Germany   
Rotator RS-24 Biosan, Riga, Lettland 
Scales 
SCALTEC Instruments GmbH, 
Heiligenstadt, Germany 
Shaking incubator 37°C Ceromat R 
B. Braun Biotech International GmbH, 
Melsungen, Germany 
Short Plates Mini PROTEAN® 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Spacer Plates Mini PROTEAN® 0.75 mm 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
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Spacer Plates Mini PROTEAN® 1.5 mm 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
Spectralphotometer Ultraspec 2100 pro 
Amersham Biosciences, Life Technologies, 
Carlsbad, CA, USA 
Sterile work bench Heraeus Holding GmbH, Hanau, Germany 
Thermocycler T3 Biometra GmbH, Göttingen, Germany 
Thermocyler Peqstar 2x gradient 
VWR International Germany GmbH, 
Darmstadt, Germany 
Thermomixer compact Eppendorf AG, Hamburg, Germany 
Trans-Blot® Turbo™ Transfer System  
Bio-Rad Laboratories GmbH, Munich, 
Germany  
Transferpipette ® 10 µl Brand, Wertheim, Germany 
Transferpipette ® 100 µl Brand, Wertheim, Germany 
Transferpipette ® 1000 µl Brand, Wertheim, Germany 
Transilluminator UST-30_M-8R BioView Ltd., Billerica, MA, USA 
Vacuumpump MZ 2 C  Vacuubrand GmbH, Wertheim, Germany 
Vibra Cell VCX400 Ultrasound device Sonics& Materials, Newtown, CT,USA 
VisiScope CSU-X1 Confocal System 
Microscope 
Visitron Systems, Puchheim, Germany 
Vortex Genie2 Scientific Industries, Bohemia, NY, USA 
Water destiller GFL GmbH, Burgwedel, Germany 
Waterbath W12 Labortechnik Medingen, Arnsdorf, Germany 
Workbench Heraguard Heraeus Holding GmbH, Hanau, Germany 
 
2.17  Software 
Table 19: List of softwares used  
Software  Source 
ApE - A Plasmid Editor  
M.Wayne Davis, Department of Biology, 
University of Utah  
AxioVision LE 4.8  Zeiss, Oberkochen, Germany 
Corel Draw   Corel Corporation, Ottawa, Canada   
Diva Ver 7.0 BD Biosciences, San Jose, CA, USA 
Image Studio 
LI-COR Biosciences GmbH, Lincoln, NE, 
USA 
ImageJ  
Wayne Rasband, National Institutes of 
Health, USA  
Microsoft Office  
Microsoft Cooperation, Redmond, WA, 
USA  
Photoshop Elements Adobe Systems GmbH, Munich, Germany  
SigmaPlot Version12.5 Systat Software, San Jose, CA, USA 
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3 Methods  
3.1 Cloning of Expression Constructs 
3.1.1 RNA Isolation 
RNA isolation from cells was carried out using the Qiagen RNeasy Mini Kit according to the 
manufacturer’s instructions. RNA was eluted in RNase-free water and RNA concentration was 
determined using a NanoDrop® ND1000 Spectrophotometer. RNA was stored at -80 °C until 
further use.  
3.1.2 cDNA Synthesis 
For cDNA synthesis, 1 µl of poly(dT) primer (30 nmol) was added to 1 µg of RNA and the final 
reaction volume was adjusted to 12.5 µl using RNase-free H2O. This mixture was incubated 
for 5 min at 65 °C (step 1 in Table 21). After incubation, samples were immediately put on ice 
and 7.5 µl of the cDNA synthesis reaction mix given in Table 20 were added. Subsequently, 
cDNA synthesis was carried out in a thermocycler with the program given in Table 21 (step 2). 
Table 20: Composition of cDNA synthesis reaction mix 
Component Volume 
RNase-free H2O 0.5 µl 
5x Reaction Buffer for RevertAid™ Reverse 
Transcriptase 4 µl 
dNTPs (1.25 mM) 2 µl 
RevertAid™ Reverse Transcriptase 1 µl 
 
Table 21: Thermocycler program for cDNA synthesis  
Reactionstep Temperature Duration 
Step 1: Annealing 65 °C 5 min 
Step 2: cDNA 
synthesis and heat-
inactivation 
25 °C 10 min 
42 °C 60 min 
70 °C 10 min  
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3.1.3 PCR Amplification of Coding Sequences 
Coding sequences of genes to be cloned into expression vectors were amplified from cDNA 
or plasmid DNA using a mixture of 7 parts GoTaq® DNA polymerase and 1 part Pfu DNA 
polymerase. The PCR reaction mix is given in Table 22 and the thermocycler program in  
Table 23. PCR conditions were adjusted to the requested coding sequence by changing 
annealing temperature (primers given in Table 4, respective annealing temperatures were 
determined with ApE – a plasmid editor) and elongation time (1 min/1000 bp).  
Table 22: PCR reaction mix 
Component Volume 
5X Green GoTaq® Reaction Buffer 5 µl 
Primer forward (10 µM) 0.8 µl 
Primer reverse (10 µM) 0.8 µl 
dNTPs (1.25 mM) 1 µl 
cDNA (25 ng/µl) /Plasmid DNA (25 ng/µl) 2 µl 
GoTaq® DNA polymerase +Pfu DNA polymerase  0.5 µl 
H2O (Millipore) 14.9 µl  
 
Table 23: Thermocycler program for PCR amplification  
Reactionstep Temperature Duration Cycles 
Initial denaturation 95 °C 3 min  
Denaturation  94 °C 30 s 
30 Annealing x °C 30 s 
Elongation 72 °C x min 
Final elongation 72 °C 5 min  
Pause 4 °C  min  
 
x indicates variable temperature and time, adjusted for each sequence to be amplified  
3.1.4 Agarose Gel Electrophoresis 
PCR products were run on agarose gels to check for correct size and purity of the amplification 
products. Agarose gels were prepared by heating 1 % (w/v) agarose in TBE buffer until the 
agarose had melted completely, cooling the solution down to <45 °C and adding 4 drops of a 
0.003 % ethidiumbromide solution.   
Bromphenolblue loading buffer (5x solution) was added to DNA samples before loading them 
onto the gel. 3 µl GeneRuler™ DNA Ladder Mix were used as a size standard and gels were 
run at 190 V for 20 min.  
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3.1.5 Purification of PCR Products from Agarose Gels 
PCR products of the correct size were excised from agarose gels and purified using the 
NucleoSpin® Gel and PCR Clean-up kit according to the manufacturer’s instructions. DNA 
was eluted from columns in 25 µl of Millipore H2O and stored at -20 °C until further use.  
3.1.6 Ligation into pGEM®-T 
Successfully amplified PCR products were ligated into the pGEM®-T vector using the ligation 
protocol given in Table 24 and ligase supplied with the pGEM®-T vector kit. Ligation mixtures 
were incubated at 4 °C over night.  
Table 24: pGEM®-T vector ligation mix  
Component Volume 
pGEM®-T vector 1 µl 
PCR fragment 2 µl 
T4 DNA Ligase Puffer (2x) 5 µl 
T4 DNA Ligase 1 µl 
H2O (Millipore)  1 µl 
3.1.7 Heat Shock Transformation of E. coli  
E. coli strain DH5α cells were transformed with plasmid DNA via a heat shock procedure. 100 
µl aliquots of competent E. coli cells were thawed on ice before the complete ligation mixture 
was added to the cells. DNA and cells were mixed by flicking the tube and then incubated on 
ice for 30 min. Cells were then heat shocked at 42 °C for 45 s and put back on ice for 10 min. 
400 µl of SOC medium were added and cells were incubated at 37 °C for 45 min before plating 
them on LB plates containing 100 µg/ml ampicillin. When transforming E. coli with pGEM®-T, 
LB plates were pre-treated with a mixture of 10 µl IPTG and 50 µl X-Gal solutions as this vector 
is suitable for blue/white screening. IPTG/X-Gal treatment was omitted when plating E. coli 
cells transformed with any other vector.  
3.1.8 Plasmid DNA Miniprep  
Single clones were picked from LB plates and transferred into 5 ml of LB medium containing 
100 µg/ml ampicillin. After incubation at 37 °C over night, DNA isolation was carried out using 
the NucleoSpin® Plasmid kit according to the manufacturer’s instructions. Plasmid DNA was 
eluted from columns in 25 µl of Millipore H2O and the concentration was determined using a 
NanoDrop® ND1000 Spectrophotometer.  
  
Methods 
41 
3.1.9 Sanger Sequencing 
Sanger sequencing of full length inserts was performed to verify that DNA fragments cloned 
into pGEM®-T were correct. For sequencing, the BigDye® Terminator v1.1, v3.1 Cycle 
Sequencing Kit was used. Reaction mix and thermocycler program are given in Table 25 and  
Table 26. 
Table 25: Reaction mix for Sanger sequencing  
Component Volume  
Plasmid DNA (25 ng/µl) 2 µl 
BigDye® Terminator Reaction Mix 0.3 µl 
5x BigDye® Terminator Sequencing Buffer 2 µl 
Primer (10 µM) 1 µl 
H2O (Millipore) 4.7 µl 
 
Table 26: Thermocycler program for Sanger sequencing  
Reactionstep Temperature Duration Cycles 
Initial denaturation 94 °C 2 min  
Denaturation 94 °C 30 s 
27 Annealing 58 °C 30 s 
Elongation 60 °C 3 min 
Final elongation 60 °C 5 min  
Pause 4 °C  min  
 
For DNA precipation, 2 µl 3 M sodium acetate and 25 µl 100 % ethanol were added to each 
sample. Samples were vortexed and then centrifuged for 45 min at 4000 rpm (Megafuge 
1.0R/3L by Heraeus) at 4 °C. The supernatant was discarded and pellets were washed in 100 
µl of 70 % ethanol (4000 rpm, 20 min, 15°C). The supernatant was discarded again and pellets 
were resuspended in 15 µl of HiDi™ formamide before transferring them into a 96-well plate 
to be run on a Abi3130x1 Genetic Analyser. Obtained sequences were analysed using ApE - 
A Plasmid Editor.  
3.1.10 Restriction Digestion 
After confirming the correct sequence, inserts were transferred from pGEM®-T into eukaryotic 
expression vectors pCEP4 or pCDNA3.1. Inserts were excised from pGEM®-T using 
restriction sites which were added to PCR products by the amplification primers. Restriction 
digestion mixtures were pepared according to Table 27 and incubated over night at 37 °C. For 
inserts to be excised from pGEM®-T, 3 µg of DNA were digested, while 500 ng of target 
expression vector was digested with the same enzymes.   
Digested DNA was run on agarose gels, DNA fragments of the correct size were excised from 
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the gel and purified as described in 3.1.4 and 3.1.5. DNA concentrations were determined 
using a NanoDrop® ND1000 Spectrophotometer.  
Table 27: Reaction mix for restriction digestion of plasmid DNA  
Component Volume  
Plasmid DNA 3 µg or 500 ng, respectively 
Enzyme 1 1 µl 
Enzyme 2  1 µl 
10x NEB Endonuclease Buffer 2 µl 
H2O (Millipore) ad. 20 µl 
3.1.11 Ligation into Expression Vectors  
Inserts and expression vectors were ligated in a 3:1 molar ratio using T4 DNA ligase according 
to Table 28. Ligations were incubated at 4 °C over night and subsequently transformed into E. 
coli.  
Table 28: Reaction mix for ligation of inserts into expression vectors  
Component Volume 
Vector DNA 10-20 ng 
Insert DNA  x µl 
T4 DNA Ligase Puffer (10x) 1 µl 
T4 DNA Ligase 1 µl 
H2O (Millipore)  ad. 10 µl  
3.1.12 Colony PCR 
Colony PCR was performed to pre-select positively transformed E. coli clones. 
Single clones were picked from selection plates, transferred into 20 µl LB medium containing 
100 µg/ml ampicillin and incubated at 37 °C for 2 h. This culture was then used as DNA 
template in the subsequent PCR reaction described in Table 29 and Table 30. Vector primers 
given in Table 4 were used for amplifying insert fragments.  
Table 29: Reaction mix for colony PCR  
Component Volume 
E. coli culture  3 µl 
Primer forward (10 µM)  0.8 µl 
Primer reverse (10 µM) 0.8 µl 
dNTPs (1.25 mM) 0.5 µl  
House Taq DNA polymerase  0.4 µl 
Buffer 10x (15 mM MgCl2) 2.5 µl 
H2O (Millipore)  17 µl 
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Table 30: Thermocycler program for colony PCR  
Reactionstep Temperature Duration Cycles 
Initial denaturation 94 °C 10 min  
Denaturation 94 °C 30 s 
27 Annealing 58 °C 30 s 
Elongation 72 °C 1 min/1000 bp 
Final elongation 72 °C 5 min  
Pause 10 °C  min  
3.1.13 Plasmid DNA "Midi" Preparation 
Expression constructs were isolated from 100 ml over night E. coli cultures using the 
NucleoBond® XtraMidi according to the manufacturer's instructions. Elution was done with 100 
µl of Millipore H2O. DNA concentration was determined using a NanoDrop® ND1000 
Spectrophotometer and adjusted to 1 µg/µl. Plasmid DNA was stored at -20 °C.  
3.1.14 Preparation of Glycerolstocks for Long Term Storage 
For long term storage of bacterial cultures, 825 µl of fresh over night culture were mixed with 
175 µl sterile 87 % glycerol and immediately frozen at -80 °C. Specifications about plasmid 
constructs were entered into the Institute of Human Genetics ’ database for glycerol cultures.   
3.2 Generating Myc-tagged RS1 Variants  
To generate N-terminally Myc-tagged retinoschisin, a Myc-tag was inserted in between the 
signal peptide and the RS1 specific domain of retinoschisin. For this, the N‐terminal part of the 
RS1 coding sequence from nucleotide positions 1 to 69 (aa 1–23) was fused to the N‐terminal 
half of the Myc-tag sequence via PCR. The N‐terminal half of the Myc-tag was added by the 
applied reverse primer in this amplification step. The C‐terminal part of the RS1 coding 
sequence (nucleotide position 70 to stop codon) was fused to the C‐terminal half of the Myc-
tag sequence. The C‐terminal half of the Myc-tag was added by the applied forward primer in 
this amplification step. pCEP_RS1 (Table 8) was used as a template, primers are given in 
Table 4. The full sequence was then fused together and ligated into a pCDNA3.1™ expression 
vector via HindIII and XhoI restriction sites, as described in 3.1.10 and 3.1.11. 
3.3 Generating RS1-C59C Expression Constructs 
The RS1-C59S expression constructs pCEP_RS1_C59S and pCDNA_RS1_C59S_Myc were 
generated by site directed mutagenesis using PfuUltra II Fusion HotStart DNA Polymerase 
and the reaction mixture and thermocycler program given in Table 31 and Table 32. 
pCEP_RS1 and pCDNA_RS1_Myc were used as templates (Table 8) and mutagenesis 
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primers are given in Table 5. 
After PCR amplification, the reaction mix was subjected to a DpnI digestion to specifically 
remove methylated template DNA. The digestion mix given in Table 33 was incubated for 2 h 
at 37 °C and then used to transform E. coli as described in 3.1.7. Mutagenesis was controlled 
by sequencing of single clones as described in 3.1.9. Successfully mutagenized sequences 
were then cloned into pCEP4 using EcoRI and XhoI restriction sites, and into pcDNA3.1 using 
HindIII and XhoI restriction sites, as described in 3.1.10 and 3.1.11. 
Table 31: Reaction mix for site directed mutagenesis using PfuUltra II Fusion HotStart DNA Polymerase 
Component Volume 
Template DNA  (20 ng/µl) 2 µl 
Primer forward (10 µM)  2 µl 
Primer reverse (10 µM) 2 µl 
dNTPs (1.25 mM) 4 µl 
PfuUltra II Fusion HotStart DNA Polymerase 0.2 µl 
Reaction Buffer 10x  2.5 µl 
H2O (Millipore)  12.3 µl 
 
Table 32: Thermocycler program for site directed mutagenesis using PfuUltra II Fusion HotStart DNA 
Polymerase 
Reactionstep Temperature Duration Cycles 
Initial denaturation 94 °C 10 min  
Denaturation 94 °C 1 min 
18x Annealing 55 °C 1 min 
Elongation 72 °C 1min/1000 bp 
Final elongation 72 °C 5 min  
Pause 10 °C  min  
 
Table 33: Reaction mix for DpnI digestion  
Component Volume 
PCR product 20 µl 
DpnI  1 µl 
10x Endonuclease Reaction Buffer 3 µl 
H2O (Millipore)  7 µl 
3.4 Generating Expression Constructs for ATP1B2-ATP1B1 Chimeras 
Expression constructs for the ATP1B2-ATP1B1 chimeras ATP1B2_I163L, 
ATP1B2_T199Q_A201T, and ATP1B2_K247Q_L249T (ATP1B2 mutated in Patch I Regions 
1, 2 or 3) as well as for ATP1B2_MIRPKT_83-88_TQIPQI, ATP1B2_KMNR181-184_KLNR, 
and ATP1B2_T240L (ATP1B2 mutated in Patch II Regions 1, 3 or 4) were generated with the 
Q5® Site Directed Mutagenesis Kit using the pTLN1_ATP1B2 vector (Table 8) as template. 
Primers (see Table 5) were designed using the NEBaseChanger v1.2.6 tool available at 
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http://nebasechanger.neb.com/. All further steps were carried out according to the 
manufacturer’s protocol.  
The ATP1B2-ATP1B1 chimera ATP1B2_QKLNKFLEPYNDSI108_121_LNIVRFLEKYKDSA 
(ATP1B2 mutated in Patch II Region 2) was also generated with the Q5® Site Directed 
Mutagenesis Kit and pTLN1_ATP1B2 vector (Table 8) as first template. However, three 
subsequent mutagenesis reaction with three different sets of primers were required to 
introduce all required nucleotide exchanges as there were too many to be mutagenized at 
once. Primers for the subsequent reactions are given in Table 5. 
To generate the ATP1B2-ATP1B1 chimera ATP1B2_227-237_ATP1B1, a different approach 
was used. This construct contains 8 aa exchanges and two additional aa compared to the 
normal ATP1B2 sequence. PCR primers given in Table 5 and were used to amplify the N-
terminal and the C-terminal part of ATP1B2 with overhangs for the additional aa and a ScaI 
restriction site. Both fragments were sub-cloned in pGEM®-T and then fused together via their 
ScaI restriction site. 
Mutagenesis of ATP1B2 was confirmed via Sanger sequencing (described in 3.1.9) of single 
clones. Successfully mutagenized sequences were cloned into pCEP expression vector using 
KpnI and XhoI restriction sites as described in 3.1.10 and 3.1.11. 
3.5 Cell Culture 
All cell lines were kept in a Hera Cell 150 incubator at a constant temperature of 37 °C and a 
5 % CO2 atmosphere. Cells were passaged under sterile conditions. All cell culture media and 
supplies were stored at 4 °C unless indicated differently by the manufacturer and pre-warmed 
to 37 °C before use. Current condition and confluency of cells was checked under a 
microscope each time they were passaged or before used in experiments.  
3.5.1 Cultivation of Hek293 Cells 
Human embryonic kidney (Hek293) cells were cultivated in 10 cm dishes in 10 ml DMEM High 
Glucose Medium (4.5 g/L) to which 10 % FCS, 1 % Penicillin/Streptomycin (5000 units/ml 
Penicillin and 5000 µg/ml Streptomycin) as well as 1 % Geneticin™ Selective Antibiotic (G418 
Sulfate) had been added. Hek293 cells were passaged when they reached about 90 % 
confluency. Old medium was removed and cells were washed off the dish with fresh medium. 
Hek293 cells were sub-cultured at a 1:10 ratio twice a week for maintenance.   
For cultivation of Hek293 cells stably transfected with an retinoschisin expression vector (see 
Friedrich et al., 2011), the medium was additionally supplemented with 1500 µg/ml Hygromycin 
B. To obtain retinoschisin containing supernatant from this cell line, the cells were kept in 
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OptiMEMTM containing 1% Penicillin/Streptomycin (5000 units/ml Penicillin and 5000 µg/ml 
Streptomycin) and 1500 µg/ml Hygromycin B for 72 h and the supernatant was harvested 
afterwards.   
3.5.2 Cultivation of Y-79 Cells  
The human retinoblastoma cell line Y-79 was cultured in RPMI 1640 medium supplemented 
with 10 % FCS and 1 % Penicillin/Streptomycin (5000 units/ml Penicillin and 5000 µg/ml 
Streptomycin). Y-79 cells are suspension cells and were grown in T25 tissue culture flasks 
with ventilated caps in 10 ml medium. Cells were subcultured in a 1:3 ratio when they reached 
a concentration of 4 -5 x 105 cells/ml. Only cells passaged less than ten times were used for 
signaling pathway experiments.  
3.5.3 Transfection of Hek293 Cells – TransIT® -LTI Transfection Reagent 
For transfection of Hek293 cells in 6-Wells, the TransIT® -LTI Transfection reagent was used 
according to the manufacturer's instructions. Cells used for transfection were seeded the day 
before so they reached 70 % confluency when being transfected (1:18 of total cells from a 100 
% confluent 10 cm dish, in 3 ml of medium).  
3.5.4 Transfection of Hek293 cells – Calcium-Phosphate Method 
For generation of large volumes of supernatants containing (Myc-tagged) retinoschisin 
variants, the Calcium Phosphate method was used for transfection of Hek293 cells. Cells were 
seeded on Poly-L-Lysine coated 10 cm dishes the day before transfection so they reached 70 
% confluency the next day (1:3 of total cells from a 100 % confluent 10 cm dish, ad 10 ml with 
medium). On the day of transfection, the culture medium was changed to DMEM High Glucose 
Medium (4.5 g/L) containing 10 % FCS, 1 % Penicillin/Streptomycin (5000 units/ml Penicillin 
and 5000 µg/ml Streptomycin) and 1 µM Chloroquine. After one hour of incubation, the medium 
was changed back to DMEM High Glucose Medium (4.5 g/L) with 10 % FCS, 1 % 
Penicillin/Streptomycin (5000 units/ml Penicillin and 5000 µg/ml Streptomycin) as well as 1 % 
Geneticin™ Selective Antibiotic (G418 Sulfate). The transfection mix was prepared according 
to Table 34 by first mixing DNA with H2O followed by adding CaCl2 and then gently adding 2x 
HBS dropwise. The mixture was aerated using a 1 ml pipet before dropwise adding it to cells. 
7 h after transfection the medium was changed to OptiMEMTM containing 1 % 
Penicillin/Streptomycin (5000 units/ml Penicillin and 5000 µg/ml Streptomycin) and cells were 
grown for 72 h.  
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Table 34: Transfection mix for Calcium Phosphate transfection  
Component Volume/Amount  
Plasmid DNA 20 µg 
H2O (Millipore) ad. 438 µl 
CaCl2 62 µl 
2x HBS  500 µl 
3.6 Purification of Myc-tagged Retinoschisin Variants 
N-terminally Myc-tagged retinoschisin variants were purified from supernatant of transiently 
transfected Hek293 cells by immunoprecipitation using Pierce™ Anti-c-Myc Agarose and an 
adapted version of the manufacturer's protocol. 100 µl of Agarose beads were transferred into 
a 1.5 ml Eppendorf tube, centrifuged for 30 s at 12000 rpm (Biofuge fresco by Heraeus) and 
the supernatant was discarded. Beads were washed once in 100 µl TBS (30 s, 12000 rpm) 
and then incubated with 4 ml cell culture supernatant over night at 4 °C on a rotator. After over 
night incubation, beads were spun down (3 min, 4000 rpm, 4 °C) and washed three times in 
TBS-T (3 min, 4000 rpm, 4 °C). Bound proteins were eluted by applying 100 µl 0.25 mg/ml c-
Myc peptide and incubating the beads at room temperature for 15 min before collecting the 
eluate. Elution was repeated once and both eluates were pooled for further analysis and 
experiments. Purified retinoschisin variants were stored in 100 µl aliquots at -20 °C until further 
use. A control eluate was obtained by transfecting Hek293 cells with an empty pCDNA3.1 
expression vector and subjecting the supernatant from those cells to the procedure described 
above. This control eluate served as negative control in any experiments conducted with 
purified retinoschisin variants.  
3.7 Dialysis of Purified Retinoschisin Variants  
Retinoschisin variants to be used in a Na/K-ATPase activity assay were dialysed against the 
respective test buffers. 100 µl of purified protein were put into a Slide-A-Lyzer™ MINI Dialysis 
Device (10K MWCO) and the device was put in a glass beaker containing 500 ml of the dialysis 
buffer. Dialysis was carried out at 4 °C for 18 h and the dialysis buffer was exchanged for fresh 
buffer after 5 h.  
3.8 Sodiumdodecylsulfate Polyacrylamide Gel Electrophoresis (SDS PAGE) 
3.8.1 Reducing SDS PAGE 
Unless stated otherwise, proteins analysed in Western blot experiments or via Coomassie or 
silver staining were separated by reducing SDS PAGE on 12.5 % acrylamide gels. The gels 
were cast according to Table 35 and Table 36 using Bio-Rad MiniPROTEAN® equipment.  
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Samples to be run on SDS gels were prepared by sonicating for 10 s at 40 % intensity before 
adding 5x Laemmli buffer and heating samples at 95 °C for 10 min. 3.5 µl of PageRuler™ 
Prestained Protein Ladder were used as a size standard. Gels were run in SDS running buffer 
at 50 V until samples had entered the resolving gel and then at 150 V for 1 h to 1.5 h depending 
of the size of the proteins to be analysed.  
Table 35: Composition of 12.5% acrylamide resolving gels  
Component Volume 
1 M Tris-HCl pH 8.8 3.38 ml 
H2O dest. 2.42 ml 
Polyacrylamide (40 %) 3.75 ml 
SDS (20 %) 100 µl 
APS (10 %) 100 µl 
TEMED 10 µl 
 
Table 36: Composition of 3% acrylamide stacking gels  
Component Volume 
1 M Tris-HCl pH 6,8 2.76 ml 
H2O dest. 1.69 ml 
Polyacrylamide (40 %) 0.55 ml 
SDS (20 %) 50 µl 
APS (10 %) 50 µl 
TEMED 5 µl 
3.8.2 Non-reducing SDS PAGE 
For analysis of retinoschisin multimers the SDS PAGE protocol was changed by using a non-
reducing sample loading buffer (4x Loading Protein Loading Buffer by LI-COR Biosciences) 
and pre-cast 4-20% Mini-PROTEAN® TGX® gradient gels by Bio-Rad. The size standard used 
was the Color-coded Prestained Protein Marker, High Range by Cell Signaling Technologies 
(20 µl per lane). Gradient gels were run in SDS running buffer at 40 V and 4 °C for 8 h. The 
SDS running buffer was replaced by fresh buffer after 4 h.  
3.9 Western Blot 
3.9.1 Semi-Dry Blot 
After reducing SDS PAGE, proteins were transferred onto Polyvinyldiflouride (PVDF) 
membranes by semi-dry blotting using the Bio-Rad Transblot Transfer System. Membranes 
were activated in methanol for 30 s, transferred into Towbin buffer and equilibrated for 5 min. 
Two 3 mm Whatman papers as well as the SDS gels were also equilibrated in Towbin buffer. 
Protein transfer from gels to membranes was performed at 24 V for 40 min. For Western blot 
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analysis of retinoschisin, blotting time was reduced to 35 min. After blotting, membranes were 
submerged in blocking solution for 1 h at room temperature and then incubated with primary 
antibodies over night at 4 °C. Before incubation with secondary antibodies, membranes were 
washed three times for 5 min in TBS-T at room temperature. Incubation with secondary 
antibodies was carried out at room temperature for 1 h. After washing membranes again (3 x 
5 min in TBS-T), protein bands were visualized using Clarity™ ECL Western Blotting Substrate 
(Bio-Rad) according to the manufacturer’s instructions and an Odyssey FC imager. For protein 
targets with weak signals, Clarity Max™ Western Blotting Substrate was used to increase 
signal intensity.  
3.9.2 Wet Blot  
Wet blot protein transfer was used for analysis of retinoschisin multimers. After running a non-
reducing SDS PAGE as described in 3.8.2, proteins were blotted onto PVDF membranes at 
30 V for 14 h at 4 °C. Pre-cooled Towbin buffer was used for this experiment. After blotting, 
membranes were blocked and subjected to antibody staining as described in 3.9.1. 
3.10 Coomassie Staining  
For Coomassie staining of proteins in SDS gels, the gels were transferred into Coomassie 
staining solution directly after protein separation as described in 3.8.1. After 2 h of staining the 
gels were destained using Coomassie destaining solution which was changed for several times 
until the background was clear. The staining and destaining procedure was carried out under 
gentle agitation on a shaker.  
3.11 Silver Staining 
For silver staining of proteins in SDS gels, gels were fixed in silver staining solution A for 30 
min, subsequently transferred into silver staining solution B and incubated over night. 2 µl of 
37 % formaldehyde were added to 10 ml of solution C right before use and gels were washed 
3 times in H2O dest., before they were submerged in silver staining solution C for 20 min. Silver 
staining solution D was prepared by adding 1 µl 37 % formaldehyde to 10 ml solution right 
before use. Solution C was replaced by solution D and gels were incubated until staining of 
proteins bands became visible. Solution D was discarded once protein bands had reached the 
desired intensity and replaced by silver staining solution E. All silver staining solutions were 
prepared freshly and incubation steps were carried out at room temperature with gently 
agitation. 
  
Methods 
50 
3.12 Bradford Assay 
For protein quantification a Bradford assay was performed using Roti® Quant. 800 µl H2O 
(Millipore) were mixed with 200 µl of Roti® Quant solution and 5-50 µl of the protein sample to 
be measured were added. After 20 min of incubation at room temperature, absorbance at 595 
nm was measured using a photometer. Defined amounts of bovine serum albumin were used 
to generate a calibration curve.  
3.13 Cell Surface Biotinylation Assay 
Isolation of cell surface proteins was performed to address membrane expression of different 
Na/K-ATPase subunits and ATP1B2-ATP1B1 chimeras. Hek293 cells were transfected with 
expression constructs for the different Na/K-ATPase subunits in a 6-well format. 48 h after 
transfection, cell surface proteins were biotinylated and isolated using the Pierce™ Cell 
Surface Protein Isolation Kit according to the manufacturer’s instructions. Purified membrane 
proteins were analysed by Western blotting. 
3.14 Fluorescence Activated Cell Sorting (FACS) Analysis 
FACS analyses were performed to additionally investigate cell surface localization of different 
Na/K-ATPase subunits and ATP1B2-ATP1B1 chimeras. 3x105 transfected Hek293 cells were 
harvested, washed twice in 300 µl PBS +1% FCS (5 min, 300xg, 4°C) and then incubated in 
primary antibodies against Na/K-ATPase ß-subunits ATP1B2, ATP1B2 and ATP1B3 for 25 
min. After two washing steps in 300 µl PBS +1% FCS (5 min, 300xg, 4°C), cells were incubated 
in secondary antibody solution (Alexa-Fluor 488 conjugated anti-mouse or anti-rabbit, 1:100 in 
PBS +1% FCS) for 25 min and subsequently washed again twice. Cell pellets were 
resuspended in 100 µl PBS + 1 % FCS and transferred to 5 ml polystyrene round-bottom tubes. 
During the whole antibody staining procedure, cells were kept on ice, centrifugation steps were 
carried out at 4 °C and all solutions used were pre-cooled. FACS analysis were performed 
using a FACSCanto-II flow cytometer which was run by Diva software (Ver. 7.0). 
FACS experiments were done in cooperation with Dr. Jens Wild, Institute of Clinical 
Microbiology, University of Regensburg.  
3.15 Quantitative Real-Time PCR  
For quantitative real-time PCR (qRT PCR) all primers were designed using the “Universal 
Probe Library” by Hoffmann-La Roche. The qRT PCR experiments were run on a 
QuantStudio™ 5 Real-Time PCR System utilizing a comparative experimental approach. All 
samples were analysed in triplicates on 384-well plates. Reaction mixture and amplification 
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conditions for qRT PCR are given in Table 37 and Table 38.  
Data was analysed using the ΔΔCt-approach and statistical significance of results obtained 
was evaluated with Student’s t-test.  
Table 37: Reaction mix for qRT PCR analysis  
Component  Volume 
cDNA (20 ng/µl) 2.5 µl 
2x TaqMan Gene Expression Master Mix 5 µl 
Primer forward (50 µM) 1 µl 
Primer reverse (50 µM) 1 µl 
Probe  0.125 µl 
H2O (Millipore) 0.375 µl 
 
Table 38: qRT PCR cycling conditions   
Reactionstep  Temperature Duration Cycles 
Denaturation 95°C 40 s  
Annealing 60°C 60 s  
Elongation 72°C  2 min  40 
3.16 Animal Model 
The Rs1h-/Y mouse was generated as described earlier (Weber et al., 2002) and kept on a 
C57BL/6 background. Mice were housed under specific pathogen-free barrier conditions at the 
Central Animal Facility of the University of Regensburg and maintained under conditions 
established by the institution for their use, in strict compliance with European Union and 
German legal guidelines. Mice were killed 10, 14, 16 or 18 days after birth (postnatal day 10, 
14, 16, or 18, p10, p14, p16, or p16) by decapitation or cervical dislocation, respectively.  
3.17 Retina Preparation 
Rs1h-/Y mice were killed at p10, p14, p16 or p18, eyes were enucleated and transferred into 
1x PBS. Using scissors and cutting along the Ora Serrata, cornea, lens and vitreous body were 
separated from retina, choroid and sclera. The lens, cornea and vitreous body were carefully 
removed and the retina was gently released from the retinal pigment epithelium. Retinae were 
either stored at -80 °C or used immediately.  
3.18 Immunohistochemistry on Retinal Cryosections 
Retinal explants were briefly rinsed in PBS and subsequently submerged in 4 % (w/v) 
paraformaldehyde for 1 h at room temperature. Retinae were then washed in PBS twice before 
they were put into 30 % (w/v) sucrose over night. Single retinae were embedded in Richard-
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Allan Scientific™ Neg-50™ Frozen Section Medium and fast frozen on dry ice. 10 µm 
cryosections were cut and stained with different antibodies as described in Friedrich et al., 
2011. In brief, cryosections were allowed to thaw and covered in 1x PB, which was then 
replaced by blocking solution and sections were incubated for 30 min at room temperature. 
The blocking solution was removed and sections were covered in antibody solution and 
incubated at 4°C over night. Cryosections were washed 3 times for 5 min in 1x PB the next 
day before they were incubated in secondary antibody solution for 30 min at room temperature. 
The antibody solution was removed, sections were washed 3 times for 5 min with 1x PB and 
then a small droplet of Dako fluorescence mounting medium was put on each section and 
covered with a cover slip. Cone visualization was performed with Alexa Fluor™ 488-
conjugated peanut agglutinin. All sections were counterstained with 4′,6-diamidino-2-
phenylindol (DAPI, 1:1000). Images were taken with custom-made VisiScope CSU-X1 
Confocal System (Visitron Systems, Puchheim, Germany) equipped with high-resolution 
sCMOS camera (PCO AG, Kelheim, Germany). 
3.19 Retinoschisin Binding Assay 
3.19.1 Retinoschisin Binding to Hek293 Cells Transfected with Different Na/K-
ATPase Subunit Combinations 
Analysis of retinoschisin binding to Hek293 cells transiently transfected with Na/K-ATPase 
subunits was performed as described by Friedrich et al., 2011, with minor modifications. 
Hek293 cells were grown in 6-well plates and transfected with different Na/K-ATPase subunits. 
48 h after transfection, the medium was replaced by 1 ml of retinoschisin containing cell culture 
supernatant (obtained from Hek293 cells stably transfected with a retinoschisin expression 
vector, “Input“ in later analysis). Cells were incubated with retinoschisin for 1 h at 37 °C and 
then harvested by centrifugation (3 min, 1000 rpm, Biofuge fresco by Heraeus). The 
supernatant was removed and collected as ”Flowthrough“ fraction for later analysis. The cell 
pellet was resuspended in 400 µl of PBS and centrifuged for 3 min at 4600 rpm. This washing 
step was repeated three times and the supernatant of the last washing step (”Wash“ fraction) 
was collected for later analysis. The pellet was resuspended in 200 µl of PBS and processed 
for Western blot analysis. 
3.19.2 Binding of Retinoschisin Variants to Y-79 cells  
For comparing binding affinities of retinoschisin and RS1-C59S to Y-79, 4 x 106 Y-79 cells 
were incubated in 5 ml medium containing 1 µg of purified (Myc-tagged) retinoschisin or RS1-
C59S at 37 °C for 10 min, 30 min or 1 h. Subsequent steps were performed as described in 
3.19.1. 
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3.19.3 Binding of Retinoschisin Variants to Retinal Explants 
For comparing binding affinities of retinoschisin and RS1-C59S to Rs1h-/Y murine retinal 
membranes, homogenized tissue of 2 retinae (from mice aged 14 to 18 days) were incubated 
with 1 µg of purified (Myc-tagged) retinoschisin or RS1-C59S in 800 µl RPMI medium at 37 °C 
for 10 min, 30 min or 1 h. After that, 3 washing steps in 200 µl PBS followed by centrifugation 
at 4600 rpm for 15 min at 4°C (Biofuge fresco by Heraeus) were performed. Homogenization 
was achieved with an Eppendorf tube pistil. Fractions for Western blot analysis were collected 
as described for Hek293 cells.   
For localization of bound recombinant RS1 variants on Rs1h-/Y murine retinae, Rs1h-/Y murine 
retinal explants from postnatal day 10 were incubated with 1 µg RS1, RS1-C59S or control 
eluate in 800 µl pre-warmed DMEM-Hams F12 with 10% FCS, 100 U/ml 
penicillin/streptomycin, 2 mM L-glutamine, and 2 µg/ml insulin. After 30 min of incubation, the 
retinal tissue was washed with PBS once before immunolabelling of retinal cryosections (3.18) 
was performed.  
3.20 Investigations on the Effect of Retinoschisin on Signaling Pathways in 
Retinal Model Systems  
For analysing an effect of retinoschisin on signaling pathway activity, Y-79 cells or Rs1h-/Y 
murine retinal explants were treated with retinoschisin, RS1-C59S or control eluate for 10 or 
30 min. Activation of signaling pathways was followed by Western blot analysis or qRT-PCR 
for marker proteins or target genes, respectively.  
Y-79 cells were grown to a concentration of 4-5 x 105 cells/ml in 10 ml medium. The experiment 
was started by adding 1 µg of purified retinoschisin, RS1-C59S, or equal volume of control 
eluate. After 10 or 30 min of incubation at 37 °C, cells were harvested by centrifugation (3 min, 
1000 rpm, Biofuge fresco by Heraeus). For Western blotting, cells were resuspended in 200 µl 
of pre-cooled PBS with PhosSTOP™ and lysed by sonication (10 sec, 40 % intensity). For 
RNA isolation, cells were washed once with pre-cooled PBS before they were subjected to 
RNA isolation as described in 3.1.1. 
Retinal explants from Rs1h-/Y mice at postnatal day 10 were dissected as prepared and 
described in 3.17. Immediately after preparation, explants were transferred into 2 ml Eppendorf 
tubes containing 800 µl pre-warmed DMEM-Hams F12 with 10 % FCS, 100 U/ml 
penicillin/streptomycin, 2 mM L-glutamine, and 2 µg/ml insulin), to which 1 µg purified 
retinoschisin or RS1-C59S, or equal volumes of control eluate had been added. After 10 or 30 
min of incubation at 37 °C, retinal explants were removed from medium and transferred to 200 
µl of pre-cooled PBS containing PhosSTOP™ phosphatase inhibitor. For Western blot 
analysis, retinal explants were sonicated for 10 sec at 40 % intensity. For RNA isolation, retinal 
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explants were immediately transferred into lysis buffer of the PureLink™ RNA Micro Kit and 
RNA isolation was done with PureLink™ RNA Micro Kit according to the manufacturer’s 
protocol.  
3.21 Investigations on the Effect of Retinoschisin on Cellular Processes in Y-
79 Cells 
3.21.1 MTT Assay to Assess Cell Viability 
MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide ) assays were performed 
to determine viability and proliferation of Y-79 cells after treatment with retinoschisin. For 
treatment with increasing amounts of retinoschisin, 900000 cells/well were seeded on Poly-L-
Lysine coated 24 well plates and incubated with 0.015, 0.03, 0.75, 0.15 or 0.3 µg of 
retinoschisin or equal volumes of control eluate in 0.5 ml RPMI medium with 5000 units/ml 
Penicillin and 5000 µg/ml Streptomycin but without FCS. Proliferation was assessed after 24 
h. For analysis of cell viability after treatment with H2O2 and retinoschisin, 900000 cells/well 
were seeded onto Poly-L-Lysine coated 24 well plates and allowed to adhere over night. After 
over night incubation, 0.1 µg of purified retinoschisin or RS1-C59S, or equal volumes of control 
eluate were added to each well. After 1 h, the culture medium was changed to 1 ml RPMI 
(containing retinoschisin variants or control eluate as before) and 0.2 mM or 0.5 mM H2O2 to 
induce apoptosis or 0 mM H2O2 as control. After 2 h, the medium was replaced again by 0.5 
RPMI containing retinoschisin variants or control eluate as before. Cells were allowed to 
recover for 18 h before they were subjected the MTT assay procedure. 
To start the MTT assay, the culture medium was removed and cells were washed twice with 
pre-warmed PBS before 500 µl of fresh medium were added. 50 µl of MTT solution were added 
to the medium and cells were incubated for 30 min, until violet crystals were visible. The 
medium was removed, cells were washed twice in PBS, and finally, 200 µl of 0.1 M HCl in 
isopropanol were added to each well to dissolve the violet crystals. After ten minutes of gentle 
agitation, all the crystals had dissolved and samples were transferred into 1.5 ml Eppendorf 
tubes and centrifuged for 5 min at 10000 rpm (Biofuge fresco by Heraeus). The supernatant 
was transferred into 96-well flat-bottom assay plates and absorbance at 540 nm was measured 
using a FLUOstar™ OPTIMA Microplate Reader.  
3.21.2 CASY TT Cell Analyzer to Assess Cell Number and Diameter 
A CASY TT Cell Analyzer was used to determine cell numbers and mean cell diameters of Y-
79 cells after treatment with retinoschisin. Y-79 cells were seeded at a starting concentration 
of 200000 cells/well in 24 well plates and 0.1 µg of recombinant retinoschisin or control eluate 
were added. Cells were then incubated for 24, 72, and 96 h, and measurements were 
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performed on 60 µl of the cell suspensions after each time point. All measurements were 
carried out according to the manufacturer's directions using a 1:100 dilution of cells in 6 ml of 
CASY-Ton solution.  
3.21.3 Caspase-3 Assay to Assess Apoptosis 
Y-79 cells were seeded onto Poly-L-Lysine coated 24 well plates at a concentration of 2 x 106 
cells/well and allowed to adhere over night. After over night incubation, 0.1 µg of purified 
retinoschisin or RS1-C59S, or equal volumes of control eluate were added to each well. After 
1 h, the culture medium was changed to 1 ml RPMI (containing retinoschisin variants or control 
eluate as before) and 0.2 mM H2O2 to induce apoptosis or 0 mM H2O2 as control. After 2 h, the 
medium was replaced again by 1 ml RPMI containing retinoschisin variants or control eluate 
as before. Cells were allowed to recover for 18 h before they were subjected to analysis of 
caspase activity using the EnzChek® Caspase-3 Assay Kit #2 according to the manufacturer’s 
directions. 
3.22 Investigations on the Effect of Retinoschisin on the Na/K-ATPase Activity  
3.22.1 Na/K-ATPase Catalyzed ATP Hydrolysis in Murine Retinal Explants 
A plasma membrane-enriched fraction was collected from retinae of Rs1h-/Y mice at postnatal 
day 16 as described before (Friedrich et al., 2011) and solubilized in TBS or Na+ free ATPase 
test buffer (the latter only for Na+ affinity experiments). Protein concentrations of enriched 
membrane fractions were determined using a Bradford assay as described in 3.12.   
For testing the effect of recombinant retinoschisin on Na/K-ATPase catalysed ATP hydrolysis, 
Rs1h-/Y retinal membrane fractions were incubated for 30 min with or without recombinant 
retinoschisin (1.25 µg/ml) before starting the experiment. ATP hydrolysis reactions were 
performed at 37 °C for 60 min in a buffer system containing 100 mM Tris/HCl, pH 7.4, 120 mM 
NaCl, 20 mM KCl, 3 mM ATP, and 3 mM MgCl2, with and without 0.1 mM ouabain. 10 µl of 
each sample were transferred into a 96-well flat-bottom assay plate at 0 and 60 min, and kept 
on ice.  
Pi release (Jones et al., 2005) was measured colourimetrically (Howard and Ridley, 1990). To 
start the colorimetric reaction, 300 µl of phosphate reagent (freshly prepared during the 1 h 
incubation step, Triton-X added right before use) were added to each sample and the reaction 
was stopped after 3 min by adding 60 µl of 34 % citric acid. A calibration curve containing 
defined amounts of phosphate (1 nM, 2 nM, 3 nM, 4 nM, 5 nM, 6 nM, and 7 nM) was included. 
The photometric measurement at 630 nm was performed on a FLUOstar™ OPTIMA 
Microplate Reader.  
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To test whether the addition of retinoschisin influences Na/K-ATPase affinity towards its 
substrates the Na/K-ATPase activity was carried out as described above, but with varying 
concentrations of Na+ (0-130 mM), K+ (0–25 mM) or ATP (0-3 mM). All other test parameters 
remained unchanged.   
The amount of phosphate generated in presence of ouabain was accounted as background P i 
release by enzymes other than the Na/K-ATPase and subtracted from the overall free 
phosphate measured.   
Less than 5 % of the ATP was hydrolysed during the assay. Data were analysed by nonlinear 
regression using Sigma Plot Graph System 12.5 (Jandel Scientific). Activation curves were 
fitted according to the Hill model for ligand binding. Michaelis-Menten constants (Km values) 
were derived from the Michaelis-Menten equation. 
Binding of recombinant retinoschisin to murine Rs1h-/Y retinal membranes under the different 
buffer conditions was investigated in binding assays as described in 3.19.3, with following 
modifications: recombinant retinoschisin (1 µg/ml), which had previously been dialysed against 
the respective test buffers was applied and the different Na/K-ATPase test buffers were used 
for incubation and wash steps. 
3.22.2 Na/K-ATPase Pump Function in Xenopus leavis Oocytes  
All experiments on X. leavis oocytes were conducted by the laboratory of Prof. Thomas 
Friedrich, Institute of Chemistry, Technical University of Berlin, Germany.  
The cRNAs for ouabain insensitive ATP1A3 (ATP1A3_RD, expression vector kindly provided 
by Dr. Jan B. Koenderink, Department of Pharmacology and Toxicology, Nijmegen University, 
Netherlands) and ATP1B2 were transcribed in vitro using the mMESSAGE mMACHINE™ SP6 
Transcription Kit. Oocyte isolation, cRNA injection, heterologous Na/K-ATPase expression in 
oocytes, as well as Rb+ uptake experiments were performed as described in (Dürr et al., 2013). 
All assay were conducted in the presence of 10 µM ouabain to inhibit endogenous Na/K-
ATPase activity. Rb+ uptake was assessed with an AAnalyst 800 utilizing the THGA Furnace 
System and evaluated as described in (Dürr et al., 2013). Oocytes were incubated for 1 h with 
or without recombinant retinoschisin (1 or 8 µg/ml) before starting the experiment. 
3.23 Investigations on the Effect of Retinoschisin on Na/K-ATPase Stability  
To analyse a potential influence of retinoschisin on Na/K-ATPase protein stability and turnover, 
murine Rs1h-/Y retinal explants and transiently transfected Hek293 cells were treated with 
retinoschisin or control eluate and the amounts of Na/K-ATPase subunit proteins were 
analysed after different time points.   
For experiments with heterologously expressed Na/K-ATPase, Hek293 cells were transiently 
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transfected with pCEP_ATP1A3+ATP1B2 vector (enabling bicistronic expression of ATP1A3 
and ATP1B2) in a 12-well format and the experiment was started 72 h later. 0.5 µg of 
recombinant retinoschisin or equal volume of control eluate was added to each well and cells 
were incubated at 37 °C for 0, 4, 8, or 24 h before they were harvested. Cell pellets were 
resuspended in 150 µl PBS and immediately frozen until further analysis.   
As an alternative approach, retinae were isolated from Rs1h-/Y at p14 and transferred into 500 
µl pre-warmed DMEM-Hams F12 with 10 % FCS, 100 U/ml penicillin/streptomycin, 2 mM L-
glutamine, and 2 µg/ml insulin. 0.5 µg of purified retinoschisin or equal volume of control eluate 
were added to the medium. Retinae were incubated at 37 °C for 0, 4, 8, or 24 h before they 
transferred were into 150 µl PBS and immediately frozen until further analysis.   
Collected Hek293 cells and retinae were finally sonicated at 40 % intensity for 30 s and 50 µl 
of the lysate was saved for later analysis (total fraction). 100 µl of PBS were added to the 
remaining sample and a membrane enrichment was carried out as described in Friedrich et 
al., 2011. The enriched membranes were resuspended in 100 µl and analysed via Western 
blot.  
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4 Results 
4.1 Cloning and Characterization of Recombinant Myc-tagged Retinoschisin 
Variants 
4.1.1 Cloning of N-terminal Myc-tagged Retinoschisin and RS1-C59S 
Functional properties of retinoschisin were analysed conducting experiments with 
heterologously expressed, purified retinoschisin (NM_000330.3) and an XLRS-associated 
variant harbouring an aa exchange from Cysteine to Serine at aa position 59, termed RS1-
C59S (NM_000330.3(RS1): c.175T>A [p.Cys59Ser]). RS1-C59S is one of the rare XLRS 
variants which are not subjected to co- or posttranslational degradation, but instead are 
translated and secreted from cells, although, in case of RS1-C59S not as a stable octamer but 
as a dimer (Wu et al., 2003. Wu et al., 2005).  
To enable enrichment and purification of the recombinant proteins, non-mutant retinoschisin 
and RS1-C59S were fused to an N-terminal Myc-tag. N-terminal Myc-tagged retinoschisin had 
previously been used by another group and was shown to be stable and oligomerize into 
octamers (Dyka and Molday, 2007). Due to cleavage of the signal peptide upon secretion, the 
tag was inserted between the signal peptide and the RS1 domain (Figure 7). The coding 
sequences of Myc-tagged retinoschisin and RS1-C59S were introduced into a pCDNA3.1 
expression vector.  
 
Figure 7: Schematic representation of N-terminal Myc-tagged retinoschisin 
To obtain an N-terminal tagged protein after secretion the Myc-tag peptide sequence (green) was inserted between 
the signal peptide (yellow) and the RS1 domain (purple). The position of the pathogenic aa exchange at aa position 
59, C59S, is marked by the black arrow.  
4.1.2 Purification of Recombinant Retinoschisin Variants  
An immunoprecipitation protocol was applied to purify retinoschisin and RS1-C59S from 
supernatant of Hek293 cells transiently transfected with the generated expression vectors for 
Myc-tagged retinoschisin or RS1-C59S (pCDNA3_RS1_Myc or pCDNA3_RS1_C59S_Myc). 
As an additional control, the same protocol was applied on supernatant of Hek293 cells 
transfected with an empty pCDNA3.1 expression vector. Purity and enrichment of the purified 
retinoschisin variants was analysed by Coomassie staining, silver staining and Western 
blotting (Figure 8).    
Coomassie and silver staining revealed prominent protein bands of 55 to 100 kDa in the 
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unpurified supernatants of all samples. In the supernatants of retinoschisin or RS1-C59S 
expressing Hek293 cells, weak signals at 25 kDa, the expected size for retinoschisin 
monomers, were additionally observed. After purification, a distinct band of 25 kDa was visible 
in the eluates of retinoschisin and RS1-C59S containing supernatants, but not in the control. 
No other bands were detected in the stained gels after purification (Figure 8 A and B). Western 
blot analyses with antibodies against retinoschisin and the Myc-tag (Figure 8 C) showed 
signals at around 25 kDa in the samples with unpurified and purified retinoschisin variants, but 
not in the control. The detected signals of tagged retinoschisin variants showed a slightly 
increased molecular weight compared to untagged retinoschisin, in consistence with increased 
molecular weight due to the fused Myc-tag. Signal intensity of Myc-tagged retinoschisin in the 
purified protein fractions was stronger than in the applied supernatant.   
Together, these data indicate successful enrichment and purification of the recombinant 
proteins.   
 
  
Figure 8: Purification of Myc-tagged RS1 variants. 
Proteins before (supernatant of Hek293 cells transfected 
with RS1 expression vectors) and after purification were 
subjected to SDS PAGE and analysed via A) silver 
staining, B) Coomassie staining and C) immunoblots using 
antibodies against the Myc-tag and retinoschisin. Control: 
protein from supernatant of empty expression vector 
transfected cells; RS1: Myc-tagged retinoschisin; RS1-
C59S: Myc-tagged RS1-C59S; RS1 untagged: untagged 
retinoschisin. (Figure modified from Plössl et al., 2017a) 
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To check for correct oligomerization of the recombinant retinoschisin variants, unpurified and 
purified proteins were further subjected to a non-reducing SDS page and subsequent Western 
blot analysis (Figure 9). Unpurified as well as purified normal retinoschisin migrated at the 
expected size for retinoschisin octamers of around 200 kDa. RS1-C59S (unpurified and 
purified) migrated as a single band of about 50 kDa in size, consistent with previously 
described oligomerization properties of this variant (Wu et al., 2003, Wu et al., 2005, Figure 
9, left panel). The same samples separated via SDS-PAGE under reducing conditions 
migrated as distinct single bands at 25 kDa, the expected size for retinoschisin monomers 
(Figure 9, right panel).   
This shows that addition of the Myc-tag and the purification process do not alter the 
oligomerization properties of the Myc-tagged retinoschisin variants. 
 
4.1.3 Binding of Retinoschisin Variants to Retinal Membranes 
Previous studies showed that retinoschisin binds to retinal membranes via its interaction with 
the retinal Na/K-ATPase, consisting of the two subunits ATP1A3 and ATP1B2 (Molday et al., 
2007, Friedrich et al., 2011). To investigate binding properties as well as functionality of Myc-
tagged retinoschisin variants, their affinity to retinal membranes was analysed. Retinoschisin 
binding was tested on murine retinal membranes from Rs1h-/Y mice as well as on membranes 
of the human retinoblastoma cell line Y-79. Previous studies at the Institute of Human 
Genetics, University of Regensburg, showed that this cell line also endogenously expresses 
ATP1A3 and ATP1B2 (published in Plössl et al., 2017a).   
Y-79 cells and Rs1h-/Y retinal explants exposed to purified retinoschisin for 10, 30, and 60 min 
stably bound the externally added retinoschisin, even after only 10 min of incubation (Figure 
10). In comparison, RS1-C59S exhibited a strongly reduced binding affinity to Y-79 cells and 
Rs1h-/Y retinal explants (Figure 10). 
  
Figure 9: Oligomerization of Myc-
tagged retinoschisin variants 
Proteins before (supernatant of Hek293 
cells transfected with RS1 expression 
vectors) and after purification were 
subjected to SDS PAGE under non-
reducing and reducing conditions, 
followed by Western blot analyses using 
an anti-retinoschisin antibody. RS1: Myc-
tagged retinoschisin; RS1-C59S: Myc-
tagged RS1-C59S. (Figure modified from 
Plössl et al., 2017a) 
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In a next step, immunohistochemical analyses were applied to test for correct localization of 
bound recombinant retinoschisin on retinal membranes. Rs1h-/Y retinal explants incubated with 
recombinant retinoschisin for 30 min showed an intense retinoschisin staining in the inner 
segments, colocalizing with the endogenously expressed retinal Na/K-ATPase of the murine 
retina (Figure 11). Similar staining patterns were obtained for retinoschisin and the Na/K-
ATPase at the photoreceptor inner segments of wildtype retinae (Molday et al., 2007, Friedrich 
et al., 2011). However, in contrast to wildtype retinae, no recombinant retinoschisin was 
detected in the plexiform layers of the retinal explants. This could be a result of limited diffusion 
of the externally added retinoschisin through the retinal layers. No retinoschisin signals were 
obtained when Rs1h-/Y retinal explants were incubated with RS1-C59S or control eluate 
(Figure 11). 
 
Figure 11: Localization of recombinant retinoschisin variants on retinal membranes  
Rs1h-/Y retinal explants (P10) were incubated for 30 min with retinoschisin, RS1-C59S, or control protein. After 
washing and embedding, cryosections of these explants were subjected to immunohistochemical analyses using 
antibodies against ATP1B2 and retinoschisin. DAPI staining shows the nuclei of the different retinal layers. IS, inner 
segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner  plexiform layer; 
GCL, ganglion cell layer (Figure modified from Plössl et al., 2017a) 
  
Figure 10: Binding of recombinant 
retinoschisin and RS1-C59S to retinal cells 
Y-79 cells and murine Rs1h-/Y retinal explants 
were incubated with 1 µg/ml of purified 
retinoschisin variants in cultivation medium (I, 
input) for 10, 30 and 60 min. Subsequently, cells 
were centrifuged and supernatant (FT, 
flowthrough) was discarded. After several 
washing steps (last supernatant, W), cells were 
pelleted (pellet, P). Fractions were subjected to 
Western blot analyses using an anti-retinoschisin 
antibody. (Figure modified from Plössl et al., 
2017a) 
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4.2 Influence of Retinoschisin on Na/K-ATPase Stability and Turnover  
Na/K-ATPase binding members of the FXYD family were reported to stabilise Na/K-ATPases 
in membranes, thus exerting an important effect of regulating Na/K-ATPase activity (Mishra et 
al., 2011). Likewise, retinoschisin could also affect stability of the retinal Na/K-ATPase in retinal 
membranes, or influence Na/K-ATPase levels at other stages like protein expression or export. 
An effect of retinoschisin on Na/K-ATPase levels was thus assessed in Rs1h-/Y retinal explants 
or Hek293 cells heterologously expressing ATP1A3 and ATP1B2. These were incubated with 
recombinant retinoschisin or control eluate. Retinal Na/K-ATPase expression was analysed 
after various time points (0, 4, 8, and 24 h) by Western blot, applying antibodies against 
ATP1A3 and ATP1B2. To distinguish between total Na/K-ATPase and Na/K-ATPase levels at 
plasma membranes, total cell lysate and a plasma membrane enriched membrane fraction of 
the treated Hek293 cells or retinal explants were included in the study.  
Hek293 cells were transiently transfected with a bicistronic expression vector for ATP1A3 and 
ATP1B2 and incubated for 72 h before addition of recombinant retinoschisin or control eluate. 
Western blot analyses (Figure 12) detected bound recombinant retinoschisin in total cell 
lysates as well as in enriched membrane fractions of the retinoschisin treated Hek293 cells 
(except for the 0 h control sample). Na/K-ATPase subunits ATP1B2 and ATP1A3 were present 
in all fractions and their signal intensities were evaluated by densitometry. ATP1B2 and 
ATP1A3 expression was not affected by retinoschisin treatment at any time point, neither in 
total cell lysates nor in enriched membrane fractions (Figure 12).  
  
Results 
63 
 
 
Murine Rs1h-/Y retinal explants also showed binding of recombinant retinoschisin. Both total 
cell lysates as well as enriched membrane fractions showed specific 25 kDa bands in samples 
exposed to recombinant retinoschisin (Figure 13). The anti-retinoschisin staining also gave 
unspecific signals with a size slightly smaller than for retinoschisin in all samples. Densitometric 
evaluation of ATP1B2 and ATP1A3 in total tissue lysates failed to reveal any differences 
between control or retinoschisin treated samples at any time point (Figure 13 A). Signal 
intensities of ATP1A3 and pan-Cadherin in enriched membrane fractions of murine Rs1h-/Y 
retinal explants were too faint to be evaluated. ATP1B2 signals in enriched membrane fractions 
in contrast were clearly visible, but their densitometric evaluation showed no effect due to 
retinoschisin treatment (Figure 13 B).  
  
Figure 12: Effect of retinoschisin 
on retinal Na/K-ATPase levels after 
heterologous Na/K-ATPase 
expression in Hek293 cells  
Hek293 cells were transfected with a 
bicistronic expression vector for 
ATP1A3 and ATP1B2. 72 h after 
transfection, they were treated with 
recombinant retinoschisin (+) or 
control eluate (-). After 0, 4, 8, and 24 
h of incubation samples from A) total 
cell lysates as well as B) enriched 
membrane fractions were subjected 
to Western blot analyses with 
antibodies against retinoschisin, 
ATP1B2, ATP1A3 and retinoschisin. 
ACTB and pan-Cadherin (CAD) 
served as loading controls. 
Densitometric quantification was 
done with ImageJ. Signals for 
ATP1A3 and ATP1B2 (only the 55 
kDa mature protein band) in total cell 
lysates were normalized against 
ACTB and calibrated against the 
control. Signals for ATP1B2 and 
ATP1A3 in enriched membrane 
fractions were normalized against 
Cadherin and calibrated against the 
control. Data given are means + SD 
(n=3). 
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4.3 Influence of Retinoschisin on Na/K-ATPase Ion Pump Activity 
4.3.1 Effect of Retinoschisin on Na/K-ATPase Mediated ATP Hydrolysis and 
Substrate Affinity in Retinal Membranes 
Na/K-ATPase binding proteins such as the extracellular fragment of amyotrophic lateral 
sclerosis associated glycoprotein non-metastatic melanoma protein B (GNMPB) (Ono et al., 
2016) or FXYD family members (Béguin et al.,1997, Arystarkhova et al., 1999, Therien et al., 
1999, Pu et al., 2001, Jones et al., 2005, Geerig, 2006) were reported to affect Na/K-ATPase 
ion transport activity. Likewise, retinoschisin could also affect the active ion pump function of 
the retinal Na/K-ATPase. The following experiments were performed to assess an effect of 
recombinant retinoschisin on retinal Na/K-ATPase mediated ATP hydrolysis and cation 
transport. 
Enriched Rs1h-/Y retinal membranes were pre-incubated with recombinant retinoschisin for 30 
min before the enzymatic assay was started. A colorimetric assay was used to determine free 
phosphate generated by ATP hydrolysis after 1 h of incubation. Ouabain sensitive ATP 
hydrolysis in Rs1h-/Y retinal explants was 5.6 ± 1.3 nmol Pi /(μg protein*h) and did not change 
in the presence of recombinant retinoschisin (5.5 nmol ± 1.1 nmol Pi /[μg protein*h]; P=0.76, 
n=11).  
Binding of FDXY2 to the Na/K-ATPase was reported to influence its substrate affinity but not 
its activity under optimal test conditions (Jones et al., 2005). Substrate affinity of the murine 
retinal Na/K-ATPase in presence or absence of retinoschisin was thus additionally addressed 
Figure 13: Effect of retinoschisin on 
retinal Na/K-ATPase protein stability in 
murine Rs1h-/Y retinal explants  
Murine retinal explants were treated with 
recombinant retinoschisin (+) or control 
eluate (-). After 0, 4, 8, and 24 h of 
incubation samples from A) total cell 
lysates as well as B) enriched membrane 
fractions were subjected to Western blot 
analyses with antibodies against 
retinoschisin, ATP1B2, ATP1A3, and 
retinoschisin. ACTB served as loading 
controls. Densitometric quantification was 
done with ImageJ. In total cell lysates 
signals for ATP1B2 (only the 55 kDa 
mature protein band) and ATP1A3 were 
normalized against ACTB and calibrated 
against the control. Signals for ATP1B2 in 
enriched membrane fractions were 
calibrated against the control. Data given 
are means + SD (n=3).   
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via the ouabain sensitive ATP hydrolysis assay. For this approach, Na/K-ATPase activity was 
measured as a function of Na+ (0-130 mM), K+ (0-25 mM) or ATP (0-3 mM). Addition of 
recombinant retinoschisin did not affect Na/K-ATPase affinities for either Na+, K+ or ATP 
(Figure 14).  
 
Figure 14: Influence of retinoschisin on substrate affinity of the retinal Na/K-ATPase  
Rs1h-/Y retinal membrane fractions were pre-incubated for 30 min with (open circles) or without (closed circles) 
retinoschisin (1.25 µg/ml). Subsequently, Na/K-ATPase catalysed ATP hydrolysis was measured as a function of 
Na+ (A, n=4), K+ (B, n=4), and ATP (C, n=3). Data are given as means + SD. (Figure modified from Plössl et al., 
2017b) 
 
The corresponding Michaelis-Menten constants for Na+, K+, and ATP were derived from the 
Michaelis-Menten equation and reveal no statistically significant differences (Table 39).  
Table 39: Michaelis-Menten constants (Km) for Na/K-ATPase from murine Rs1h-/Y retinal membranes 
incubated with or without recombinant retinoschisin (RS1). (Table modified from Plössl et al., 2017b) 
 
 
 
Recombinant retinoschisin was dialysed against the different Na/K-ATPase test buffers before 
its application to the enzymatic assays. In addition, the utilized Na/K-ATPase test buffers were 
different to the buffers usually applied in retinoschisin binding assays. To confirm binding of 
recombinant retinoschisin to the retinal membranes under these experimental conditions, 
binding assasys were performed using dialyzed retinoschisin and the different Na/K-ATPase 
test buffers. As shown in Figure 15 the altered conditions did not affect retinoschisin binding 
to retinal membranes of Rs1h-/Y mice.   
  
 Rs1h-/Y +RS1 wildtype P 
Km (Na+), mM 12.32 ± 0.42 12.17 ± 0.60 0.6975 
Km (K+), mM 2.20 ± 0.16 2.20 ± 0.45 1.000 
Km (ATP), mM 0.29 ± 0.06 0.29 ± 0.06 0.956 
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An identical set of experiments comparing Na/K-ATPase activity and substrate affinities in 
Rs1h-/Y retina versus wildtype retina was carried out by Melanie Royer as part of her master 
thesis which she conducted at the Institute of Human Genetics, University of Regensburg from 
March to September 2016. Similar results were obtained for Na/K-ATPase activities and 
Michaelis-Menten constants for Na+, K+, and ATP and showed no statistical significant 
differences between samples Rs1h-/Y and wildtype retina (published in Plössl et al., 2017b). 
4.3.2 Effect of Retinoschisin on Rb+ Import into X. leavis Oocytes Mediated by 
Heterologously Expressed Retinal Na/K-ATPase 
A putative influence of retinoschisin on Na/K-ATPase pump function was further addressed 
using X. leavis oocytes heterologously expressing both subunits (ATP1A3 and ATP1B2) of the 
retinal Na/K-ATPase as a model system. All experiments on X. leavis oocytes were performed 
by the group of Prof. Thomas Friedrich at the Technical University of Berlin. 
For analysis of ion pump function in oocytes a mutated, ouabain insensitive version of the 
ATP1A3 subunit was used. Two aa exchanges (Q108R and N119D) were introduced into the 
coding sequence of ATP1A3 which leads to a reduced ouabain affinity of this mutated enzyme 
with half-maximal inhibitory concentration (IC50) in the millimolar range (Price and Lingrel, 
1988; Dürr et al., 2013). This allows for distinction between heterologously expressed pumps 
and endogenous X. leavis Na/K-ATPases, which can be inhibited by 10 µM ouabain (Dürr et 
al., 2013). 
To confirm that retinoschisin is also capable of binding to the ouabain insensitive Na/K-
ATPase, a binding assay was performed in Hek293 cells heterologously co-expressing 
ATP1B2 and the ouabain insensitive ATP1A3 subunit. Like to the normal retinal ATP1A3 
subunit, retinoschisin efficiently bound to the ouabain-insensitive ATP1A3 variant (Figure 16 
A).  
Atomic Absorption Spectroscopy (AAS) determined the import of Rb+ ions, which act as a 
congener of K+, into ATP1A3 and ATP1B2 expressing oocytes. Upon heterologous expression 
Figure 15: Binding of recombinant retinoschisin 
to retinal Na/K-ATPases under different Na/K-
ATPase test buffer conditions.  
Rs1h-/Y retinal membrane fractions were incubated 
with 1.25 µg/ml retinoschisin dialysed against 
different Na/K-ATPase test buffers (control buffer, 
Na+-free buffer and K+-free buffer) in the respective 
test buffer for 1 h. I = input, respective buffer + 
dialysed retinoschisin; FT = flowthrough; W = last 
wash with respective buffer, P = pellet, final murine 
retinal membrane fraction. (Figure modified from 
Plössl et al., 2017b) 
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of the retinal Na/K-ATPase, Rb+ uptake by oocytes increased about 6 fold compared to 
untransfected oocytes (Figure 16). The average uptake was 7 ng Rb+ per transfected oocyte 
in 3 min (corresponding to 7899 nC), which is in line with published results for Na/K-ATPase 
activity in transfected oocytes (Dürr et al., 2013). 10 mM ouabain lead to an inhibition of the 
heterologously expressed Na/K-ATPase by around 80 % (Figure 16 B and C). The addition of 
1 µg/ml retinoschisin had no effect on ion pumping activity of the Na/K-ATPase (Figure 16 B). 
An increase to 8 µg/ml retinoschisin also revealed no effects (Figure 16 C). 
 
Figure 16: Analysis of Na/K-ATPase pump function in X. leavis oocytes  
A) Hek293 cells were transfected with an expression vector for ATP1A3 or ouabain insensitive ATP1A3 (ATP1A3-
OI) in combination with an expression vector for ATP1B2. 72 h after transfection, cells were incubated for 60 min 
with retinoschisin containing cell culture supernatant (input). After intensive washing, retinoschisin binding was 
assessed by subjecting cell pellets to Western blot analyses with antibodies against retinoschisin. The ACTB 
immunoblot was performed as loading control. I = input; FT = flowthrough; W = last wash, P = final Hek293 cell 
pellet. B) and C) Oocytes were injected with cRNAs for human ATP1A3 and ATP1B2 and incubated for 3 days. Rb+ 
uptake was determined with or without ouabain (10 mM) at pH 5.5 in a solution containing 5 mM Rb +. Oocytes were 
preincubated for 1 h with or without 1 (B) or 8 (C) µg/ml retinoschisin. The number of replicates (nu mber of 
cells/number of independent cell batches) is given in brackets. Data are presented as means + SEM. (Figure 
modified from Plössl et al., 2017b) 
4.4 Influence of Retinoschisin on Intracellular Signaling 
Protein and mRNA expression profiling revealed an upregulation of MAPK signaling, in 
particular of the ERK pathway, in Rs1h-/Y mice compared to wildtype littermates at different 
postnatal stages (Gehrig et al., 2007). Yet, whether these differences are a primary 
consequence of retinoschisin deficiency or a secondary effect due to retinal degeneration, 
remained unresolved. Subsequently, two different retinal model systems, P10 Rs1h-/Y- retinal 
explants and Y-79 cells, were used to address this question and analyse a possible role for 
retinoschisin in the direct regulation of the ERK pathway, potentially via its effect on the Na/K-
ATPase. In addition, an involvement of two more Na/K-ATPase associated signaling pathways, 
IP3/AKT signaling and Ca2+ signaling, was also addressed in this study.  
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4.4.1 Effect of Retinoschisin on the ERK Pathway Activity in Retinal Model 
Systems 
To assess an effect of retinoschisin on ERK signaling, Y-79 cells or retinal explants were 
treated with recombinant retinoschisin, RS1-C59S, or equal volumes of control eluate and 
incubated for 10 or 30 min. Phosphorylation and hence activation of ERK signaling constituents 
was then followed by Western blotting. In specific, these analyses addressed phosphorylation 
of extracellular-signal-regulated kinases 1 and 2 (ERK1/2) and C-RAF, a central constituent of 
the ERK pathway, the activation of which precedes and is required for Erk1/2 phosphorylation 
(Roskoski, 2012). 
In Y-79 cells a downregulation of phosphorylated C-RAF (77.6 ± 9.7 %) was observed after 10 
min of treatment with recombinant retinoschisin, but not upon treatment with RS1-C59S. 
Differences in phosphorylated C-RAF levels between retinoschisin treatment and control or 
RS1-C59S-treatment were statistically significant. (P < 0.05). After 30 min of treatment with 
retinoschisin, the effect of retinoschisin on C-RAF phosphorylation was still evident, with a 
reduction of phosphorylated C-RAF activation to 78.4 ± 17.0 % (Figure 17 A). In contrast to 
its effect on C-RAF, 10 min of incubation with retinoschisin failed to show an effect on ERK1/2 
phosphorylation. However, 30 min of retinoschisin treatment reduced ERK activation to around 
69.6 ± 5.3 % in Y-79 cells (P < 0.05 compared to control protein or RS1-C59S) (Figure 17 B). 
No alterations in total C-RAF and total ERK1/2 protein levels were seen after 10 or 30 min, 
excluding an effect of retinoschisin on expression or stability of the two proteins (Figure 17). 
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Figure 17: Influence of retinoschisin on the ERK pathway in Y-79 cells. 
Y-79 cells were treated for 10 min or 30 min with 1 µg/ml retinoschisin, RS1-C59S, or equal volumes of control 
eluate. Cell lysates were subjected to Western blot analyses with antibodies against A) phosphorylated c-Raf (pRaf) 
and total c-Raf (Raf), or B) phosphorylated Erk1/2 (pErk1/2), or total Erk1/2 (Erk1/2). ActB served as a loading 
control. Densitometric quantification was done with ImageJ. Signals for pRaf, Raf, pErk1/2 and Erk1/2 were 
normalized against ActB and calibrated against the control. Data given are means + SD (n=5).  
Asterisks mark statistically significant (*P < 0.05) and highly significant (**P < 0.01) differences. (Figure modified 
from Plössl et al., 2017a) 
 
A comparable effect of retinoschisin on ERK signaling was also observed in murine Rs1h-/Y 
retinal explants. After 10 min of incubation with retinoschisin, phosphorylated c-Raf levels were 
reduced to 73.4 ± 16.3 %, while RS1-C59S treatment had no effect on c-Raf phosphorylation. 
The differences in phosphorylated c-Raf were statistically significant (P < 0.05) between 
retinoschisin and control or RS1-C59S treatment. The reduction of c-Raf phosphorylation by 
retinoschisin treatment was still observable after 30 min of retinoschisin treatment, with a 
decrease in c-Raf phosphorylation to 81.4 ± 14.1 %, compared to control (Figure 18 A). 
Likewise to the effects seen in Y-79 cells, Erk1/2 phosphorylation murine Rs1h-/Y retinal 
explants was not affected after 10 min of treatment with recombinant retinoschisin. A clear 
reduction of phosphorylated Erk1/2 (68.7 ± 18.2 % compared to control) was observed after 
30 min of treatment with retinoschisin (P < 0.05 compared to control or RS1-C59S treatment). 
RS1-C59S did not decrease Erk1/2 phosphorylation after 10 or 30 min (Figure 18 B). Total c-
Raf and total Erk1/2 protein levels in retinal explants were unaffected by the different 
treatments (Figure 18). 
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Figure 18: Influence of retinoschisin on the ERK pathway in murine Rs1h-/Y retinal explants.  
P10 Rs1h-/Y retinal explants were treated for 10 min or 30 min with 1 µg/ml retinoschisin, RS1 -C59S, or equal 
volume of control eluate. Subsequently, lysates were subjected to Western blot analyses with antibodies against 
A) phosphorylated c-Raf (pRaf) and total c-Raf (Raf), or B) phosphorylated Erk1/2 (pErk1/2) and total Erk1/2 
(Erk1/2). ActB served as a loading control. Densitometric quantification was done with ImageJ. Signals for pRaf, 
Raf, pErk1/2 and Erk1/2 were normalized against ActB and calibrated against the  control. Data given are means + 
SD (n=5). Asterisks mark statistically significant differences (*P < 0.05). (Figure modified from Plössl et al., 2017a) 
 
In a next step, the effect of retinoschisin on the expression of two MAPK target genes, early 
growth response protein 1 (EGR1) and FBJ murine osteosarcoma viral oncogene homolog 
gene (C-FOS) (Whitmarsh and Davis, 1996, Hazzalin and Mahadevan, 2002, Hess et al., 2004, 
Murphy and Blenis, 2006, Whitmarsh, 2007) were also addressed via qRT-PCR in both model 
systems. 
Upon treatment with recombinant retinoschisin, C-FOS mRNA in Y-79 cells was decreased to 
84.6 ± 7.7 % in Y-79 cells and to 68.1 ±18.9 % in Rs1h-/Y murine retinal explants (P < 0.05). 
RS1-C59S treatment, in contrast, had no prominent effect on C-FOS transcripts levels. The 
differences between the retinoschisin and control or RS1-C59S treatment were statistically 
significant (P < 0.05) in both model systems (Figure 19 A).  
Similarly, retinoschisin treatment also caused a marked decrease in EGR1 expression (Figure 
19 B). EGR1 transcript levels were reduced to 82.0 ± 8.8 % in Y-79 cells and to 76.6 ± 18.8 % 
in Rs1h-/Y murine retinal explants (P < 0.05) when compared to control treatment. No prominent 
decrease of EGR1 mRNA levels was found after treatment with RS1-C59S compared to 
retinoschisin treatment.  
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4.4.2 Role of SRC in the Retinoschisin Induced Inhibition of ERK Singaling 
For further studies on the mechanism of signaling regulation by retinoschisin, a focus was set 
on the retinal explant model system.  
Activation of the non-receptor tyrosine-protein kinase SRC was described as an initial step in 
ERK1/2 activation by Na/K-ATPases (Haas et al., 2002; Tian et al., 2005; Quintas et al., 2010; 
Reinhard et al., 2013; Banerjee et al., 2015; Yosef et al., 2016). A possible influence of 
retinoschisin on Src phosphorylation was hence addressed by incubating retinal explants with 
retinoschisin or controls. Src activation was followed by Western blot analyses against 
phosphorylated and thus activated Src. To assess an involvement of Src in Erk1/2 activation, 
additional assays were performed in the presence of the specific Src kinase inhibitor PP2 (4-
amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine). 
Murine Rs1h-/Y retinal explants were treated for 10 and 30 min with recombinant retinoschisin, 
RS1-C59S, control eluate, or PP2. 10 min of retinoschisin treatment slightly reduced Src 
phosphorylation to 86.8 ± 2.9 % compared to control treatment, (P < 0.01). Src activity was not 
decreased by RS1-C59S treatment (110.9 ± 23.8 %, compared to control). The reduction of 
Src activity was no longer visible after 30 min of incubation with retinoschisin (Figure 20 A). 
Treatment with PP2 lead to an almost complete de-phosphorylation of Src (pSrc levels about 
25 % at 10 min, 10 % at 30 min). Total Src levels were not affected by any of the treatments, 
which excludes an effect on overall Src protein stability or expression levels. Addition of the 
Src inhibitor PP2 to retinal explants resulted in a strong and statistically highly significant 
downregulation of Erk1/2 phosphorylation after 30 min of incubation (50.0 ± 11.8 %, P < 0.01 
compared to control treatment). Total Erk1/2 protein levels were not affected by PP2, excluding 
an effect on expression or stability of Erk1/2 (Figure 20 B). 
Figure 19: Influence of retinoschisin 
on expression of ERK1/2 pathway 
target genes 
A) Y-79 cells or B) Rs1h-/Y retinal 
explants were treated with 
recombinant retinoschisin, RS1-C59S 
or control eluate for 2 h (Y-79 cells) 
and 30 min (murine retinal explants). 
C-FOS and EGR1 mRNA expression 
was determined via qRT-PCR. Results 
were normalized to HPRT transcript 
levels and calibrated against the 
control. Data given are means +  
SD (n=5). Asterisks mark statistically 
significant differences (*P < 0.05). 
(Plössl et al., 2017a) 
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4.4.3 Effect of Retinoschisin on PI3K/AKT and Ca2+ Signaling  
An influence of retinoschisin on PI3K/AKT signaling was investigated by following 
phosphorylation of its central signaling constituent Akt (Tang et al., 2017) in Rs1h-/Y murine 
retinal explants. However, no differences in Akt activation could be seen in retinoschisin 
treated explants compared to control treatments, neither after 10 nor after 30 min of incubation. 
Total Akt levels were also not affected by any of the treatments (Figure 21 A). 
A potential influence of retinoschisin on Ca2+ signaling was tested using Ca2+/calmodulin-
dependent protein kinase II (Camk2) phosphorylation as a marker (Illario et al., 2003). Camk2 
activation was not affected by 10 min of treatment with retinoschisin or RS1-C59S. In contrast, 
after 30 min of incubation with retinoschisin, but not with RS1-C59S, phosphorylated Camk2 
levels were significantly reduced (61.4 ± 15.5 % compared to control eluate treatment (P < 
0.05) or to explants treated with RS1-C59S (107.2 ± 32.3 %, P < 0.05). Total Camk2 protein 
levels were not affected by the treatments (Figure 21 B).   
  
Figure 20: Involvement of Src on retinoschisin 
mediated signal transduction 
Murine Rs1h-/Y retinal explants were treated with 1 µg/ml 
recombinant retinoschisin, RS1-C59S, control eluate, or 
Src inhibitor PP2 (5 x 10-5 M) for 10 or 30 min. Western 
blot analyses were performed with antibodies against (A) 
phosphorylated Src (pSrc) and total Src, as well as (B) 
phosphorylated Erk1/2 (pErk1/2) and total Erk1/2. Actb 
staining served as a loading control. Densitometric signals 
were normalized against Actb and calibrated against the 
control. Data given are means + SD (n = 5). Underlined 
asterisks mark statistically highly significant (** = P < 0.01) 
differences between two different treatments, two 
asterisks on PP2 treated sample depicts statistically highly 
significant difference (** = P < 0.01) to control treatment. 
(Figure modified from Plössl et al., 2017b) 
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Figure 21: Effect of retinoschisin on PI3K/AKT-signaling and Ca2+ signaling 
A) and B) Rs1h-/Y retinal explants were treated with retinoschisin, RS1-C59S, or control eluate for 10 and 30 min. 
Subsequently, Western blot analyses with antibodies against phosphorylated Akt (pAkt), total Akt, phosphorylated 
Camk2 (pCamk2), and total Camk2, as well as Actb as control were performed. Rs1h-/Y retinal explants were treated 
with Ca2+ signaling inhibitor 2-APB for 30 min. Subsequently, they were subjected to Western blot analyses with 
antibodies against phosphorylated Erk1/2 (pErk1/2), total Erk1/2 (Erk1/2), as well as Actb as control.   
Signals for pAkt, Akt, pCamk2, Camk2, pErk1/2 and Erk1/2 were normalized against Actb and calibrated against 
the control. Data are given as means + SD (n=5). Underlined asterisks mark statistically significant (* = P < 0.05) 
and statistically highly significant (** = P < 0.01) differences . (Figure modified from Plössl et al., 2017b) 
 
Since Ca2+ signaling can also influence ERK activation (e.g. Illario et al., 2003; Rusciano et al., 
2010), the effect of the Ca2+ signaling inhibitor 2-APB (2-Aminoethoxydiphenyl borate, inhibits 
IP3R function) on phosphorylation of Erk1/2 was also tested in Rs1h-/Y murine retinal explants. 
A marked decrease in phosphorylated Erk1/2 levels was seen after 30 min of incubation with 
2-APB (36.0 ± 9.6 %, P < 0.05). Total Erk1/2 protein levels were not affected (Figure 22). 
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4.4.4 Colocalization of the Retinoschisin-Na/K-ATPase Complex with Signaling 
Constituents in the Murine Retina  
To date, there are different hypotheses about how Na/K-ATPases actually transduce signals 
from outside a cell onwards to intracellular signaling cascades. Scaffolding proteins like ankyrin 
or caveolin have been suggested to anchor and concentrate Na/K-ATPases to special 
signaling membrane microdomains (Liu et al., 2003, Wang et al., 2004, Liang et al., 2007). In 
addition, a direct interaction or close proximity of the Na/K-ATPase to intracellular signal 
transmitters was described to be essential for mediating Na/K-ATPase signaling (Wang et al., 
2004; Liang et al., 2007; Liu et al., 2008; Quintas et al., 2010; Bai et al., 2016). Colocalization 
of the retinoschisin-Na/K-ATPase complex with scaffolding proteins and intracellular Na/K-
ATPase associated signal transmitters was thus assessed in 10 day old murine wildtype 
retinae. A focus on the retinoschisin containing retinal layers (inner segments, outer nuclear 
layer and outer plexiform layer) revealed colocalization between retinoschisin and the Na/K-
ATPase subunits Atp1a3 (Figure 23 A) and Atp1b2 (Figure 23 B). Computational analysis of 
signal overlaps resulted in Pearson’s coefficients above 0.5 and overlap coefficients above 0.9 
(Table 40). 
The scaffolding protein ankyrin-B and the retinal Na/K-ATPase have been shown to perfectly 
colocalize in murine and other vertebrate retinae (Kizhatil et al., 2009). A putative colocalization 
with the scaffolding protein caveolin-1 was now additionally investigated. Caveolin-1 is 
responsible for concentrating Na/K-ATPases in so called “caveolae” in cardiac myocytes, 
cardiac ventricles, kidney cell lines, and kidney outer medulla (Liu et al., 2003, Wang et al., 
2004, Zhang et al., 2008). This process is supposed to play an important role in the regulation 
of Na/K-ATPase mediated signaling in these tissues (Wang et al., 2004; Liang et al., 2007; 
Quintas et al., 2010; Bai et al., 2016). Strong caveolin-1 signals were detected in the outer 
plexiform layer and in a horizontal line between inner segments and outer nuclear layer. 
Figure 22: Influence of Ca2+ signaling 
inhibitor 2-APB on Erk1/2 activation in 
murine retina 
Rs1h-/Y retinal explants were treated with 
Ca2+ signaling inhibitor 2-APB for 30 min. 
Subsequently, they were subjected to 
Western blot analyses with antibodies 
against phosphorylated Erk1/2 (pErk1/2), 
total Erk1/2 (Erk1/2), as well as Actb as 
control. Signals for pAkt, Akt, pCamk2, 
Camk2, pErk1/2 and Erk1/2 were 
normalized against Actb and calibrated 
against the control. Data are given are 
means + SD (n=5). Underlined asterisks 
mark statistically highly significant (** = P < 
0.01) differences. (Figure modified from 
Plössl et al., 2017b) 
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Additional signals were found in the outer nuclear layer and weak caveolin-1 staining was seen 
in the inner segments. This pattern is consistent with previous publications, where caveolin-1 
was described to be expressed predominantly in Müller cells (Li et al., 2012; Gu et al., 2014), 
but also weakly in photoreceptor inner segments (Berta et al., 2011; Li et al., 2012). An overlap 
between retinoschisin and caveolin-1 staining was seen in inner segments and outer nuclear 
layer. However, retinoschisin did not overlap with the prominent caveolin-1 staining from Müller 
cells (the horizontal line between inner segments and outer nuclear layer) (Figure 23 C). This 
cellular distribution makes quantification by Pearson’s coefficient’s unsuitable (Dunn et al., 
2011), but overlap coefficients depicted high values (Table 40). 
The localization of intracellular signal transmitters playing a role in the mediation of ERK and 
Ca2+ signaling by the Na/K-ATPase (Src, Plc, and IP3R, see Figure 23) were also analysed 
via IHC. The non-receptor tyrosine kinase Src shows a retinal staining pattern similar to 
caveolin-1, with additional signals in the outer segments (Figure 23 D), as published before 
(Berta et al., 2011). Overlap coefficients of around 0.9 were obtained for Src and retinoschisin 
(Table 40).  
Signals for IP3R were particularly strong in inner segments and outer plexiform layers, and 
weaker signals were obtained in the outer nuclear layer, in agreement with previous results 
(Day et al., 1993). A partial overlap between retinoschisin and the IP3R was seen in inner 
segments, outer nuclear layer, and outer plexiform layer with Pearson’s values around 0.5 and 
overlap coefficients of around 0.9 (Figure 23 E, Table 40). The localization of Plc is similar to 
the one seen for the IP3R. A partial overlap between retinoschisin and Plc can be seen in inner 
segments (Figure 23 F). Overlap coefficients were around 0.9, but Pearson’s coefficients were 
rather low (around 0.2, Table 40). 
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Figure 23: Localization of retinoschisin, the Na/K-ATPase and Na/K-ATPase associated signaling mediators 
in murine retinae 
Retinal cryosections from wildtype mice at postnatal day 10 were labe lled with antibodies against retinoschisin 
(Rs1h) and Atp1a3 (A) Atp1b2 (B) caveolin-1 (cav, C), Src (D), Plc (E) or IP3R (F). Confocal microscope images 
were taken under 100x magnification. Retinal layers are indicated on the right; IS, inner segment; ONL, outer 
nuclear layer; OPL, outer plexiform layer. Scale bar, 10 μm. (Figure modified from Plössl et al., 2017b) 
 
Table 40: Evaluation of colocalization between retinoschisin (RS1) and the retinal Na/K-ATPase subunits 
Atp1a3 and Atp1b2, as well as between retinoschisin (RS1) and caveolin-1 (Cav), Src, IP3R, and Plc. 
Colocalization was assessed in the entire retinal sections from Figure 25. Pearson’s coefficient (linear correlation 
between retinoschisin and tested protein X) normal and with Costes’ randomization. Overlap coefficient (size of the 
intersection divided by the smaller of the size of the two sets) are given with automatically and manually set 
thresholds. Mander’s colocalization coefficients M1 and M2 are given applying manually set thresholds and 
thresholds set by Costes’ method (Pearson's corre lation coefficient as a tool for setting the thresholds). (Plössl et 
al., 2017b)  
 
X Pearson's 
coefficient 
overlap 
coefficient 
M1 (RS1 overlap X) M2 (X overlap RS1) 
  Costes’ 
randomi-
zation 
 manual 
threshold 
manual 
threshold 
Costes’ 
threshold 
manual 
threshold 
Costes’ 
threshold 
ATP1
A3 
0.648 0.557,  
P = 1.0 
0.967 0.974 0.773 0.939 0.69 0.885 
ATP1
B2 
0.585 0.529,  
P = 1.0 
0.958 0.983 0.867 0.998 0.396 0.852 
Cav 0.182 -0.061,  
P = 1.0 
0.882 0.904 0.515 0.999 0.223 0.757 
Src -0.098 0.0,  
P = 0.0 
0.899 0.928 0.816 0.0 0.098 0.0 
IP3R 0.555 0.489,  
P = 1.0 
0.914 0.897 0.639 0.999 0.418 0.871 
Plc 0.218 0.128,  
P = 1.0 
0.915 0.858 0.56 0.999 0.158 0.708 
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4.5 Influence of Retinoschisin on Cellular Integrity and Homeostasis 
Na/K-ATPases are involved in the regulation of a variety of cellular processes like apoptosis, 
proliferation, neuronal development, or regulation of cellular osmolality (reviewed in Clausen 
et al., 2017), all processes involved in XLRS pathogenesis (reviewed in Molday et al., 2012). 
To investigate whether retinoschisin binding to the Na/K-ATPase could directly influence 
cellular integrity, several of these processes were addressed in a set of experiments using Y-
79 cells or murine retinal explants as a model system. 
4.5.1 Influence of Retinoschisin on Proliferation and Cell Size of Y-79 Cells 
Firstly, the influence of retinoschisin on proliferation and cell size (as a measure for regulation 
of osmolality) was assessed. Y-79 cells (2 million cells/ml) were cultivated in the presence of 
0.1 µg recombinant retinoschisin or equal volumes of control eluate and their growth and cell 
size were analysed with the CASY® TT Cell Counter and Analyzer after 48, 72 and 96 h. The 
total cell number increased over time and had doubled after 72 h. The addition of retinoschisin 
had no influence on the growth rate (Figure 24 A). The mean diameter of the cells was also 
recorded, and slightly increased from 1.0 to 1.2 µm, but it was not influenced by recombinant 
retinoschisin (Figure 24 B). 
 
4.5.2 Influence of Retinoschisin on Viability of Y-79 Cells 
The effect of retinoschisin on cell viability was investigated in dependence of increasing 
retinoschisin concentrations as well as after oxidative stress. The MTT assay was applied to 
assess NAD(P)H-dependent cellular oxidoreductase dependent reduction of MTT to its 
insoluble form formazan. This assay is frequently used to determine metabolic activity and 
hence viability of cells (Riss et al., 2013). 
Increasing retinoschisin concentrations had no effect on cellular viability of Y-79 cells after 24 
h of treatment (Figure 25 A). Treatment with 0.2 mM H2O2 for 2 h reduced cell viability to about 
80% and treatment with 0.5 mM H2O2 resulted in only 40 % viability. However, survival rates 
were not altered in the presence of recombinant retinoschisin (Figure 25 B).  
Figure 24: Influence of retinoschisin on 
proliferation and cell size of Y-79 cells 
Y-79 cells were treated with 0.1 µg recombinant 
retinoschisin (+) or control eluate (-) cell growth A) 
as well as cell diameter B) were evaluated with a 
CASY® TT Cell Counter and Analyzer after 48, 72, 
and 96 h. Measurements were calibrated against 
the number/diameter of cells with which the 
experiment was started (control, c). Data are given 
are means + SD (n=8). 
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Figure 25: Influence of retinoschisin on cell viability of Y-79 cells 
A) Y-79 cells were treated with increasing amounts of recombinant retinoschisin (0 to 0.3 µg) or equal volumes of 
control eluate (-). 24 h later, cell viability was measured using a MTT assay. Results were calibrated against the 
control (cells treated with 0 µg control eluate). B) Y-79 cells were treated with H2O2 for 2 h in the presence of 0.1 
µg recombinant retinoschisin (+) or control eluate (-). 24 h after subsequent cultivation in the presence of 
recombinant retinoschisin (+) or control eluate (-), cell viability was determined by MTT assay. Results were 
calibrated against the control (cells treated with 0 mM H2O2 and control eluate). Data given are means + SD (n=4). 
4.5.3 Retinoschisin Impairs Apoptosis in Retinal Model Systems  
It has been shown earlier, that apoptotic activity is increased in Rs1h-/Y retinal tissue compared 
to wildtype (Gehrig et al., 2006). Therefore, a possible influence of retinoschisin on apoptosis 
was addressed in Y-79 cells and Rs1h-/Y retinal explants. 
Firstly, an influence of retinoschisin on the expression of apoptosis marker BAX was analysed. 
Short time exposure to retinoschisin did not change BAX transcript levels in Y‐79 cells (data 
not shown). 20 h of incubation with retinoschisin, however, significantly reduced BAX 
transcription (77.6 ± 14.0%) compared to control (P < 0.05) or RS1‐C59S treatment (P < 0.01, 
Figure 26 A). In Rs1h-/Y retinal explants, relative BAX transcription was reduced to 85.4 ± 9.3 
% after 30 min of incubation with retinoschisin (P < 0.01 compared with control and RS1‐C59S‐
treated retinae, Figure 26 A). Incubation with RS1‐C59S had no significant effect on BAX 
expression in Y‐79 cells or retinal explants. 
In an independent approach, an enzymatic assay was applied to analyse Caspase-3 activity 
as a marker for apoptosis. H2O2 treatment of Y-79 cells caused an about 2.5 fold increase in 
caspase-3 activity compared to unstimulated cells (Figure 26 B) Retinoschisin treatment of 
H2O2 stimulated cells strongly decreased caspase-3 activation (67.6 ± 9.9%) compared to 
control eluate or RS1-C59S (P < 0.01). RS1-C59S led to a slight reduction of caspase-3 activity 
(87.6 ± 9.1 %, P = 0.59) in H2O2 treated cells, which, however, was not statistically significant 
(Figure 26 B).  
Photoreceptor cell death in Rs1h−/Y mice is initiated by apoptotic events around 14 days after 
birth (P14) (Gehrig et al., 2006). The effect of retinoschisin on photoreceptor survival was thus 
assessed in murine Rs1h −/Y retinae explanted at 18 days after birth (P18, after the apoptotic 
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burst at P14). Rs1h-/Y retinal explants were cultured in the presence of retinoschisin, RS1-
C59S or control eluate for 7 days. After incubation, cryosections were cut and stained against 
markers for cone as well as rod photoreceptors. 
One week of cultivation resulted in a strong degeneration of retinal explants, shown by a 
markedly decreased thickness of the central retina and a significant reduction in photoreceptor 
cells (Figure 26 C-F). Compared to untreated, freshly explanted retinae which were not 
cultured for one week, 7 day cultivation reduced the number of cones to around 25 % in control 
and RS1-C59S treated explants (25.6 ± 8.5 % for control and 24.8 ± 8.9 % for RS1-C59S 
treatment (Figure 26 C and D). Noteworthy, in explants treated with retinoschisin, cone 
number was decreased to only about 50 % (50.3 ± 7.3 % compared to untreated retinae). The 
difference between retinoschisin treatment and control as well as RS1-C59S treated explants 
was statistically highly significant (P < 0.01). 
Comparable results were also seen for rod photoreceptors. After one week of cultivation, 
rhodopsin signals decreased to around 24.8 ± 9.3 % for control treated, and to 28.9 ± 4.7 % 
for RS1-C59S treated explants. In contrast, in retinal explants treated with retinoschisin, 
rhodopsin signals only decreased to 59.3 ± 7.6 % compared to untreated retinae. Differences 
between retinoschisin and control or RS1-C59S treated explants were again statistically highly 
significant (P < 0.01) (Figure 26 E and F). 
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Figure 26: Influence of Retinoschisin on Apoptosis  
A). Y-79 cells or retinal explants were treated with retinoschisin, RS1-C59S, or control protein for 20 h or 30 min, 
respectively. BAX mRNA expression was determined via qRT-PCR. Results were normalized to HPRT transcript 
levels and calibrated against the control. Data given are means + SD (n=5). B) Y-79 cells, exposed to retinoschisin, 
RS1-C59S, or control protein were treated with 0.2 mM H2O2 for 2 h. 18 h later, apoptosis was assayed by following 
caspase-3 specific proteolytic activity. Data given are means + SD (n=6). C) - F) P18 retinal explants were cultured 
for 1 week in medium containing retinoschisin, RS1-C59S, or control eluate. After washing and embedding, 
cryosections of these explants were subjected to staining for nuclei, cones and rods. OS, outer segments; IS, inner 
segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; 
GCL, ganglion cell layer. DAPI staining shows the nuclei of the different retinal layers. C) Alexa488-conjugated 
peanut agglutinin (PNA) staining was applied to visualize cones. D) The total number of cones per analysed section 
was counted after staining with PNA. E) Anti-Rho-1D4 antibody staining was applied to visualize rod specific 
Rhodopsin. F) Rhodopsin signals per analysed section were measured using ImageJ. Data given are means + SD 
(n=5). Asterisks mark statistically significant (*P < 0.05) and highly significant (**P < 0.01) d ifferences. (Plössl et al., 
2017a) 
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4.6 Identification of the Retinoschisin-Interaction Site on the Na/K-ATPase 
Previous studies revealed that retinoschisin can be co-immunoprecipitated with the retinal 
Na/K-ATPase subunits α3 (ATP1A3) and β2 (ATP1B2) and that expression of these subunits 
is required for anchorage of retinoschisin to plasma membranes (Molday et al., 2007, Friedrich 
et al., 2011). However, it remained unclear, whether retinoschisin binding requires the complex 
of both subunits or if retinoschisin specifically interacts with either ATP1A3 or ATP1B2. This 
project aimed to define the interface of the Na/K-ATPase binding to retinoschisin.  
4.6.1 ATP1B2 is Responsible for Retinoschisin Binding  
Nine different Na/K-ATPase subunit isozyme combinations (α1-β1, α1-β2, α1-β3, α2-β1, α2-
β2, α2-β3, α3-β1, α3-β2, or α3-β3) were heterologously expressed in Hek293 cells and 
assessed for their retinoschisin binding capacity. The ATP1A4 subunit was omitted in this 
analysis as it was shown to be exclusively expressed in testis (Hlivko et al., 2006) and hence 
no physiological relevance of an interaction between this isoform and retinoschisin is to be 
expected.  
Retinoschisin efficiently bound to Na/K-ATPases containing the ATP1B2 subunit, independent 
of the co-expressed α-subunit. Quantification of the binding efficiency in three independent 
experiments showed increased retinoschisin binding to α1-β2 expressing Hek293 cells (1.50 
± 0.33 compared to α3-β2, P = 0.12) (Figure 27 A). Whether this increase is caused by 
increased membrane expression or increased retinoschisin affinity of α1-β2 Na/K-ATPases 
was not determined in this study. No retinoschisin binding was observed to Na/K-ATPase 
complexes containing ATP1B1 or ATP1B3 (Figure 27 A). Chimeric ß subunits were generated 
to further narrow down the retinoschisin interaction site on ATP1B2. Two different chimeras 
were constructed, one consisting of the inner- and transmembrane domain of ATP1B2 (aa 1 
to 79) fused to the outer domain of ATP1B1 (aa 74 to 303), termed “ATP1B1-OD”, and another 
one consisting of the inner- and transmembrane domain of ATP1B1 (aa 1 to 71) fused to the 
outer domain of ATP1B2 (aa 77 to 291), termed “ATP1B2-OD”. In three independent 
experiments, efficient retinoschisin binding was seen to ATP1B2-OD, but not to ATP1B1-OD, 
although binding to ATP1B2-OD was significantly weaker than binding to normal ATP1B2 (0.36 
+/- 0.16, P < 0.05) (Figure 27 B). 
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Figure 27: Binding of retinoschisin to Na/K-ATPases of different subunit combinations.  
A) Hek293 cells were transfected with expression vectors for ATP1A1, ATP1A2 or ATP1A3 in combination with 
expression vectors for ATP1B1, ATP1B2 or ATP1B3. B) Hek293 cells were transfected with an expression vector 
for ATP1A3 in combination with an expression vector for ATP1B2, ATP1B1, or with expression vectors for ATP1B1 -
OD (outer domain of ATP1B1, fused to inner and transmembrane domains of ATP1B2), or ATP1B2 -OD (outer 
domain of ATP1B2, fused to inner and transmembrane domains of ATP1B1). 48 h after transfection, cells were 
incubated with retinoschisin containing Hek293 supernatant from a Hek293 line, which stably expresses 
retinoschisin. After 60 min of incubation cells were washed thoroughly and retinoschisin binding was assessed by 
subjecting cell pellets to Western blot analysis applying antibodies against retinoschisin. The ACTB immunoblot 
was performed as loading control. Densitometric signals for retinoschisin were normalized against ACTB and 
calibrated against binding to ATP1B2-ATP1A3 transfected cells. Data given are means + SD (n=3). Underlined 
asterisks mark statistically significant (* = P < 0.05) differences. (Plössl et al., 2017b) 
To assure that the lack of retinoschisin binding to ATP1B1 and ATP1B3 containing Na/K-
ATPases is not due to difficulties in expression or membrane trafficking of the artificially co-
expressed subunits, expression as well as cell surface localization of the different Na/K-
ATPases isozymes were analysed. Western blot analysis of transfected Hek293 cells with 
antibodies against the different Na/K-ATPase subunits revealed good expression of all 
heterologously expressed subunits (Figure 28 A). ATP1A1 was stained in all cells, since this 
subunit is endogenously expressed by Hek293 cells, but still strongest ATP1A1 signals were 
detected upon transfection with an ATP1A1 expression vector. Weak cross-staining of the 
ATP1A2 antibody was seen in ATP1A3 transfected cells and is likely due to sequence 
homologies of the α subunits (Pierce and Lingrel, 1994). All other Na/K-ATPase subunits 
showed specific immunoblot signals only in cells heterologously expressing the respective 
subunits. 
Cell surface localization of Na/K-ATPases was analysed by two independent approaches, 
Western blot analyses of isolated cell surface proteins and FACS. For the first approach, cell 
surface proteins of Hek293 cells transfected with the different Na/K-ATPase subunit 
combinations were biotinylated and isolated via affinity chromatography against streptavidin. 
Western blot analysis with antibodies against the different Na/K-ATPase subunits revealed the 
presence of all heterologously expressed Na/K-ATPase subunits in the isolated cell surface 
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proteins, documenting membrane expression of all subunits (Figure 28 B). Notably, Na/K-
ATPase β subunit isoforms in whole cell extracts showed several protein bands with a 
molecular weight between 25 and 55 kDa (Figure 28 A), reflecting different glycosylation 
intermediates of this subunit due to elongation and branching by the Golgi-resident 
glycosidases (Tokhtaeva et al., 2010). The Na/K-ATPase β subunit isoforms in isolated cell 
surface proteins only revealed one or two bands between 40-55 kDa (Figure 28 B), most likely 
representing the mature, fully processed ß subunit isoform exported to plasma membranes 
(Tokhtaeva et al., 2010).  
 
Figure 28: Protein expression and plasma membrane localization of heterologously expressed Na/K-
ATPase subunit isoforms 
Na/K-ATPase subunit combinations (α1-β1, α1-β2, α1-β3, α2-β1, α2-β2, α2-β3, α3-β1, α3-β2, or α3-β3, as well as 
α3 in combination with ATP1B1-OD or ATP1B2-OD) were heterologously expressed in Hek293 and protein 
expression was investigated 48 h after transfection. A) Hek293 cells were harvested, lysed, and subjected to 
Western blot analyses using antibodies against the different Na/K-ATPase subunits (ATP1A1, ATP1A2, ATP1A3 
and ATP2B1, ATP1B2, ATP1B3). The ACTB immunoblot was performed as loading control. B) Cell surface proteins 
were biotinylated, purified by s treptavidin affinity chromatography and analysed by Western blotting using 
antibodies against the different Na/K-ATPase subunits (ATP1A1, ATP1A2, ATP1A3 and ATP2B1, ATP1B2, 
ATP1B3). The pan-Cadherin (Cadherin) immunoblot was performed as loading control. (Plössl et al., 2017b) 
 
In an independent approach to assess plasma membrane expression of Na/K-ATPase β 
subunit isoforms, whole Hek293 cells transfected with the different Na/K-ATPase subunit 
combinations were subjected to FACS analyses applying antibodies against ATP1B1, ATP1B2 
and ATP1B3. FACS suitable antibodies against α subunits were not available in this study. 
ATP1B1, ATP1B2, and ATP1B3 were successfully detected on the cell surface by their 
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respective antibodies in the FACS experiments (Figure 29), confirming the observed results 
from Western Blot analyses of isolated cell surface proteins. However, ATP1B1-OD was not 
recognized in FACS analyses, in contrast to its detection in the isolated cell surface protein 
fractions by Western blot (Figure 28 B). A possible explanation for this discrepancy could be 
that ATP1B1-OD may display altered protein folding compared to normal ATP1B1. Proteins 
are not denatured before they are subjected to antibody staining in FACS, but they are when 
used in Western blot analyses. The epitope recognized by the anti-ATP1B1 antibody could be 
hidden in the native ATP1B1-OD constructs addressed in FACS but it could be accessible after 
denaturation for Western blot. This phenomenon has been observed for many other proteins 
before (e.g. Laman et al., 1993; McKnight et al., 1996). 
FACS signals for ATP1B2-OD were different from those seen for non-mutated ATP1B2 which 
may also indicate a slight difference in the 3-D structure of the outer domain of the chimeric 
ATP1B2-OD construct compared to non-mutated ATP1B2.  
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Figure 29: Analysis of cell surface expression of Na/K-ATPase subunit combinations by FACS 
Hek293 cells were transiently transfected with the indicated constructs for different Na/K-ATPase subunit isozyme 
combinations and subjected to FACS analysis 48 h after transfection. A) Representative histograms of 
untransfected cells stained with secondary antibodies only (unstained control in light grey). (B-D) Representative 
histograms of cells transfected with the indicated Na/K-ATPase subunit isoform combinations stained with the 
indicated antibodies in combination with their corresponding secondary antibody (Figure modified from Plössl et al., 
2017b). 
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4.6.2 Analysis von Hydrophobic Protein Surface Patches on ATP1B2 - 
Importance for Retinoschisin Binding 
4.6.2.1 Bioinformatical Identification of Hydrophobic Protein-Protein Interaction 
Regions on ATP1B2 
To further refine the retinoschisin binding region on ATP1B2, a cooperation with Prof. Dr. 
Rainer Merkl and Ms. Kristina Heyn (Institute for Biophysics and Physical Biochemistry, 
University of Regensburg, Germany) was established. By in silico prediction tools putative 
protein-protein interaction regions were identified on the ATP1B2 surface. Since the 3D 
structure of human ATP1B2 has not been resolved yet, a homology model was generated 
using the I-TASSER software (Zhang et al., 2008) and a known ß subunit structure from 
Squalus acanthias (PDB-ID 3a3y available at 
http://www.rcsb.org/pdb/explore.do?structureId=3a3y, accessed September 1st 2017) as 
template. The RMSD (Root-Mean-Square-Deviation) between the template and the model was 
0.98 Å, which is an indicator for very good model quality. The PresCont Interface Prediction 
Tool (Zellner et al., 2012) was then used to identify putative hydrophobic protein-protein 
interaction sites on ATP1B2. Two different "docking patches", hydrophobic protein surfaces 
putatively involved in interaction processes, were identified by this approach (Figure 30), 
termed “Patch I" and "Patch II". Each patch consists of four individual sequence stretches as 
shown in Table 41. 
 
 
 
 
Figure 30: Docking Patch 
interface prediction 
A) Aa residues in the ATP1B2 
homology model are coloured 
according to a score. B) The pPPI 
score represents the likelihood 
that a specific residue is part of a 
protein-protein interface. The 
transmembrane domain of 
ATP1B2 is composed of aa 
residues very similar to those 
found in interface regions and 
hence shows up as false positive 
prediction.  
(Figure kindly provided by 
Kristina Heyn, Institute for 
Biophysics and Physical 
Biochemistry, University of 
Regensburg, Germany) 
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4.6.2.2 Binding of Retinoschisin to ATP1B2 Docking Patch Variants 
To evaluate the importance of the predicted patches for the interaction between retinoschisin 
and the Na/K-ATPase, specific ATP1B2-ATP1B1 chimeras were generated. Since ATP1B1 is 
not capable of retinoschisin binding (shown in 4.6.1), the aa sequences of the computed 
docking patches in ATP1B2 were replaced by the corresponding aas of ATP1B1 (given in 
Table 41) applying site directed mutagenesis on the ATP1B2 coding sequence.  
Table 41: Characterization of computed ATP1B2 docking patches: Involved aas in ATP1B2 and 
corresponding aa sequence in ATP1B1.  
aa Position in 
ATP1B2 
aa Sequence in 
ATP1B2 
Corresponding aa 
Sequence in ATP1B1 
referred to as 
Patch I 
aa 158-163 GNCSGI GNCSGL Patch I Region 1 
aa 198-201 VTCA, VQCT Patch I Region 2 
aa 246-249 VKFL VQFT Patch I Region 3 
aa 213-221 NFVMFPANG NVEYFGLGNSP Patch I Region 4 
Patch II 
aa 83-88 MIRPKT TQIPQI Patch II Region 1 
aa 108-121 QKLNKFLEPYNDSI LNIVRFLEKYKDSA Patch II Region 2 
aa 181-184 KMNR KLNR Patch II Region 3 
aa 240 T L Patch II Region 4 
 
Retinoschisin binding to the ATP1B2 docking patch variants was tested on Hek293 cells 
heterologously expressing ATP1A3 and the respective ATP1B2 variant. Efficient retinoschisin 
binding was seen to all ATP1B2 variants exhibiting ATP1B1 sequences in either of the 4 
stretches of Patch I (Patch I Region 1, Region 2, Region 3 and Region 4 according to Table 
41, labelled orange in Figure 31 A). Since the combined surface structure of several sequence 
stretches may be required for protein interaction, a complete ATP1B2 Patch I mutant, where 
all of the four regions from this patch were changed at once, was generated (Patch I Region 
1+2+3+4, blue in Figure 31 A). No retinoschisin binding was seen to this complete ATP1B2-
Patch I mutant. To further refine specific binding sites on Patch I, mutants were generated 
containing mutations in three of the four regions (Patch I Region 1+2+3, Patch I Region 1+2+4, 
Patch I Region 1+3+4 and Patch I Region 2+3+4, purple in Figure 31 A). Mutations of Patch I 
Region 1+2+3 still enabled efficient retinoschisin binding, suggesting that Patch I Region 
1+2+3 is not the specific interaction site for retinoschisin binding. The other triple mutants did 
not show retinoschisin binding. Since those mutants share mutations in Patch I Region 4, 
double mutants of Patch I Region 4 and the other three regions were generated (Patch I Region 
1+4, Patch I Region 2+4 and Patch I Region 3+4, red in Figure 31 A). Retinoschisin 
successfully bound to ATP1B2 mutated in Patch I Regions 2+4. Binding was also observed to 
ATP1B2 mutated in Patch I Region 1+4, although weaker than for normal ATP1B2. In contrast 
ATP1B2 mutated Patch I Region 3+4 failed to bind retinoschisin (Figure 31 A).  
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ATP1B2 variants mutated in Patch II were also generated. At first, binding was assessed to 
ATP1B2-variants exhibit mutations in either of the individual regions (orange in Figure 31 B). 
Efficient retinoschisin binding was seen to ATP1B2 mutated in Patch II Region 1 and Patch II 
Region 3. Patch II Region 2 and Patch II Region 4, however, failed to bind retinoschisin. A 
Patch II Region 1+3 double mutant (red in Figure 31 B) also effectively bound retinoschisin. 
 
Figure 31: Binding of Retinoschisin to ATP1B2 Docking Patch Mutants 
Hek293 cells were all transfected with expression vectors for ATP1A3 in combination with expression vectors for 
different ATP1B2 variants mutated in the Patch Regions depicted within the figure. A) ATP1B2 variants with different 
mutations of Patch I. B) ATP1B2 variants with different mutations of in Patch II. Hek293 cells transfected only with 
ATP1B2 served as negative control, ATP1A3-ATP1B2 expressing cells served as a positive control for retinoschisin 
binding. 48 h after transfection, cells were incubated with retinoschisin containing supernatant for 1 h and intensively 
washed afterwards. Retinoschisin binding to cell pellets was analysed by Western blot analyses with anti -
retinoschisin antibodies. Heterologous ATP1A3 and ATP1B2 expression was confirmed by Western blotting with 
the respective antibodies. The ACTB staining served as  loading control.   
 
The binding assays with ATP1B2 variants mutated in Patch I or II revealed several mutants 
that were no longer able to bind retinoschisin (ATP1B2 variants exhibiting mutations in Patch 
I Regions 2 or 3 combined with Region 4, or in Patch II Regions 2 or 4). To test that the absent 
retinoschisin binding capacity of these ATP1B2 mutants is not a result of their decreased 
membrane expression, expression and cell surface localization of all ATP1B2 docking patch 
mutants was analysed by Western blotting and FACS analysis.  
Analysis of ATP1B2 expression in total cell lysates from transfected Hek293 cells revealed 
good expression of all mutant constructs (Figure 31 A). Cell surface protein isolation showed 
that all ATP1B2-variants exhibiting mutations Patch I localize to the plasma membrane (Figure 
32 A). However, in FACS analyses with an anti-ATP1B2 antibody, only ATP1B2 variants 
exhibiting mutations in individual Regions 1, 2, or 3 of Patch I were detected (Figure 33). The 
ATP1B2-epitope against which the antibody was generated (aa 115 to 141 of ATP1B2) 
overlaps for 6 aas with Region 2 of Patch I, but with none of the other regions in Patch I (or II). 
As the ATP1B2 variant mutated in Patch I Region 2 is detected in FACS analysis, the epitope 
for ATP1B2-antibody binding was thus not destroyed by the mutation. All other ATP1B2 
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variants mutated in Patch I were not recognized in FACS analyses (Figure 33). This again (as 
seen before for ATP1B1-OD), may be a result of altered protein folding of these ATP1B2 
mutants which inhibits detection by the anti-ATP1B2 antibody in the folded state. Together, the 
two experimental setups (cell surface protein isolation and FACS experiments) thus indicate 
that protein structure of Patch I double, triple and complete mutants strongly differs from normal 
ATP1B2. Their effects on retinoschisin binding might thus not be caused by specific disruption 
of Patch I surface residues but by an overall alteration of ATP1B2 folding affecting more than 
Patch I (e.g. the anti-ATP1B2 epitope, aa 115-141). 
All ATP1B2 variants mutated in Patch II were also expressed in transfected in Hek293 cells 
(Figure 31 B). Cell surface protein isolation of Patch II mutants revealed plasma membrane 
localization of all mutants despite Patch II Region 2 (Figure 32 B). This is in line with findings 
from FACS analysis, where cell surface staining was seen for all ATP1B2 Patch II mutants, 
but Patch II Region 2 (Figure 34).  
 
Figure 32: Cell surface protein isolation of ATP1B2 Docking Patch Mutants 
Hek293 cells were transiently co-transfected with expression constructs for ATP1A3 and different ATP1B2 docking 
patch mutants A) Patch I, B) Patch II. Cell surface proteins were biotinylated, purified by s treptavidin affinity 
chromatography and analysed by Western blotting using antibodies against the Na/K-ATPase subunits ATP1A3 
and ATP1B2. The ATP1A1 immunoblot was performed as loading control. 
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Figure 33: FACS Analysis of ATP1B2 Docking Patch I mutants  
Hek293 cells were transiently transfected with the indicated constructs for ATP1B2 Docking Patch mutants and 
subjected to FACS analysis 48 h after transfection.  
A) Representative histograms of untransfected cells stained with secondary antibody only (unstained control in light 
grey). B) Representative histograms of cells transfected with the indicated Na/K-ATPase subunit isoform 
combinations and stained with the anti-ATP1B2 antibody. Light grey: histogram of untransfected Hek293 cells 
depicting unspecific background signals. Dark grey: histogram of transfected Hek293 cells. 
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Figure 34: FACS analysis of ATP1B2 Docking Patch II mutants 
Hek293 cells were transiently transfected with the indicated constructs for different ATP1B2 Docking Patch II 
mutants and subjected to FACS analysis 48 h after transfection.  
A) Representative histograms of untransfected cells stained with secondary antibody (unstained control in light 
grey). B) Representative histograms of cells transfected with the indicated Na/K-ATPase subunit isoform 
combinations stained with the anti-ATP1B2 antibody. Light grey: histogram of untransfected Hek293 cells depicting 
unspecific background signals. Dark grey: histogram of transfected Hek293 cells. 
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5 Discussion 
XLRS is a common retinal dystrophy in young males, but the molecular mechanisms 
underlying XLRS pathogenesis are still unresolved. Therefore, the aim of this work was to 
elucidate molecular processes associated with XLRS. The work focused on the interaction 
between retinoschisin and its interaction partner in retinal membranes, the retinal Na/K-
ATPase, a heterodimer consisting of ATP1A3 and ATP1B2.  
The results revealed no influence of retinoschisin on Na/K-ATPase protein levels or membrane 
stability, as well as on Na/K-ATPase ion pump activity. In contrast, retinoschisin regulated 
Na/K-ATPase associated signaling pathways, specifically MAPK and Ca2+ signaling. This was 
revealed by following the activation of marker proteins and expression of target genes of these 
pathways in Western Blot or qRT-PCR analyses, respectively. Immunohistochemistry in retinal 
cryosections revealed an overlap of the retinoschisin-Na/K-ATPase complex and proteins 
involved in Na/K-ATPase signaling, confirming a potential regulation of signaling cascades via 
the retinoschisin-Na/K-ATPase complex.  
Further studies testing an influence of retinoschisin on retinal homeostasis revealed no effects 
on cell viability, proliferation, or cell size of Y-79 cells. Apoptotic activity, assessed by qRT-
PCR, caspase-3 activation and photoreceptor degeneration, in contrast, was decreased upon 
retinoschisin treatment in Y-79 cells and Rs1h-/Y murine retinal explants. 
Finally, a bioinformatics approach identified two putative retinoschisin interaction regions each 
consisting of 4 hydrophobic stretches on the retinal Na/K-ATPase. After mutating each of these 
stretches by site directed mutagenesis, retinoschisin binding assays identified aa residue T240 
on ATP1B2 as being required for retinoschisin binding. This leaves this residue and its 
associated hydrophobic patch on ATP1B2 as a potential candidate for the retinoschisin 
interacting region on the retinal Na/K-ATPase. 
5.1  Pathomechanism of the Retinoschisin Mutant RS1-C59S 
The vast majority of RS1 mutations results in a loss of secreted retinoschisin in the retina, 
representing true null alleles or leading to a failure in retinoschisin secretion (reviewed in 
Molday et al., 2012). RS1-C59S is one of the rare retinoschisin mutants which is secreted from 
cells. However, it can no longer form octamers, as these are stabilized by disulfide bonds 
between the cystein residues at aa positions 59 and 223 (Wu et al., 2005). A possible 
pathomechanism underlying RS1-C59S and other secreted retinoschisin mutants has not been 
described yet. Binding experiments conducted within this work revealed that in contrast to 
normal retinoschisin, RS1-C59S is not able to bind to retinal membranes and thus to interact 
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with the retinal Na/K-ATPase. Consequently, RS1-C59S also failed to show regulation of 
intracellular signaling or apoptosis as attributed to retinoschisin within this thesis work. 
Several molecular mechanisms can explain the loss of binding capacity of RS1-C59S to the 
retinal Na/K-ATPase. In the retinoschisin octamer, C59 is a central component within the 
interface of two adjacent retinoschisin monomers, thus likely not accessible for the retinal 
Na/K-ATPase (Tolun et al., 2016). However, defective octamerization might lead to alterations 
in the 3-D structure of the single retinoschisin monomer, and thus the surface of the actual 
interaction site. Several studies suggest the exposed three spikes of retinoschisin as being 
responsible for retinoschisin binding to its interaction partner in the retina (Dyka et al., 2008, 
Molday et al., 2012, Ramsay et al., 2016). Spike regions of discoidin domains were previously 
shown to form a hypervariable cave which is involved in the interaction with a variety of 
interaction partners, whereas the core regions of discoidin domains are less variable and 
function as a scaffold for the spikes (Kiedzierska et al., 2007). Alterations of the scaffold 
structure by defective octamerization could thus negatively affect the folding of the spikes. An 
alternative explanation could be that multiple discoidin domains are required to enable binding 
of retinoschisin to retinal membranes. This assumption is strengthened by the fact that most 
discoidin domain containing proteins have either multiple discoidin domains within their 
polypeptide chain or assemble as oligomers (Baumgartner et al., 1998, Kiedzierska et al., 
2007).  
5.2 Effect of Retinoschisin on the Retinal Na/K-ATPase 
Na/K-ATPase binding members of the FXYD protein family can influence the Na/K-ATPase 
complex at many levels, including overall protein expression of the α subunit, stability of the 
Na/K-ATPase complex as well as ion transport and substrate affinity of the α subunit (Garty et 
al., 2002, Jones et al., 2005, Jia et al., 2005, Lifshitz et al., 2006, Lifshitz et al., 2007, Mishra 
et al., 2011). Another Na/K-ATPase interacting protein, glycoprotein nonmetastatic melanoma 
protein B (GNMPB) was reported to modify Na/K-ATPase mediated signal transduction as well 
as ion pump activity upon binding to the Na/K-ATPase from the extracellular site (Ono et al., 
2016). Furthermore, several intracellular proteins like caveolin (Liang et al., 2007; Quintas et 
al., 2010; Yosef et al., 2016), ankyrin, actin, and adducin (reviewed by Therien and Blostein, 
2000) have been shown to interact with the Na/K-ATPase and modify its function, with regard 
to both ion transport as well as signal transduction. Similar to these proteins, retinoschisin 
could also act as a modulator of the retinal Na/K-ATPase.  
At first, an effect of retinoschisin on retinal Na/K-ATPase levels was assessed within this work. 
A study from Jia and colleagues showed that Fxyd1 deficiency in mice reduces expression of 
the α2 subunit in heart tissues by 40 % (Jia et al., 2005). Other groups reported on increased 
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stability of FXYD associated Na/K-ATPase complexes (Lifshitz et al., 2007, Mishra et al., 
2011). To test whether retinoschisin could similarly influence Na/K-ATPase protein levels or 
stability, Rs1h-/Y murine retinal explants or Hek293 heterologously expressing the retinal Na/K-
ATPase were incubated with recombinant retinoschisin for up to 24 h. These experiments, 
however, did not reveal an effect of retinoschisin on retinal Na/K-ATPase protein expression 
in both model systems, neither in total cell lysate nor in enriched membrane fractions. These 
findings are in line with previous results, which showed no differences in retinal Na/K-ATPase 
levels in total cell extract or enriched membrane fractions from retina from Rs1h-/Y mice and 
wildtype mice (Friedrich et al., 2011).  
Interestingly, IHC of Rs1h-/Y retinae compared to wildtype retinae revealed that retinoschisin 
deficiency alters Na/K-ATPase localization from a prominent staining in photoreceptor inner 
segments in the wildtype to a weak staining in inner segments but additional disperse staining 
in the nuclear layers of the Rs1h-/Y retina (Friedrich et al., 2011). This could imply that 
retinoschisin is responsible for anchoring the retinal Na/K-ATPase to specific membrane 
compartments. Local changes in Na/K-ATPase protein levels in different membrane 
compartments would not have been detectable in the experimental set-up used in this study, 
analysing total cell lysates and membrane fractions. Membrane trafficking to and protein 
stability in specific membrane compartments could rather be followed by FCS (fluorescence 
correlation spectroscopy) or FRAP (fluorescence recovery after photobleaching) 
measurements on fluorescently labelled Na/K-ATPase, methods that are frequently used to 
assess lateral diffusion or stability of membrane proteins (e.g. Gonzales Bardeci et al., 2016, 
Appelhans and Busch, 2017).  
Several FXYD proteins were shown to influence Na/K-ATPase ion pump activity (Béguin et al. 
1997, Arystarkhova et al. 1999, Therien et al., 1999, Pu et al., 2001, Garty et al., 2002, Jones 
et al., 2005, Lifshitz et al., 2006), a property which has also been suggested for GNMPB (Ono 
et al., 2016). It was thus tested whether retinoschisin could also influence Na/K-ATPase pump 
activity and/or substrate affinities. Of note, Na/K-ATPase ion pump dysregulation due to 
retinoschisin deficiency could provide an explanation for pathological changes seen in XLRS. 
On the one hand, Na/K-ATPase function is crucial for the maintenance and re-establishment 
of the transmembrane Na+ gradient and is also a major determinant of neuronal resting 
membrane potentials (Blanco and Mercer, 1998, Dobretsov and Stimers, 2005). Specifically 
the α3 subunit has been attributed an important position in the clearance of intracellular Na+ 
after neuronal excitation (Azarias et al., 2016). Hence, misregulation of the α3 containing 
photoreceptor Na/K-ATPase due to retinoschisin deficiency could be the cause of defective 
signal transmission from photoreceptors to bipolar cells, as seen in XLRS patients and mouse 
models (reviewed by Molday et al., 2012). On the other hand, dysregulation and malfunctioning 
of ion transport and hence disturbed ion homeostasis could also induce the formation of 
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extracellular cavities, as it has been observed for example in bestrophinopathies which are 
linked to Ca2+- and volume regulated Cl- channel dysfunction (Hartzell et al., 2008, Song and 
Dunaief, 2013). The fluid filled cystic cavities, as observed in the Rs1h-/Y mouse but also in 
XLRS patients (Eriksson et al. 2004, Weber et al. 2002, Xu et al. 2010), could thus be caused 
by osmotic changes due to disturbed ion homeostasis. However, in assays following the ion 
transport dependent ATP cleavage by the Na/K-ATPase as a measure for ion pump activity in 
Rs1h-/Y retinal membrane fractions, recombinant retinoschisin did not affect active ion pump 
activity or substrate affinities of the retinal Na/K-ATPase. A corresponding set of experiments 
comparing Na/K-ATPase activity in wildtype and Rs1h-/Y retinal membranes has been 
conducted by Melanie Royer during her Master’s thesis at the Institute of Human Genetics, 
University of Regensburg. These experiments did also not reveal any influence of retinoschisin 
deficiency (published in Plössl et al., 2017b). Consistently, recombinant retinoschisin did not 
affect Rb+ influx into oocytes heterologously expressing the human retinal Na/K-ATPase. 
Taken together, these data point against an influence of retinoschisin on Na/K-ATPase 
catalysed ion transport. 
The second project of this thesis thus focused on an effect of retinoschisin on another Na/K-
ATPase function, namely Na/K-ATPase mediated signaling. Various studies described an 
effect of the Na/K-ATPase on intracellular signaling pathways, specifically MAPK signaling, 
IP3/AKT signaling and Ca2+ signaling (reviewed in Aperia et al., 2016, Cui and Xie, 2017, Orlov 
et al., 2017). Intracellular, transmembrane or extracellular interaction partners like caveolin-1, 
FXYD family members, or GNMPB were reported to modify Na/K-ATPase signaling activity 
(e.g. Liu et al., 2008, Bai et al., 2016, Ono et al., 2016). It was thus assessed whether 
retinoschisin could exert a regulatory effect on Na/K-ATPase mediated signaling. Of note, the 
addition of recombinant retinoschisin had an immediate and significant influence on MAPK 
signaling in Y-79 cells and murine Rs1h-/Y retinal explants, reflected by decreased activity of 
MAPK cascade constituents C-RAF and ERK1/2. C-RAF deactivation occurred before ERK1/2 
deactivation, which is in line with the established timeline of C-RAF and ERK1/2 activation in 
the ERK signaling cascade (Qi and Elion, 2005, Roskoski 2012). In addition, treatment with 
recombinant retinoschisin also decreased expression of MAPK target genes C-FOS and EGR1 
in both model systems. Interestingly, the RS1-C59S variant failed to regulate the investigated 
markers for MAPK activation. These data suggest that retinoschisin acts as a direct modulator 
of MAPK signaling in the retina, potentially via its effect on the retinal Na/K-ATPase. These 
data are consistent with results from expression profiling of the XLRS mouse revealing 
upregulation of MAPK signaling target genes and Erk1/2 activation at different postnatal stages 
(Gehrig et al., 2007).  
Considering the importance of MAPK signaling on fundamental cellular processes like 
apoptosis, adhesion, proliferation, differentiation, or development (Kolkova et al., 2000, Chang 
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and Karin, 2001, Zhang and Liu, 2002), it may not be surprising that a variety of disease 
processes have been linked to MAPK dysregulation. Several retinal dystrophies, such as age-
related macular degeneration (Dridi et al., 2012, SanGiovanni and Lee, 2013, Yating et al., 
2015), diabetic retinopathy (Dong et al., 2014), or retinitis pigmentosa (Sekimukai et al., 2009, 
Kang et al., 2012), were linked to malfunctioning MAPK pathways. Also, neuronal degenerative 
diseases, like Alzheimer disease, Parkinson disease, or amyotrophic lateral sclerosis were 
associated with aberrant MAPK signaling (Gartner et al., 1999, Arendt et al., 2000, Holasek et 
al., 2005, Cali et al., 2013, Cali et al., 2014, Wang et al., 2014). The retinoschisin induced 
changes in MAPK pathway deactivation (to around 75 %) may seem rather small, but a similar 
effect size was observed for other ERK associated pathological processes: Early disease 
stages of Alzheimer disease present with 25 % less ERK1/2 activation in temporal cortex of 
healthy individuals compared to patients (Arendt et al., 1995). Similar effect sizes were also 
observed in a mouse model of ocular ischemic syndrome where 29 % less ERK1 and 21 % 
less ERK2 activation was seen in retinae of control mice than in the model (Du et al., 2016). 
Comparably small alterations in MAPK signaling were further observed in lymphocytes of 
Alzheimer and Parkinson patients (Wang et al., 2014) and in natural killer cells of Chronic 
Fatigue Syndrome patients (Huth et al., 2016).  
The next experiments assessed an effect of retinoschisin on other Na/K-ATPase associated 
signaling cascades. Several studies suggested the non-receptor tyrosine kinase SRC to be an 
initial signal transmitter in Na/K-ATPase dependent signaling (e.g. Haas et al., 2000, Quintas 
et al., 2010). It was thus tested whether recombinant retinoschisin influences Src activation in 
murine Rs1h-/Y retinal explants. Treatment with recombinant retinoschisin, but not with RS1-
C59S, indeed decreased Src activation. Moreover, the application of Src inhibitor PP2 almost 
completely abolished Erk1/2 activation in the retinal model system. These findings are 
consistent with the established time line and interdependency for Src and Erk1/2 activation by 
the Na/K-ATPase (Haas et al., 2002). Even though the differences in Src activation that were 
induced by retinoschisin treatment were statistically significant, they were rather small (14 % 
reduction compared to control). One explanation for this could be found within the α subunit 
isozyme composition of retinal Na/K-ATPases: 85 % of retinal Na/K-ATPases complexes 
contain α3, and about 15 % α1 (Schneider and Craig, 1990). Na/K-ATPases containing α3 
were recently reported to activate ERK signaling in a Src independent manner (Madan et al., 
2017). It would thus be conceivable that the rather small changes in Src activation seen upon 
retinoschisin treatment are a result of Src regulation by only α1 containing Na/K-ATPases. 
Alternatively, the retinal distribution of Src may play a role: Immunohistochemical analyses of 
murine wildtype retinae revealed that Src is indeed expressed in photoreceptor inner 
segments, the outer nuclear layer and the outer plexiform layer, which are all retinal layers 
also depicting retinoschisin expression (Molday et al., 2007, Friedrich et al., 2011). However, 
Discussion 
97 
strongest Src protein expression was detected in the inner nuclear and the inner plexiform 
layers where no retinoschisin was detected. This Src fraction is thus most likely not subjected 
to regulation by retinoschisin.  
Addressing the remaining two Na/K-ATPase associated signaling pathways, recombinant 
retinoschisin did not influence PI3K/AKT signaling, but it showed an inhibitory effect on Ca2+ 
signaling: Activation of Camk2, a marker for activated Ca2+ signaling (Illario et al., 2003) was 
markedly reduced upon treatment with retinoschisin. Furthermore, inhibition of the IP3R, a 
central constituent in the Ca2+ signaling, by 2-APB resulted in a strong Erk1/2 deactivation, 
demonstrating an involvement of Ca2+ signaling in the regulation of the ERK pathway, which 
has been previously shown for other cell types (Illario et al., 2003, Rusciano et al., 2010). It is 
thus conceivable that retinoschisin modifies MAPK signaling via regulation of both Src and 
Ca2+ signaling in the retina. Nevertheless, Ca2+ signaling as such can also exert an influence 
in disease pathogenesis, as documented for Parkinson disease (Cali et al., 2014) and 
Alzheimer disease (Cali et al., 2013), or amyotrophic lateral sclerosis (Cali et al., 2013).  
The assembly of Na/K-ATPase signaling complexes is reported to be significantly involved in 
the induction and regulation of Na/K-ATPase mediated signaling (Therien and Blostein, 2000; 
Xie and Askari, 2002, Xie and Cai, 2003; Wang et al., 2004; Yuan et al., 2005, Quintas et al., 
2010, Reinhard et al., 2013). Thus, immunohistochemical analyses were performed to 
investigate colocalization of the retinal Na/K-ATPase complex with scaffolding proteins and 
intracellular signal transducers, contributing to Na/K-ATPase signal transmission. In several 
tissues, caveolin-1, was shown to concentrate Na/K-ATPases into caveolae, leading to the 
formation of so called “signaling microdomains” (Wang et al., 2004; Liang et al., 2007; Quintas 
et al., 2010; Bai et al., 2016). Immunohistochemical analyses of murine retina revealed an 
overlap of the retinoschisin-Na/K-ATPase complex with caveolin-1 in photoreceptor cells, but 
no enrichment of caveolin-1 along with the Na/K-ATPase, as it was observed for signaling 
microdomains in cultured cardiac myocytes, a kidney proximal tubule cell line, and cardiac T 
tubules (Liu et al., 2003, Liu and Askari, 2006, Cai et al., 2008) In contrast, a perfect 
colocalization was described for the Na/K-ATPase and ankyrin-B in the retina (Kizhatil et al., 
2009). Of note, ankyrin-B was described to tether the IP3R and the Na/K-ATPase in a signaling 
complex which was capable of activating Ca2+ signaling in monkey kidney cells (Liu et al., 
2008).  
The conducted immunohistochemical analyses also revealed an overlap of the retinoschisin-
Na/K-ATPase complex with Src. Although it is widely accepted that Src is one possible initial 
signal transmitter in Na/K-ATPase mediated signaling, the mechanism underlying signal 
transduction from the Na/K-ATPase to Src is controversially discussed: Some studies suggest 
a direct interaction between the Na/K-ATPase and Src (e.g. Wang et al., 2004; Tian et al., 
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2005; Banerjee et al., 2015), while others were not able to verify these results and presented 
data refuting a direct interaction between the Na/K-ATPase and Src (e.g. Weigand et al., 2012; 
Clifford et al., 2013; Gable et al., 2014; Yosef et al., 2016). Similar to caveolin-1, the 
immunohistochemical data showed no enrichment of Src along with the Na/K-ATPase-
retinoschisin complex at the photoreceptor membrane. Nevertheless, the Src fraction detected 
in photoreceptors could be affected by Na/K-ATPase signaling. Plc and the IP3R are 
implicated in the induction of Ca2+ signaling by the Na/K-ATPase (Aizman and Aperia, 2003, 
Miyakawa-Naito et al., 2003, Yuan et al., 2005, Liu et al., 2008). No specific enrichment of the 
IP3R and Plc was seen for plasma membrane regions of inner segments, but the retinoschisin-
Na/K-ATPase complex overlapped with the IP3R as well as with Plc, bringing the Na/K-ATPase 
in close proximity to both signal transducers.  
5.3 Effect of Retinoschisin on Retinal Homeostasis 
Both MAPK and Ca2+ signaling pathways control important cellular events like degeneration, 
adhesion, proliferation, differentiation, or development (reviewed by Kolkova et al., 2000, 
Chang and Karin, 2001), which are also involved in XLRS pathogenesis (reviewed by Khan et 
al., 2001, Sikkink et al., 2007, Molday et al., 2012). Therefore, a possible influence of 
retinoschisin on cellular homeostasis was analysed. Retinoschisin treatment failed to show an 
influence on cell size, proliferation rate or viability of Y-79 cells. However, it revealed a 
protective effect against apoptosis in Y-79 cells and murine Rs1h-/Y retinal explants. This result 
is in line with previous studies, revealing increased, apoptosis induced retinal cell death in 
Rs1h-/Y mice compared to wildtype (Gehrig et al., 2006). Whether increased apoptosis under 
retinoschisin-deficiency might also be causative for the XLRS associated characteristic 
alterations in retinal homeostasis, schisis and defects in neuronal signal transmission, remains 
to be shown. Increased apoptosis is also observed in kidney cells of patients suffering from 
polycystic kidney disease (PKD), which, similar to the schisis in XLRS, is characterized by the 
formation of fluid filled cysts (Lanoix et al., 1996). Moreover, a mouse model deficient for the 
anti-apoptotic protein Bcl-2 shows cyst formation in the kidney (Veis et al., 1993, Sorenson et 
al., 1996). However, the interdependency of apoptosis and cyst formation is discussed 
controversially (Zhou and Kukes, 1996, Goilav 2011). Furthermore, apoptotic cell loss was 
observed in a variety of disorders associated with neuronal dysfunction (reviewed by Honig 
and Rosenberg, 2000, Mattson 2000). In particular, in amyotrophic lateral sclerosis (ALS), a 
disease characterized by loss of motor neurons in the spinal cord, analysis of human autopsy 
tissue revealed apoptotic cells in the spinal cord of ALS patients (Troost et al., 1995). 
Additionally, anti-apoptotic Bcl-2 mRNA was downregulated and pro-apoptotic Bax mRNA was 
upregulated in spinal cord neurons of ALS patients (Mu et al., 1996). The importance of 
apoptotic cell death in ALS is further highlighted by the fact that overexpression of Bcl-2 and 
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administration of caspase inhibitors delays degeneration and death of motor neurons in an 
ALS mouse model (Kostic et al., 1997, Li et al., 2000). Interestingly, early stages of the disease 
are characterized by dysfunction of the neuromuscular junction, a specialized cholinergic 
synapse allowing signaling between muscle and nerve (Campanari et al., 2016).  
5.4 Identification of the Retinoschisin Binding Site at the Na/K-ATPase  
The importance of the retinal Na/K-ATPase consisting of ATP1A3 and ATP1B2 for anchoring 
retinoschisin to retinal plasma membranes has been established (Friedrich et al., 2011). In the 
last project of my thesis it was first addressed, whether retinoschisin binding requires Na/K-
ATPase isozymes consisting of ATP1A3 and ATP1B2, or whether retinoschisin specifically 
interacts with only one of the two subunits. Therefore, nine different Na/K-ATPase α and ß 
subunit combinations (α1-β1, α1-β2, α1-β3, α2-β1, α2-β2, α2-β3, α3-β1, α3-β2, or α3-β3) were 
tested for their ability to bind retinoschisin. Only Na/K-ATPases containing the ß2 subunit were 
able to bind retinoschisin independent of the co-expressed α subunit. The ß1 and ß3 containing 
Na/K-ATPases, although experimentally confirmed to be expressed at the membrane, failed 
to bind retinoschisin. The finding that retinoschisin interacts with the extracellular domain of 
ATP1B2 is in line with previous data by Friedrich and colleagues who tested retinoschisin 
binding to different tissues like muscle, liver, kidney, brain, lung, heart and spleen (Friedrich et 
al., 2011). Besides retina, the only tissue which showed successful retinoschisin binding was 
brain, which, interestingly, was also shown to express ß2. All other tissues failed to bind 
retinoschisin and did not express ß2 (Friedrich et al., 2011). 
The experimental data presented in this part of my thesis cannot fully exclude an interaction 
between retinoschisin and the α subunit. As all α subunits show a high extent of conservation 
(reviewed by Kaplan, 2002), retinoschisin interaction might be possible with all three α subunit 
isoforms tested in the study. However, it was shown that retinoschisin specificity is restricted 
to the binding of the ß2-subunit. In addition, X-ray crystallography analyses on the 3-D 
structure of the Na/K-ATPase revealed that the short extracellular domains of the α subunit 
are almost completely covered by the extracellular domain of the ß subunit (Morth et al., 2007), 
making an interaction of retinoschisin with these domains rather unlikely. Further analyses with 
ATP1B1-ATP1B2 chimeras narrowed down the retinoschisin interaction site to the extracellular 
domain of ß2. Bioinformatics analyses subsequently identified two potential protein interaction 
regions (“docking patches” I and II), which were then tested for their impact on retinoschisin-
binding by generating ATP1B2-ATP1B1 chimeras at the identified regions. One artificially 
generated chimera harbouring a mutation at T240, a bioinformatically identified hotspot for 
protein interaction in docking patch II, seemed of particular importance for retinoschisin 
interaction. Protein isolation of cell surface proteins and FACS analyses revealed that the 
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ATP1B2-construct mutated at T240 (Patch II Region 4) was secreted and folded similar to 
normal retinoschisin. However, it failed to bind retinoschisin, which makes docking patch 
(Patch II) around residue T240 a likely interface for retinoschisin binding. 
The mechanism of how retinoschisin binding to ß2 might affect signaling properties of the 
Na/K-ATPase is unclear. Interestingly, the ß2 subunit has been shown to differ from ß1 and 
ß3 when it comes to regulatory effects on the α subunit. Compared to the other two ß subunits, 
ß2 was shown to stabilize the Na/K-ATPase in its Na+ bound E1P state. This modulatory effect 
was suggested to be dependent on the tilt angle of the ß2 transmembrane domain which also 
leads to a changed tilt angle in the extracellular domain of ß2 (Hilbers et al., 2016). Different 
tilt angles of the different ß subunits may alter interaction sites between the ß and the α subunit 
which are of importance for the kinetic properties of Na+ binding (Hilbers et al., 2016). Likewise, 
retinoschisin binding to the ß2 could induce conformational changes which might alter the α-ß 
interaction site. As suggested by Hilbers et al., 2016, an altered α-ß interface could result in 
different enzymatic properties of the Na/K-ATPase, which may also include different signaling 
properties. 
Taking into account the cog-wheel like octameric or even hexadecameric structure of 
retinoschisin (Tolun et al., 2016, Ramsay et al., 2016), retinoschisin might interact with more 
than one Na/K-ATPase simultaneously and may be capable of tethering a number of Na/K-
ATPases together in clusters, as seen for Na/K-ATPase enrichment by its interaction with 
caveolin in caveolae (Liu et al., 2003). A mechanism like this could potentiate the regulatory 
properties of retinoschisin on Na/K-ATPase mediated signaling, as one molecule of 
retinoschisin could regulate more than one molecule of Na/K-ATPase. 
5.5 Implications 
Taken together, the present study provides novel insight into the pathomechanism of XLRS 
and highlights the importance of the retinal Na/K-ATPase as an interaction partner of 
retinoschisin. The data set obtained for the effect of retinoschisin on intracellular signaling and 
the overlap of the retinoschisin-Na/K-ATPase complex with intracellular signal transducers 
indicate the existence of a retinoschisin-Na/K-ATPase signalosome complex in the retina. 
Defective regulation of this signalosome complex could eventually result in aberrant regulation 
of cellular processes like apoptosis, and thus represent an initial step in XLRS pathogenesis. 
The interaction site of the retinal Na/K-ATPase to retinoschisin was refined to the extracellular 
domain of ATP1B2, suggesting the interface at a hydrophobic patch containing aa T240 in 
ATP1B2. Together, these novel findings may have implications for research into alternative 
therapeutic options for this progressive and currently untreatable disease. Specifically, 
strategies for preventing Na/K-ATPase dysregulation could be considered and are currently 
Discussion 
101 
also under investigation as novel treatment options for other diseases associated with aberrant 
activation of Na/K-ATPase signaling, such as cardiac fibrosis (reviewed by Fan et al., 2016). 
Passive immunization against marinobufagenin (MBG), as well as administration of anti-MBG 
antibodies or anti-Digoxin antibodies have been shown to attenuate fibrosis in models of 
cardiac and renal disease (Haller et al., 2014, Grigorova et al., 2016, reviewed by Fan et al., 
2016). Additionally, a synthetic peptide, called NaKTide is proposed to inhibit Na/K-ATPase 
dependent SRC activation and was also shown to reduce cardiac fibrosis in mice (Li et al., 
2009, Liu et al., 2016). A similar approach might also be feasible to reduce MAPK activation in 
XLRS retinae and thus represent a novel therapeutic option for XLRS.  
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